[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fdUmPyHzKrR5mRYEhO0-gTcp3DWQhkAGWnxZqmAaoZ7Y":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":86,"rows":93},"University of North Carolina, Chapel Hill",[4],1346,false,173,20,1064226,67,1003,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"HIV",57,{"name":18,"count":19},"Obesity",54,{"name":21,"count":22},"HIV Infections",51,{"name":24,"count":25},"Healthy",28,{"name":27,"count":28},"Depression",26,{"name":30,"count":31},"HIV Infection",23,{"name":33,"count":34},"Schizophrenia",22,{"name":36,"count":37},"Overweight",21,[39,44,49,54,59,64,69,73,76,81],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06204432","Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction","2025-12","Sodium Citrate",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06374212","Anifrolumab for Hidradenitis Suppurativa","2026-01-22","Anifrolumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06303739","Psilocybin-Assisted Therapy in Treatment-Resistant Depression","2026-04-09","psilocybin",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06352073","Dupilumab for Eosinophilic Esophagitis With Severe Strictures","2026-04-16","Dupilumab",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06263452","Beta-Blocker Influences on Inflammatory and Neural Responses to Stress","2026-05","Propranolol",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06057714","Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis","2026-06","19F MRI",{"nctId":70,"briefTitle":71,"date":67,"intervention":72},"NCT06242795","Hypertonic Saline in NCFB","7% Hypertonic Saline via nebulization",{"nctId":74,"briefTitle":75,"date":67,"intervention":68},"NCT06066723","19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04328337","Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism","2026-06-01","Intralipid, 20% Intravenous Emulsion",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06853327","Oral Ketorolac for IUD Pain Reduction","2026-06-30","Ketorolac",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,138,231,277,323,344,379,397,415,433,460,481,507,535,553,577,595,625,643,661,679,697,715,767,789,815,833,858,879,897,922,948,975,993,1017,1043,1065,1091,1114,1132,1154,1184,1248,1275,1293,1311,1335,1353,1379,1397,1429,1447,1465,1483,1501,1519,1537,1555,1573,1591,1609,1634,1652,1688,1715,1733,1760,1778,1846,1898,1930,1975,2012,2053,2085,2122,2151,2189,2224,2246,2273,2299,2317,2341,2364,2390,2408,2435,2453,2471,2489,2507,2525,2543,2569,2587,2605,2630,2655,2673,2691,2709,2727,2753,2771,2795,2813,2839,2867,2892,2914,2938,2964,2987,3013,3037,3061,3086,3104,3129,3155,3173,3198,3216,3234,3260,3285,3310,3328,3346,3364,3382,3400,3418,3436,3459,3485,3523,3541,3559,3577,3595,3613,3638,3662,3684,3708,3733,3751,3776,3835,3872,3911,3945,3976,4002,4027,4051,4074,4097,4120,4145,4171,4219,4268,4308,4352,4380,4402,4434,4461,4491,4526,4554,4589,4611,4644,4675,4711,4742,4764,4785,4809,4827,4845,4863,4885,4911,4929,4955,4973,4991,5009,5027,5052,5074,5096,5114,5141,5159,5182,5200,5226,5250,5276,5294,5321,5339,5363,5381,5405,5423,5445,5468,5486,5512,5530,5552,5570,5588,5612,5638,5656,5674,5704,5722,5740,5758,5776,5799,5820,5843,5864,5888,5906,5934,5952,5970,5988,6020,6044,6062,6080,6098,6126,6144,6168,6186,6212,6230,6255,6273,6291,6314,6332,6350,6373,6398,6422,6444,6473,6491,6509,6527,6545,6568,6591,6609,6630,6655,6677,6699,6725,6743,6761,6821,6850,6877,6913,6935,6968,6991,7014,7032,7057,7079,7102,7120,7143,7161,7183,7206,7224,7245,7270,7292,7313,7334,7359,7377,7400,7418,7440,7461,7479,7500,7521,7543,7565,7591,7609,7627,7645,7670,7692,7718,7736,7759,7781,7804,7828,7846,7869,7893,7916,7941,7964,7986,8004,8027,8050,8071,8094,8119,8137,8160,8184,8206,8239,8257,8280,8305,8329,8353,8378,8402,8449,8497,8528,8563,8596,8635,8657,8689,8723,8749,8776,8798,8830,8861,8887,8905,8926,8947,8973,8991,9009,9027,9045,9067,9101,9126,9144,9162,9184,9202,9220,9238,9263,9285,9307,9330,9359,9377,9395,9413,9435,9457,9480,9502,9520,9542,9568,9586,9609,9631,9654,9677,9695,9718,9740,9763,9781,9802,9824,9846,9870,9894,9919,9937,9955,9979,10002,10028,10052,10075,10093],{"intervention":95,"totalTrials":96,"cells":97},"Transdermal estradiol",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":136},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":126},[109,122],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT06610305","Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression","RECRUITING",[91],"2028-06-01","2024-09-02",75,[118],"Major Depressive Disorder",[95,120,121],"Progesterone","Transdermal placebo patch",{"nctId":123,"briefTitle":124,"status":112,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":132},"NCT05282277","Examining the Effects of Estradiol on Neural and Molecular Response to Reward",[91],"2026-12-31","2022-04-20",103,[27,130,131],"Psychosis","Anhedonia",[133,134,135],"Transdermal Estradiol","Micronized Progesterone","Raclopride C11",{"trials":137,"activeCount":100},[],{"intervention":139,"totalTrials":140,"cells":141},"Normal Saline",6,{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":170,"PHASE3":184,"PHASE4":186,"NA":216},{"trials":143,"activeCount":100},[],{"trials":145,"activeCount":100},[146,159],{"nctId":147,"briefTitle":148,"status":149,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":157},"NCT01541293","Intrauterine Lidocaine for Laminaria","COMPLETED",[88],"2013-10","2012-09",72,[155,156],"Abortion, Induced","Pain Management",[158,139],"Lidocaine",{"nctId":160,"briefTitle":161,"status":149,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":167},"NCT03623022","Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)",[88],"2019-09-17","2018-10-17",15,[24],[168,169],"Clinical Center Reference Endotoxin","Normal saline",{"trials":171,"activeCount":183,"soonestReadout":42},[172],{"nctId":40,"briefTitle":41,"status":173,"phases":174,"primaryCompletion":42,"completion":42,"start":175,"enrollment":176,"conditions":177,"interventions":182},"ACTIVE_NOT_RECRUITING",[89],"2023-12-01",60,[178,179,180,181],"Long Haul COVID-19","Post-Acute COVID-19 Syndrome","Anosmia","Olfaction Disorders",[43,139],1,{"trials":185,"activeCount":100},[],{"trials":187,"activeCount":183,"soonestReadout":204},[188,200],{"nctId":189,"briefTitle":190,"status":149,"phases":191,"primaryCompletion":192,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":198},"NCT01829399","Control of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic",[91],"2014-01","2013-04",24,[196,197],"Application Site Discomfort","Medical Device Discomfort",[199,139],"Bupivacaine with Epinephrine",{"nctId":201,"briefTitle":202,"status":112,"phases":203,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":214},"NCT07213635","Paracervical Injection and Opioid Use After Vaginal Hysterectomy for Prolapse",[91],"2026-10","2026-12","2025-10-20",56,[209,210,211,212,213],"Opioid Use","Surgical Recovery","Vaginal Hysterectomy","Prolapse Pelvic","Postoperative Pain",[215,169],"Bupivacaine-epinephrine",{"trials":217,"activeCount":100},[218],{"nctId":219,"briefTitle":220,"status":149,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT02781818","A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.",[92],"2017-06","2017-07","2016-06",32,[227],"Hidradenitis Suppurativa",[229,230,139],"Triamcinolone Acetonide 10mg\u002FmL","Triamcinolone Acetonide 40mg\u002FmL",{"intervention":232,"totalTrials":233,"cells":234},"Micronized progesterone",3,{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":267,"PHASE4":269,"NA":275},{"trials":236,"activeCount":100},[],{"trials":238,"activeCount":100},[],{"trials":240,"activeCount":100},[241,253],{"nctId":242,"briefTitle":243,"status":149,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT04225221","Neurobiology of Bulimia Nervosa",[89],"2022-04-04","2020-02-24",10,[249],"Bulimia Nervosa",[251,232,252],"Estradiol","Leuprolide Acetate",{"nctId":254,"briefTitle":255,"status":149,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":31,"conditions":260,"interventions":264},"NCT04051320","Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model",[89],"2022-07-15","2022-07-19","2020-01-02",[261,262,263,27],"Perinatal Depression","Post Partum Depression","Depression, Postpartum",[265,266,232],"Leuprolide Acetate 3.75 MG\u002FML","Estradiol 2 Mg",{"trials":268,"activeCount":100},[],{"trials":270,"activeCount":183,"soonestReadout":126},[271],{"nctId":123,"briefTitle":124,"status":112,"phases":272,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":273,"interventions":274},[91],[27,130,131],[133,134,135],{"trials":276,"activeCount":100},[],{"intervention":63,"totalTrials":233,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":310,"PHASE4":312,"NA":321},{"trials":280,"activeCount":100},[],{"trials":282,"activeCount":100},[],{"trials":284,"activeCount":100},[285,298],{"nctId":286,"briefTitle":287,"status":149,"phases":288,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":296},"NCT00934947","Burn Healing and Analgesia With Propranolol",[89],"2011-02","2011-06","2009-07",45,[294,295],"Burns","Pain",[63,297],"Propanolol",{"nctId":299,"briefTitle":300,"status":301,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":100,"conditions":305,"interventions":307},"NCT01007084","TRAUMA HELP: Healing and Analgesia With Propranolol","WITHDRAWN",[89],"2010-07","2009-10",[306],"Trauma",[63,308,309],"Propranolol ER","Sugar pills",{"trials":311,"activeCount":100},[],{"trials":313,"activeCount":183,"soonestReadout":62},[314],{"nctId":60,"briefTitle":61,"status":112,"phases":315,"primaryCompletion":62,"completion":62,"start":316,"enrollment":317,"conditions":318,"interventions":320},[91],"2024-05-01",120,[319],"Cardiovascular Disease",[63],{"trials":322,"activeCount":100},[],{"intervention":58,"totalTrials":183,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":342},{"trials":326,"activeCount":100},[],{"trials":328,"activeCount":100},[],{"trials":330,"activeCount":100},[],{"trials":332,"activeCount":100},[],{"trials":334,"activeCount":183,"soonestReadout":57},[335],{"nctId":55,"briefTitle":56,"status":173,"phases":336,"primaryCompletion":57,"completion":205,"start":337,"enrollment":31,"conditions":338,"interventions":341},[91],"2024-05-16",[339,340],"Eosinophilic Esophagitis","EoE",[58],{"trials":343,"activeCount":100},[],{"intervention":345,"totalTrials":183,"cells":346},"Fibrinolytic once daily",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":377},{"trials":348,"activeCount":100},[],{"trials":350,"activeCount":100},[],{"trials":352,"activeCount":100},[],{"trials":354,"activeCount":100},[],{"trials":356,"activeCount":183,"soonestReadout":361},[357],{"nctId":358,"briefTitle":359,"status":112,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":373},"NCT07095361","Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema",[91],"2028-09-30","2025-09-11",270,[365,366,367,368,369,370,371,372],"Pleural Infection Bacterial","Pleural Infections","Pleural Infections and Inflammations","Empyema, Pleural","Empyema","Complicated Pleural Effusion\u002F Empyema","Pleural Effusion Associated With Pulmonary Infection","Pleural Effusion",[345,374,375,376],"Fibrinolytic twice daily","DNA degradation once daily","DNA degradation twice daily",{"trials":378,"activeCount":100},[],{"intervention":374,"totalTrials":183,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":395},{"trials":382,"activeCount":100},[],{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":183,"soonestReadout":361},[391],{"nctId":358,"briefTitle":359,"status":112,"phases":392,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":393,"interventions":394},[91],[365,366,367,368,369,370,371,372],[345,374,375,376],{"trials":396,"activeCount":100},[],{"intervention":375,"totalTrials":183,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":413},{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"trials":404,"activeCount":100},[],{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":183,"soonestReadout":361},[409],{"nctId":358,"briefTitle":359,"status":112,"phases":410,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":411,"interventions":412},[91],[365,366,367,368,369,370,371,372],[345,374,375,376],{"trials":414,"activeCount":100},[],{"intervention":376,"totalTrials":183,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":431},{"trials":418,"activeCount":100},[],{"trials":420,"activeCount":100},[],{"trials":422,"activeCount":100},[],{"trials":424,"activeCount":100},[],{"trials":426,"activeCount":183,"soonestReadout":361},[427],{"nctId":358,"briefTitle":359,"status":112,"phases":428,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":429,"interventions":430},[91],[365,366,367,368,369,370,371,372],[345,374,375,376],{"trials":432,"activeCount":100},[],{"intervention":434,"totalTrials":183,"cells":435},"Kurvelo",{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":442,"PHASE4":444,"NA":458},{"trials":437,"activeCount":100},[],{"trials":439,"activeCount":100},[],{"trials":441,"activeCount":100},[],{"trials":443,"activeCount":100},[],{"trials":445,"activeCount":183,"soonestReadout":451},[446],{"nctId":447,"briefTitle":448,"status":449,"phases":450,"primaryCompletion":451,"completion":452,"start":79,"enrollment":453,"conditions":454,"interventions":457},"NCT07544966","Teen Vulnerability to Irritability: Brain and Estrogen Changes","NOT_YET_RECRUITING",[91],"2028-04","2029-04",50,[455,456],"Depression - Major Depressive Disorder","Irritability",[434],{"trials":459,"activeCount":100},[],{"intervention":72,"totalTrials":183,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":479},{"trials":463,"activeCount":100},[],{"trials":465,"activeCount":100},[],{"trials":467,"activeCount":100},[],{"trials":469,"activeCount":100},[],{"trials":471,"activeCount":183,"soonestReadout":67},[472],{"nctId":70,"briefTitle":71,"status":112,"phases":473,"primaryCompletion":67,"completion":67,"start":474,"enrollment":9,"conditions":475,"interventions":478},[91],"2024-10-23",[476,477],"Bronchiectasis","Non-cystic Fibrosis Bronchiectasis",[72],{"trials":480,"activeCount":100},[],{"intervention":482,"totalTrials":183,"cells":483},"LAIV nasal vaccine is chosen as a model viral infection",{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":505},{"trials":485,"activeCount":100},[],{"trials":487,"activeCount":100},[],{"trials":489,"activeCount":100},[],{"trials":491,"activeCount":100},[],{"trials":493,"activeCount":183,"soonestReadout":498},[494],{"nctId":495,"briefTitle":496,"status":112,"phases":497,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":504},"NCT06841913","Woodsmoke Exposure, Influenza Infection, and Nasal Immunity",[91],"2028-12-31","2025-09-26",112,[502,503],"Smoke Exposure","Influenza",[482],{"trials":506,"activeCount":100},[],{"intervention":508,"totalTrials":183,"cells":509},"Mirikizumab - Intravenous",{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":533},{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":100},[],{"trials":515,"activeCount":100},[],{"trials":517,"activeCount":100},[],{"trials":519,"activeCount":183,"soonestReadout":524},[520],{"nctId":521,"briefTitle":522,"status":112,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":531},"NCT06864403","Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch",[91],"2027-04","2025-08-12",25,[528,529,530],"Pouchitis","Pouches, Ileoanal","Pouch, Ileal",[508,532],"Mirikizumab - Subcutaneous",{"trials":534,"activeCount":100},[],{"intervention":532,"totalTrials":183,"cells":536},{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":545,"NA":551},{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"trials":542,"activeCount":100},[],{"trials":544,"activeCount":100},[],{"trials":546,"activeCount":183,"soonestReadout":524},[547],{"nctId":521,"briefTitle":522,"status":112,"phases":548,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":549,"interventions":550},[91],[528,529,530],[508,532],{"trials":552,"activeCount":100},[],{"intervention":554,"totalTrials":183,"cells":555},"Rifaximin 550 MG Oral Tablet [XIFAXAN]",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":564,"NA":575},{"trials":557,"activeCount":100},[],{"trials":559,"activeCount":100},[],{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":183,"soonestReadout":570},[566],{"nctId":567,"briefTitle":568,"status":112,"phases":569,"primaryCompletion":570,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":574},"NCT06312683","Rifaximin for the Secondary Prevention of Recurrent Pouchitis",[91],"2026-07","2024-07-01",16,[528],[554],{"trials":576,"activeCount":100},[],{"intervention":121,"totalTrials":183,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":593},{"trials":580,"activeCount":100},[],{"trials":582,"activeCount":100},[],{"trials":584,"activeCount":100},[],{"trials":586,"activeCount":100},[],{"trials":588,"activeCount":183,"soonestReadout":114},[589],{"nctId":110,"briefTitle":111,"status":112,"phases":590,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":591,"interventions":592},[91],[118],[95,120,121],{"trials":594,"activeCount":100},[],{"intervention":596,"totalTrials":183,"cells":597},"Initiating daily oral PrEP during pregnancy",{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":623},{"trials":599,"activeCount":100},[],{"trials":601,"activeCount":100},[],{"trials":603,"activeCount":100},[],{"trials":605,"activeCount":100},[],{"trials":607,"activeCount":183,"soonestReadout":205},[608],{"nctId":609,"briefTitle":610,"status":112,"phases":611,"primaryCompletion":205,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":619},"NCT06158126","UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study",[91],"2027-12","2024-04-17",621,[616,617,618],"Pre-exposure Prophylaxis","HIV Prevention","Pregnancy Related",[596,620,621,622],"Already using daily oral PrEP at the time of pregnancy diagnosis","Initiating injectable PrEP during pregnancy","Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis",{"trials":624,"activeCount":100},[],{"intervention":620,"totalTrials":183,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":635,"NA":641},{"trials":628,"activeCount":100},[],{"trials":630,"activeCount":100},[],{"trials":632,"activeCount":100},[],{"trials":634,"activeCount":100},[],{"trials":636,"activeCount":183,"soonestReadout":205},[637],{"nctId":609,"briefTitle":610,"status":112,"phases":638,"primaryCompletion":205,"completion":612,"start":613,"enrollment":614,"conditions":639,"interventions":640},[91],[616,617,618],[596,620,621,622],{"trials":642,"activeCount":100},[],{"intervention":621,"totalTrials":183,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":659},{"trials":646,"activeCount":100},[],{"trials":648,"activeCount":100},[],{"trials":650,"activeCount":100},[],{"trials":652,"activeCount":100},[],{"trials":654,"activeCount":183,"soonestReadout":205},[655],{"nctId":609,"briefTitle":610,"status":112,"phases":656,"primaryCompletion":205,"completion":612,"start":613,"enrollment":614,"conditions":657,"interventions":658},[91],[616,617,618],[596,620,621,622],{"trials":660,"activeCount":100},[],{"intervention":622,"totalTrials":183,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":677},{"trials":664,"activeCount":100},[],{"trials":666,"activeCount":100},[],{"trials":668,"activeCount":100},[],{"trials":670,"activeCount":100},[],{"trials":672,"activeCount":183,"soonestReadout":205},[673],{"nctId":609,"briefTitle":610,"status":112,"phases":674,"primaryCompletion":205,"completion":612,"start":613,"enrollment":614,"conditions":675,"interventions":676},[91],[616,617,618],[596,620,621,622],{"trials":678,"activeCount":100},[],{"intervention":135,"totalTrials":183,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":689,"NA":695},{"trials":682,"activeCount":100},[],{"trials":684,"activeCount":100},[],{"trials":686,"activeCount":100},[],{"trials":688,"activeCount":100},[],{"trials":690,"activeCount":183,"soonestReadout":126},[691],{"nctId":123,"briefTitle":124,"status":112,"phases":692,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":693,"interventions":694},[91],[27,130,131],[133,134,135],{"trials":696,"activeCount":100},[],{"intervention":215,"totalTrials":183,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":707,"NA":713},{"trials":700,"activeCount":100},[],{"trials":702,"activeCount":100},[],{"trials":704,"activeCount":100},[],{"trials":706,"activeCount":100},[],{"trials":708,"activeCount":183,"soonestReadout":204},[709],{"nctId":201,"briefTitle":202,"status":112,"phases":710,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":711,"interventions":712},[91],[209,210,211,212,213],[215,169],{"trials":714,"activeCount":100},[],{"intervention":120,"totalTrials":716,"cells":717},4,{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":726,"NA":754},{"trials":719,"activeCount":100},[],{"trials":721,"activeCount":100},[],{"trials":723,"activeCount":100},[],{"trials":725,"activeCount":100},[],{"trials":727,"activeCount":183,"soonestReadout":114},[728,741,745],{"nctId":729,"briefTitle":730,"status":731,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":739},"NCT03003949","The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood","TERMINATED",[91],"2020-05-10","2017-01-24",82,[737,738],"Perimenopausal Disorder","Stress, Emotional",[740,120],"Estradiol Patch, 0.1 Mg\u002F24 Hours Weekly Transdermal Film, Extended Release",{"nctId":110,"briefTitle":111,"status":112,"phases":742,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":743,"interventions":744},[91],[118],[95,120,121],{"nctId":746,"briefTitle":747,"status":149,"phases":748,"primaryCompletion":164,"completion":164,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT02255175","Perimenopausal Effects of Estradiol on Reward Responsiveness",[91],"2015-10-01",64,[752],"Perimenopausal Depression",[251,120],{"trials":755,"activeCount":100},[756],{"nctId":757,"briefTitle":758,"status":149,"phases":759,"primaryCompletion":760,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":765},"NCT01762943","Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition",[92],"2016-10-13","2013-08",36,[764],"Postpartum Depression",[252,766,120],"Micronized estradiol",{"intervention":53,"totalTrials":183,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":785,"NA":787},{"trials":770,"activeCount":100},[],{"trials":772,"activeCount":100},[],{"trials":774,"activeCount":100},[],{"trials":776,"activeCount":183,"soonestReadout":52},[777],{"nctId":50,"briefTitle":51,"status":173,"phases":778,"primaryCompletion":52,"completion":779,"start":780,"enrollment":9,"conditions":781,"interventions":784},[90],"2027-03-26","2024-04-19",[782,783],"Refractory Depression","Treatment Resistant Depression",[53],{"trials":786,"activeCount":100},[],{"trials":788,"activeCount":100},[],{"intervention":790,"totalTrials":183,"cells":791},"Liposomal bupivacaine",{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":798,"PHASE4":811,"NA":813},{"trials":793,"activeCount":100},[],{"trials":795,"activeCount":100},[],{"trials":797,"activeCount":100},[],{"trials":799,"activeCount":183,"soonestReadout":204},[800],{"nctId":801,"briefTitle":802,"status":112,"phases":803,"primaryCompletion":204,"completion":204,"start":804,"enrollment":805,"conditions":806,"interventions":809},"NCT06179004","Supraclavicular Bupivacaine Vs. Supraclavicular Liposomal Bupivacaine for Orthopedic Wrist Surgery",[90],"2024-04-10",100,[807,808],"Distal Radius Fractures","Wrist Fractures",[790,810],"Bupivacaine Hydrochloride",{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[],{"intervention":810,"totalTrials":183,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":829,"NA":831},{"trials":818,"activeCount":100},[],{"trials":820,"activeCount":100},[],{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":183,"soonestReadout":204},[825],{"nctId":801,"briefTitle":802,"status":112,"phases":826,"primaryCompletion":204,"completion":204,"start":804,"enrollment":805,"conditions":827,"interventions":828},[90],[807,808],[790,810],{"trials":830,"activeCount":100},[],{"trials":832,"activeCount":100},[],{"intervention":834,"totalTrials":183,"cells":835},"Upadacitinib 30mg Dose",{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":837,"activeCount":100},[],{"trials":839,"activeCount":100},[],{"trials":841,"activeCount":183,"soonestReadout":846},[842],{"nctId":843,"briefTitle":844,"status":449,"phases":845,"primaryCompletion":846,"completion":847,"start":570,"enrollment":848,"conditions":849,"interventions":851},"NCT07588568","A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis",[89],"2030-02","2030-06",52,[340,339,850],"Eosinophilic Esophagitis (EoE)",[834],{"trials":853,"activeCount":100},[],{"trials":855,"activeCount":100},[],{"trials":857,"activeCount":100},[],{"intervention":80,"totalTrials":183,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":873,"PHASE4":875,"NA":877},{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":100},[],{"trials":865,"activeCount":183,"soonestReadout":79},[866],{"nctId":77,"briefTitle":78,"status":112,"phases":867,"primaryCompletion":79,"completion":79,"start":868,"enrollment":869,"conditions":870,"interventions":871},[88,89],"2020-12-08",40,[18],[80,872],"Placebos",{"trials":874,"activeCount":100},[],{"trials":876,"activeCount":100},[],{"trials":878,"activeCount":100},[],{"intervention":872,"totalTrials":183,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":882,"activeCount":100},[],{"trials":884,"activeCount":100},[],{"trials":886,"activeCount":183,"soonestReadout":79},[887],{"nctId":77,"briefTitle":78,"status":112,"phases":888,"primaryCompletion":79,"completion":79,"start":868,"enrollment":869,"conditions":889,"interventions":890},[88,89],[18],[80,872],{"trials":892,"activeCount":100},[],{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"intervention":898,"totalTrials":183,"cells":899},"Finerenone Oral",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":901,"activeCount":100},[],{"trials":903,"activeCount":100},[],{"trials":905,"activeCount":183,"soonestReadout":910},[906],{"nctId":907,"briefTitle":908,"status":112,"phases":909,"primaryCompletion":910,"completion":911,"start":912,"enrollment":805,"conditions":913,"interventions":915},"NCT06059664","The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study",[89],"2027-03-31","2027-12-31","2024-04-23",[914],"Kidney Transplant; Complications",[898],{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":100},[],{"intervention":923,"totalTrials":183,"cells":924},"BXCL501",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":942,"PHASE4":944,"NA":946},{"trials":926,"activeCount":100},[],{"trials":928,"activeCount":100},[],{"trials":930,"activeCount":183,"soonestReadout":935},[931],{"nctId":932,"briefTitle":933,"status":112,"phases":934,"primaryCompletion":935,"completion":935,"start":936,"enrollment":805,"conditions":937,"interventions":941},"NCT06943404","BXCL501 After Stress to Increase Recovery Success",[89],"2026-09-29","2026-02-23",[938,939,940],"Acute Stress Reaction","Acute Stress Disorder","Post-traumatic Stress Disorder",[923],{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":100},[],{"intervention":949,"totalTrials":183,"cells":950},"Ketotifen",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":969,"PHASE4":971,"NA":973},{"trials":952,"activeCount":100},[],{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":183,"soonestReadout":961},[957],{"nctId":958,"briefTitle":959,"status":449,"phases":960,"primaryCompletion":961,"completion":961,"start":962,"enrollment":453,"conditions":963,"interventions":966},"NCT07526558","Mast Cell Treatment in Post-tick Bite Illness (PTBI)",[89],"2027-01","2026-04-30",[964,965],"Post-tick Bite Illness","Mast Cell Stabilizer",[949,967,968],"fexofenadine","Cromolyn Sodium",{"trials":970,"activeCount":100},[],{"trials":972,"activeCount":100},[],{"trials":974,"activeCount":100},[],{"intervention":968,"totalTrials":183,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":987,"PHASE4":989,"NA":991},{"trials":978,"activeCount":100},[],{"trials":980,"activeCount":100},[],{"trials":982,"activeCount":183,"soonestReadout":961},[983],{"nctId":958,"briefTitle":959,"status":449,"phases":984,"primaryCompletion":961,"completion":961,"start":962,"enrollment":453,"conditions":985,"interventions":986},[89],[964,965],[949,967,968],{"trials":988,"activeCount":100},[],{"trials":990,"activeCount":100},[],{"trials":992,"activeCount":100},[],{"intervention":994,"totalTrials":183,"cells":995},"Cashew sublingual immunotherapy",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1011,"PHASE4":1013,"NA":1015},{"trials":997,"activeCount":100},[],{"trials":999,"activeCount":100},[],{"trials":1001,"activeCount":183,"soonestReadout":1006},[1002],{"nctId":1003,"briefTitle":1004,"status":449,"phases":1005,"primaryCompletion":1006,"completion":1006,"start":67,"enrollment":292,"conditions":1007,"interventions":1010},"NCT07170540","UNC Cashew Sublingual Immunotherapy",[89],"2028-12",[1008,1009],"Cashew Nut Allergy","Tree Nut Allergies",[994],{"trials":1012,"activeCount":100},[],{"trials":1014,"activeCount":100},[],{"trials":1016,"activeCount":100},[],{"intervention":1018,"totalTrials":183,"cells":1019},"Cyclobenzaprine HCl",{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1037,"PHASE4":1039,"NA":1041},{"trials":1021,"activeCount":100},[],{"trials":1023,"activeCount":100},[],{"trials":1025,"activeCount":183,"soonestReadout":1030},[1026],{"nctId":1027,"briefTitle":1028,"status":112,"phases":1029,"primaryCompletion":1030,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1036},"NCT06636786","Prevention\u002FReduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)",[89],"2026-09","2025-03-25",180,[938,939,1034,1035],"Neurocognitive Function","Post-traumatic Stress",[1018],{"trials":1038,"activeCount":100},[],{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":100},[],{"intervention":48,"totalTrials":183,"cells":1044},{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1046,"activeCount":100},[],{"trials":1048,"activeCount":100},[],{"trials":1050,"activeCount":183,"soonestReadout":47},[1051],{"nctId":45,"briefTitle":46,"status":173,"phases":1052,"primaryCompletion":47,"completion":1053,"start":1054,"enrollment":165,"conditions":1055,"interventions":1058},[89],"2026-04","2024-06-21",[227,1056,1057],"Acne Inversa","Hidradenitis",[48],{"trials":1060,"activeCount":100},[],{"trials":1062,"activeCount":100},[],{"trials":1064,"activeCount":100},[],{"intervention":1066,"totalTrials":183,"cells":1067},"Baricitinib 4 milligram Oral",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1069,"activeCount":100},[],{"trials":1071,"activeCount":100},[],{"trials":1073,"activeCount":183,"soonestReadout":1078},[1074],{"nctId":1075,"briefTitle":1076,"status":173,"phases":1077,"primaryCompletion":1078,"completion":1030,"start":1079,"enrollment":247,"conditions":1080,"interventions":1084},"NCT06158113","Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study",[89],"2026-08","2024-03-13",[1081,1082,1083],"Lichen Planus, Oral","Lichen Planus, Mucosal","Oral Lichen Planus",[1066],{"trials":1086,"activeCount":100},[],{"trials":1088,"activeCount":100},[],{"trials":1090,"activeCount":100},[],{"intervention":1092,"totalTrials":183,"cells":1093},"18F-fluorofuranylnorprogesterone PET \u002F MRI",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1108,"PHASE4":1110,"NA":1112},{"trials":1095,"activeCount":100},[],{"trials":1097,"activeCount":100},[],{"trials":1099,"activeCount":183,"soonestReadout":1078},[1100],{"nctId":1101,"briefTitle":1102,"status":112,"phases":1103,"primaryCompletion":1078,"completion":1078,"start":1104,"enrollment":194,"conditions":1105,"interventions":1107},"NCT05480995","Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET \u002F MRI",[89],"2023-01-17",[1106],"Endometriosis",[1092],{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[],{"trials":1113,"activeCount":100},[],{"intervention":43,"totalTrials":183,"cells":1115},{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":100},[],{"trials":1121,"activeCount":183,"soonestReadout":42},[1122],{"nctId":40,"briefTitle":41,"status":173,"phases":1123,"primaryCompletion":42,"completion":42,"start":175,"enrollment":176,"conditions":1124,"interventions":1125},[89],[178,179,180,181],[43,139],{"trials":1127,"activeCount":100},[],{"trials":1129,"activeCount":100},[],{"trials":1131,"activeCount":100},[],{"intervention":85,"totalTrials":183,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1135,"activeCount":100},[],{"trials":1137,"activeCount":100},[],{"trials":1139,"activeCount":183,"soonestReadout":84},[1140],{"nctId":82,"briefTitle":83,"status":1141,"phases":1142,"primaryCompletion":84,"completion":84,"start":1143,"enrollment":1144,"conditions":1145,"interventions":1147},"ENROLLING_BY_INVITATION",[89],"2025-05-23",108,[1146],"IUD Insertion Pain",[85],{"trials":1149,"activeCount":100},[],{"trials":1151,"activeCount":100},[],{"trials":1153,"activeCount":100},[],{"intervention":1155,"totalTrials":96,"cells":1156},"Fexofenadine",{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1158,"activeCount":100},[],{"trials":1160,"activeCount":100},[],{"trials":1162,"activeCount":183,"soonestReadout":961},[1163],{"nctId":958,"briefTitle":959,"status":449,"phases":1164,"primaryCompletion":961,"completion":961,"start":962,"enrollment":453,"conditions":1165,"interventions":1166},[89],[964,965],[949,967,968],{"trials":1168,"activeCount":100},[],{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[1173],{"nctId":1174,"briefTitle":1175,"status":149,"phases":1176,"primaryCompletion":1177,"completion":1178,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1183},"NCT01526213","Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?",[92],"2010-04","2011-04","2009-09",18,[1182],"Food-drug Interaction",[1155],{"intervention":1185,"totalTrials":1186,"cells":1187},"Vorinostat",5,{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1233,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":183,"soonestReadout":205},[1192,1202,1213,1222],{"nctId":1193,"briefTitle":1194,"status":149,"phases":1195,"primaryCompletion":1196,"completion":1196,"start":1197,"enrollment":165,"conditions":1198,"interventions":1200},"NCT03803605","Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons",[88],"2021-01-28","2019-02-12",[1199],"HIV-1 Infection",[1201,1185],"VRC07-523LS",{"nctId":1203,"briefTitle":1204,"status":149,"phases":1205,"primaryCompletion":1206,"completion":1207,"start":1208,"enrollment":1209,"conditions":1210,"interventions":1211},"NCT03212989","Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)",[88],"2022-06-07","2022-07-05","2017-06-27",17,[1199],[1185,1212],"HXTC",{"nctId":1214,"briefTitle":1215,"status":731,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":140,"conditions":1219,"interventions":1220},"NCT02707900","Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection",[88],"2018-07-11","2016-03",[1199],[1185,1221],"AGS-004",{"nctId":1223,"briefTitle":1224,"status":112,"phases":1225,"primaryCompletion":205,"completion":1226,"start":1227,"enrollment":194,"conditions":1228,"interventions":1230},"NCT07217379","The DART DELIVER-02 Study",[88],"2027-02","2025-10-02",[1229],"HIV (Human Immunodeficiency Virus)",[1231,1232,1185],"MGD020","MGD014",{"trials":1234,"activeCount":100},[1235],{"nctId":1236,"briefTitle":1237,"status":149,"phases":1238,"primaryCompletion":1239,"completion":1239,"start":289,"enrollment":526,"conditions":1240,"interventions":1241},"NCT01319383","The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART",[88,89],"2016-03-31",[1199],[1185],{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[],{"intervention":1249,"totalTrials":183,"cells":1250},"[11C] PiB",{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1267,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1252,"activeCount":100},[],{"trials":1254,"activeCount":183,"soonestReadout":1259},[1255],{"nctId":1256,"briefTitle":1257,"status":173,"phases":1258,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":1262,"interventions":1264},"NCT04263337","NFL LONG Prospective Study",[88],"2028-08","2020-03-12",250,[1263],"Concussion, Brain",[1249,1265,1266],"[18F] PBR111","[18F] Flortaucipir",{"trials":1268,"activeCount":100},[],{"trials":1270,"activeCount":100},[],{"trials":1272,"activeCount":100},[],{"trials":1274,"activeCount":100},[],{"intervention":1265,"totalTrials":183,"cells":1276},{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1285,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":183,"soonestReadout":1259},[1281],{"nctId":1256,"briefTitle":1257,"status":173,"phases":1282,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":1283,"interventions":1284},[88],[1263],[1249,1265,1266],{"trials":1286,"activeCount":100},[],{"trials":1288,"activeCount":100},[],{"trials":1290,"activeCount":100},[],{"trials":1292,"activeCount":100},[],{"intervention":1266,"totalTrials":183,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":100},[],{"trials":1298,"activeCount":183,"soonestReadout":1259},[1299],{"nctId":1256,"briefTitle":1257,"status":173,"phases":1300,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":1301,"interventions":1302},[88],[1263],[1249,1265,1266],{"trials":1304,"activeCount":100},[],{"trials":1306,"activeCount":100},[],{"trials":1308,"activeCount":100},[],{"trials":1310,"activeCount":100},[],{"intervention":1312,"totalTrials":183,"cells":1313},"Lung Spheroid Stem Cells 100 million",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1327,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1315,"activeCount":100},[],{"trials":1317,"activeCount":183,"soonestReadout":612},[1318],{"nctId":1319,"briefTitle":1320,"status":173,"phases":1321,"primaryCompletion":612,"completion":612,"start":1322,"enrollment":194,"conditions":1323,"interventions":1325},"NCT04262167","Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis",[88],"2020-10-22",[1324],"Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease",[1312,1326],"Lung Spheroid Stem Cells 200 million",{"trials":1328,"activeCount":100},[],{"trials":1330,"activeCount":100},[],{"trials":1332,"activeCount":100},[],{"trials":1334,"activeCount":100},[],{"intervention":1326,"totalTrials":183,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1345,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1338,"activeCount":100},[],{"trials":1340,"activeCount":183,"soonestReadout":612},[1341],{"nctId":1319,"briefTitle":1320,"status":173,"phases":1342,"primaryCompletion":612,"completion":612,"start":1322,"enrollment":194,"conditions":1343,"interventions":1344},[88],[1324],[1312,1326],{"trials":1346,"activeCount":100},[],{"trials":1348,"activeCount":100},[],{"trials":1350,"activeCount":100},[],{"trials":1352,"activeCount":100},[],{"intervention":1354,"totalTrials":183,"cells":1355},"Anakinra 100 Mg\u002F0.67 Ml Inj Syringe",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1371,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1357,"activeCount":100},[],{"trials":1359,"activeCount":183,"soonestReadout":1364},[1360],{"nctId":1361,"briefTitle":1362,"status":449,"phases":1363,"primaryCompletion":1364,"completion":1364,"start":79,"enrollment":176,"conditions":1365,"interventions":1369},"NCT07600190","Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)",[88],"2028-12-01",[1366,1367,1368],"Asthma (Diagnosis)","Persistent Asthma","Moderate Asthma Exacerbation",[1354,1370],"Saline Placebo\u002F0.67 Ml Inj Syringe",{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":100},[],{"trials":1376,"activeCount":100},[],{"trials":1378,"activeCount":100},[],{"intervention":1370,"totalTrials":183,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1389,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1382,"activeCount":100},[],{"trials":1384,"activeCount":183,"soonestReadout":1364},[1385],{"nctId":1361,"briefTitle":1362,"status":449,"phases":1386,"primaryCompletion":1364,"completion":1364,"start":79,"enrollment":176,"conditions":1387,"interventions":1388},[88],[1366,1367,1368],[1354,1370],{"trials":1390,"activeCount":100},[],{"trials":1392,"activeCount":100},[],{"trials":1394,"activeCount":100},[],{"trials":1396,"activeCount":100},[],{"intervention":1398,"totalTrials":183,"cells":1399},"IAP086 0.3 mcg\u002Fkg",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1421,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1401,"activeCount":100},[],{"trials":1403,"activeCount":183,"soonestReadout":1408},[1404],{"nctId":1405,"briefTitle":1406,"status":449,"phases":1407,"primaryCompletion":1408,"completion":1408,"start":62,"enrollment":1409,"conditions":1410,"interventions":1412},"NCT07596888","IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study",[88],"2027-05",30,[1411],"HIV-1-infection",[1398,1413,1414,1415,1416,1417,1418,1419,1420],"IAP086 1 mcg\u002Fkg","IAP086 3 mcg\u002Fkg","IAP086 6 mcg\u002Fkg","IAP086 10 mcg\u002Fkg","IAP086 15 mcg\u002Fkg","IAP086 25 mcg\u002Fkg","IAP086 32 mcg\u002Fkg","IAP086 40 mcg\u002Fkg",{"trials":1422,"activeCount":100},[],{"trials":1424,"activeCount":100},[],{"trials":1426,"activeCount":100},[],{"trials":1428,"activeCount":100},[],{"intervention":1413,"totalTrials":183,"cells":1430},{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1439,"PHASE3":1441,"PHASE4":1443,"NA":1445},{"trials":1432,"activeCount":100},[],{"trials":1434,"activeCount":183,"soonestReadout":1408},[1435],{"nctId":1405,"briefTitle":1406,"status":449,"phases":1436,"primaryCompletion":1408,"completion":1408,"start":62,"enrollment":1409,"conditions":1437,"interventions":1438},[88],[1411],[1398,1413,1414,1415,1416,1417,1418,1419,1420],{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[],{"trials":1444,"activeCount":100},[],{"trials":1446,"activeCount":100},[],{"intervention":1414,"totalTrials":183,"cells":1448},{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1457,"PHASE3":1459,"PHASE4":1461,"NA":1463},{"trials":1450,"activeCount":100},[],{"trials":1452,"activeCount":183,"soonestReadout":1408},[1453],{"nctId":1405,"briefTitle":1406,"status":449,"phases":1454,"primaryCompletion":1408,"completion":1408,"start":62,"enrollment":1409,"conditions":1455,"interventions":1456},[88],[1411],[1398,1413,1414,1415,1416,1417,1418,1419,1420],{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":100},[],{"trials":1464,"activeCount":100},[],{"intervention":1415,"totalTrials":183,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1475,"PHASE3":1477,"PHASE4":1479,"NA":1481},{"trials":1468,"activeCount":100},[],{"trials":1470,"activeCount":183,"soonestReadout":1408},[1471],{"nctId":1405,"briefTitle":1406,"status":449,"phases":1472,"primaryCompletion":1408,"completion":1408,"start":62,"enrollment":1409,"conditions":1473,"interventions":1474},[88],[1411],[1398,1413,1414,1415,1416,1417,1418,1419,1420],{"trials":1476,"activeCount":100},[],{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":100},[],{"trials":1482,"activeCount":100},[],{"intervention":1416,"totalTrials":183,"cells":1484},{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1493,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1486,"activeCount":100},[],{"trials":1488,"activeCount":183,"soonestReadout":1408},[1489],{"nctId":1405,"briefTitle":1406,"status":449,"phases":1490,"primaryCompletion":1408,"completion":1408,"start":62,"enrollment":1409,"conditions":1491,"interventions":1492},[88],[1411],[1398,1413,1414,1415,1416,1417,1418,1419,1420],{"trials":1494,"activeCount":100},[],{"trials":1496,"activeCount":100},[],{"trials":1498,"activeCount":100},[],{"trials":1500,"activeCount":100},[],{"intervention":1417,"totalTrials":183,"cells":1502},{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1511,"PHASE3":1513,"PHASE4":1515,"NA":1517},{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":183,"soonestReadout":1408},[1507],{"nctId":1405,"briefTitle":1406,"status":449,"phases":1508,"primaryCompletion":1408,"completion":1408,"start":62,"enrollment":1409,"conditions":1509,"interventions":1510},[88],[1411],[1398,1413,1414,1415,1416,1417,1418,1419,1420],{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[],{"trials":1516,"activeCount":100},[],{"trials":1518,"activeCount":100},[],{"intervention":1418,"totalTrials":183,"cells":1520},{"EARLY_PHASE1":1521,"PHASE1":1523,"PHASE2":1529,"PHASE3":1531,"PHASE4":1533,"NA":1535},{"trials":1522,"activeCount":100},[],{"trials":1524,"activeCount":183,"soonestReadout":1408},[1525],{"nctId":1405,"briefTitle":1406,"status":449,"phases":1526,"primaryCompletion":1408,"completion":1408,"start":62,"enrollment":1409,"conditions":1527,"interventions":1528},[88],[1411],[1398,1413,1414,1415,1416,1417,1418,1419,1420],{"trials":1530,"activeCount":100},[],{"trials":1532,"activeCount":100},[],{"trials":1534,"activeCount":100},[],{"trials":1536,"activeCount":100},[],{"intervention":1419,"totalTrials":183,"cells":1538},{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1547,"PHASE3":1549,"PHASE4":1551,"NA":1553},{"trials":1540,"activeCount":100},[],{"trials":1542,"activeCount":183,"soonestReadout":1408},[1543],{"nctId":1405,"briefTitle":1406,"status":449,"phases":1544,"primaryCompletion":1408,"completion":1408,"start":62,"enrollment":1409,"conditions":1545,"interventions":1546},[88],[1411],[1398,1413,1414,1415,1416,1417,1418,1419,1420],{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":100},[],{"trials":1552,"activeCount":100},[],{"trials":1554,"activeCount":100},[],{"intervention":1420,"totalTrials":183,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1565,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1558,"activeCount":100},[],{"trials":1560,"activeCount":183,"soonestReadout":1408},[1561],{"nctId":1405,"briefTitle":1406,"status":449,"phases":1562,"primaryCompletion":1408,"completion":1408,"start":62,"enrollment":1409,"conditions":1563,"interventions":1564},[88],[1411],[1398,1413,1414,1415,1416,1417,1418,1419,1420],{"trials":1566,"activeCount":100},[],{"trials":1568,"activeCount":100},[],{"trials":1570,"activeCount":100},[],{"trials":1572,"activeCount":100},[],{"intervention":1231,"totalTrials":183,"cells":1574},{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1583,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1576,"activeCount":100},[],{"trials":1578,"activeCount":183,"soonestReadout":205},[1579],{"nctId":1223,"briefTitle":1224,"status":112,"phases":1580,"primaryCompletion":205,"completion":1226,"start":1227,"enrollment":194,"conditions":1581,"interventions":1582},[88],[1229],[1231,1232,1185],{"trials":1584,"activeCount":100},[],{"trials":1586,"activeCount":100},[],{"trials":1588,"activeCount":100},[],{"trials":1590,"activeCount":100},[],{"intervention":1232,"totalTrials":183,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1601,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1594,"activeCount":100},[],{"trials":1596,"activeCount":183,"soonestReadout":205},[1597],{"nctId":1223,"briefTitle":1224,"status":112,"phases":1598,"primaryCompletion":205,"completion":1226,"start":1227,"enrollment":194,"conditions":1599,"interventions":1600},[88],[1229],[1231,1232,1185],{"trials":1602,"activeCount":100},[],{"trials":1604,"activeCount":100},[],{"trials":1606,"activeCount":100},[],{"trials":1608,"activeCount":100},[],{"intervention":1610,"totalTrials":183,"cells":1611},"Caffeine citrate 20 mg\u002Fkg",{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1626,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":183,"soonestReadout":205},[1616],{"nctId":1617,"briefTitle":1618,"status":112,"phases":1619,"primaryCompletion":205,"completion":1620,"start":1621,"enrollment":572,"conditions":1622,"interventions":1624},"NCT06448780","Dose Optimization of Caffeine for HIE",[88],"2028-11","2024-07-26",[1623],"Hypoxic-Ischemic Encephalopathy",[1610,1625],"Caffeine citrate 30 mg\u002Fkg",{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[],{"trials":1631,"activeCount":100},[],{"trials":1633,"activeCount":100},[],{"intervention":1625,"totalTrials":183,"cells":1635},{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1644,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1637,"activeCount":100},[],{"trials":1639,"activeCount":183,"soonestReadout":205},[1640],{"nctId":1617,"briefTitle":1618,"status":112,"phases":1641,"primaryCompletion":205,"completion":1620,"start":1621,"enrollment":572,"conditions":1642,"interventions":1643},[88],[1623],[1610,1625],{"trials":1645,"activeCount":100},[],{"trials":1647,"activeCount":100},[],{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"intervention":1653,"totalTrials":96,"cells":1654},"Dihydroartemisinin piperaquine",{"EARLY_PHASE1":1655,"PHASE1":1666,"PHASE2":1668,"PHASE3":1670,"PHASE4":1672,"NA":1674},{"trials":1656,"activeCount":183,"soonestReadout":451},[1657],{"nctId":1658,"briefTitle":1659,"status":449,"phases":1660,"primaryCompletion":451,"completion":451,"start":1053,"enrollment":1661,"conditions":1662,"interventions":1664},"NCT07021430","Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy",[87],300,[1663],"Malaria Prevention",[1665],"Dihydroartemisinin Piperaquine",{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":100},[],{"trials":1671,"activeCount":100},[],{"trials":1673,"activeCount":100},[],{"trials":1675,"activeCount":183,"soonestReadout":1680},[1676],{"nctId":1677,"briefTitle":1678,"status":173,"phases":1679,"primaryCompletion":1680,"completion":1680,"start":1681,"enrollment":1682,"conditions":1683,"interventions":1686},"NCT06870344","IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding",[92],"2026-07-01","2025-03-12",36000,[1684,1685],"Malaria Infection","Malaria Falciparum",[1653,1687],"Dihydroartemisinin piperaquine + Bacillus thuringiensis israelensis",{"intervention":68,"totalTrials":96,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1696,"PHASE4":1698,"NA":1700},{"trials":1691,"activeCount":100},[],{"trials":1693,"activeCount":100},[],{"trials":1695,"activeCount":100},[],{"trials":1697,"activeCount":100},[],{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":96,"soonestReadout":67},[1702,1709],{"nctId":65,"briefTitle":66,"status":112,"phases":1703,"primaryCompletion":67,"completion":67,"start":1704,"enrollment":1409,"conditions":1705,"interventions":1708},[],"2021-01-20",[1706,1707],"Cystic Fibrosis","Ventilatory Defect",[68],{"nctId":74,"briefTitle":75,"status":112,"phases":1710,"primaryCompletion":67,"completion":67,"start":1711,"enrollment":165,"conditions":1712,"interventions":1714},[],"2025-06-16",[1713],"Cystic Fibrosis in Children",[68],{"intervention":1687,"totalTrials":183,"cells":1716},{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1723,"PHASE4":1725,"NA":1727},{"trials":1718,"activeCount":100},[],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[],{"trials":1724,"activeCount":100},[],{"trials":1726,"activeCount":100},[],{"trials":1728,"activeCount":183,"soonestReadout":1680},[1729],{"nctId":1677,"briefTitle":1678,"status":173,"phases":1730,"primaryCompletion":1680,"completion":1680,"start":1681,"enrollment":1682,"conditions":1731,"interventions":1732},[92],[1684,1685],[1653,1687],{"intervention":1734,"totalTrials":183,"cells":1735},"Bupivacaine HCl 0.5% Injectable Solution",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1737,"activeCount":100},[],{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":100},[],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":183,"soonestReadout":1752},[1748],{"nctId":1749,"briefTitle":1750,"status":112,"phases":1751,"primaryCompletion":1752,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1758},"NCT07216820","Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure",[92],"2027-11-01","2027-11-15","2026-01-21",68,[1757,18],"Shoulder Surgery",[1734,1759],"Dexamethasone 4mg",{"intervention":1759,"totalTrials":183,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1763,"activeCount":100},[],{"trials":1765,"activeCount":100},[],{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[],{"trials":1771,"activeCount":100},[],{"trials":1773,"activeCount":183,"soonestReadout":1752},[1774],{"nctId":1749,"briefTitle":1750,"status":112,"phases":1775,"primaryCompletion":1752,"completion":1753,"start":1754,"enrollment":1755,"conditions":1776,"interventions":1777},[92],[1757,18],[1734,1759],{"intervention":1779,"totalTrials":1186,"cells":1780},"Metformin",{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1819,"PHASE4":1831,"NA":1844},{"trials":1782,"activeCount":100},[],{"trials":1784,"activeCount":100},[],{"trials":1786,"activeCount":100},[1787,1798,1807],{"nctId":1788,"briefTitle":1789,"status":149,"phases":1790,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1793,"conditions":1794,"interventions":1796},"NCT00617240","Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth",[89],"2012-10","2007-01",9,[1795],"Weight Gain",[1797],"metformin",{"nctId":1799,"briefTitle":1800,"status":731,"phases":1801,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":183,"conditions":1805,"interventions":1806},"NCT00617058","Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine",[89],"2010-06","2010-09","2007-03",[1795],[1797],{"nctId":1808,"briefTitle":1809,"status":149,"phases":1810,"primaryCompletion":1811,"completion":1177,"start":1812,"enrollment":1813,"conditions":1814,"interventions":1817},"NCT00835861","Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes",[89],"2010-02","2008-08",31,[1815,1816],"Non Insulin Dependent Diabetes","Pregnancy",[1779,1818],"Insulin",{"trials":1820,"activeCount":100},[1821],{"nctId":1822,"briefTitle":1823,"status":731,"phases":1824,"primaryCompletion":1825,"completion":1825,"start":1826,"enrollment":1827,"conditions":1828,"interventions":1830},"NCT02932475","Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)",[90],"2022-06-15","2017-05-25",831,[1829,1816],"Diabetes",[1779],{"trials":1832,"activeCount":100},[1833],{"nctId":1834,"briefTitle":1835,"status":731,"phases":1836,"primaryCompletion":1837,"completion":1837,"start":1838,"enrollment":1839,"conditions":1840,"interventions":1842},"NCT02796144","MEtformin and Lorcaserin for WeighT Loss in Schizophrenia",[91],"2020-02-14","2016-09",71,[33,1841,36],"Schizoaffective Disorder",[1843,1779],"Lorcaserin",{"trials":1845,"activeCount":100},[],{"intervention":1847,"totalTrials":233,"cells":1848},"Minocycline",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1882,"PHASE4":1884,"NA":1896},{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":100},[1855,1870],{"nctId":1856,"briefTitle":1857,"status":731,"phases":1858,"primaryCompletion":1859,"completion":1860,"start":1178,"enrollment":1861,"conditions":1862,"interventions":1864},"NCT01349192","Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)",[89],"2015-01","2015-05",47,[1706,1863],"Methicillin-resistant Staphylococcus Aureus",[1865,1866,1847,1867,1868,1869],"Rifampin","Trimethoprim\u002FSulfamethoxazole","Mupirocin","chlorhexidine gluconate oral rinse","2% Chlorhexidine solution wipes",{"nctId":1871,"briefTitle":1872,"status":149,"phases":1873,"primaryCompletion":1874,"completion":1875,"start":1876,"enrollment":1877,"conditions":1878,"interventions":1879},"NCT03489629","STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)",[89],"2025-09-30","2026-01-31","2018-04-03",37,[1706],[1880,1847,1867,1881],"Trimethoprim Sulfamethoxazole","Chlorhexidine Gluconate",{"trials":1883,"activeCount":100},[],{"trials":1885,"activeCount":100},[1886],{"nctId":1887,"briefTitle":1888,"status":149,"phases":1889,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":247,"conditions":1892,"interventions":1895},"NCT06044090","Brain and Stress Study",[91],"2023-12-19","2022-09-12",[1893,1894],"Stress, Psychological","Motivation",[1847],{"trials":1897,"activeCount":100},[],{"intervention":251,"totalTrials":233,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1910,"PHASE4":1922,"NA":1928},{"trials":1901,"activeCount":100},[],{"trials":1903,"activeCount":100},[],{"trials":1905,"activeCount":100},[1906],{"nctId":242,"briefTitle":243,"status":149,"phases":1907,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":1908,"interventions":1909},[89],[249],[251,232,252],{"trials":1911,"activeCount":100},[1912],{"nctId":1913,"briefTitle":1914,"status":149,"phases":1915,"primaryCompletion":1218,"completion":1218,"start":1916,"enrollment":1917,"conditions":1918,"interventions":1921},"NCT01308814","Perimenopausal Estrogen Replacement Therapy Study",[89,90],"2010-10",172,[1919,1920,27],"Perimenopause","Menopause",[251],{"trials":1923,"activeCount":100},[1924],{"nctId":746,"briefTitle":747,"status":149,"phases":1925,"primaryCompletion":164,"completion":164,"start":749,"enrollment":750,"conditions":1926,"interventions":1927},[91],[752],[251,120],{"trials":1929,"activeCount":100},[],{"intervention":1931,"totalTrials":233,"cells":1932},"Etravirine",{"EARLY_PHASE1":1933,"PHASE1":1935,"PHASE2":1947,"PHASE3":1959,"PHASE4":1961,"NA":1973},{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[1937],{"nctId":1938,"briefTitle":1939,"status":149,"phases":1940,"primaryCompletion":1811,"completion":289,"start":291,"enrollment":1941,"conditions":1942,"interventions":1944},"NCT00855088","Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue",[88],13,[1943,21],"HIV\u002FAIDS",[1945,1946,1931],"darunavir","Ritonavir",{"trials":1948,"activeCount":100},[1949],{"nctId":1950,"briefTitle":1951,"status":149,"phases":1952,"primaryCompletion":1953,"completion":1954,"start":1179,"enrollment":1955,"conditions":1956,"interventions":1957},"NCT00959894","Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection",[89],"2014-02","2014-05",80,[21],[1931,1958],"Truvada",{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[1963],{"nctId":1964,"briefTitle":1965,"status":731,"phases":1966,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":165,"conditions":1969,"interventions":1971},"NCT00855413","HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir\u002FRitonavir and Etravirine",[91],"2013-11","2009-03",[1970,21],"Acute HIV Infection",[1972,1946,1931],"Darunavir",{"trials":1974,"activeCount":100},[],{"intervention":1976,"totalTrials":96,"cells":1977},"Gabapentin",{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1986,"NA":2010},{"trials":1979,"activeCount":100},[],{"trials":1981,"activeCount":100},[],{"trials":1983,"activeCount":100},[],{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":100},[1988,1997],{"nctId":1989,"briefTitle":1990,"status":149,"phases":1991,"primaryCompletion":1992,"completion":1992,"start":1993,"enrollment":292,"conditions":1994,"interventions":1996},"NCT03123861","Gabapentin for Postop Pain After SSLF",[91],"2020-07-25","2017-06-01",[1995],"Pelvic Organ Prolapse",[1976],{"nctId":1998,"briefTitle":1999,"status":301,"phases":2000,"primaryCompletion":2001,"completion":2001,"start":2002,"enrollment":100,"conditions":2003,"interventions":2005},"NCT02160301","Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients",[91],"2019-12","2017-11",[2004],"Post Operative Pain Control",[1976,2006,2006,2007,2008,2009],"Acetaminophen","Celecoxib","Dexamethasone","Oxycodone",{"trials":2011,"activeCount":100},[],{"intervention":2013,"totalTrials":96,"cells":2014},"Meningococcal Group B Vaccine",{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2037,"PHASE4":2039,"NA":2051},{"trials":2016,"activeCount":100},[],{"trials":2018,"activeCount":100},[],{"trials":2020,"activeCount":100},[2021],{"nctId":2022,"briefTitle":2023,"status":149,"phases":2024,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2030},"NCT05294588","Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae",[89],"2026-02-05","2022-04-18",65,[2029],"Gonorrhea Male",[2031,2032,2033,2034,2013,2035,2036],"Cefixime","Ceftriaxone","Ciprofloxacin","Neisseria gonorrhoeae strain FA1090","Influenza Vaccine","Tetanus-diptheria Vaccine",{"trials":2038,"activeCount":100},[],{"trials":2040,"activeCount":100},[2041],{"nctId":2042,"briefTitle":2043,"status":149,"phases":2044,"primaryCompletion":2045,"completion":2045,"start":2046,"enrollment":2047,"conditions":2048,"interventions":2050},"NCT04094883","Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine",[91],"2020-09-01","2019-10-09",11,[2049],"Neisseria Gonorrhoeae Infection",[2013],{"trials":2052,"activeCount":100},[],{"intervention":2035,"totalTrials":96,"cells":2054},{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2065,"PHASE4":2067,"NA":2083},{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[],{"trials":2060,"activeCount":100},[2061],{"nctId":2022,"briefTitle":2023,"status":149,"phases":2062,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":2063,"interventions":2064},[89],[2029],[2031,2032,2033,2034,2013,2035,2036],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":100},[2069],{"nctId":2070,"briefTitle":2071,"status":149,"phases":2072,"primaryCompletion":2073,"completion":2073,"start":2074,"enrollment":2075,"conditions":2076,"interventions":2081},"NCT05654441","Body and Social Behavior",[91],"2023-12-15","2022-10-17",104,[2077,2078,2079,2080],"Psychology, Social","Inflammation","Defeat, Social","Interaction, Social",[2082],"Influenza vaccine",{"trials":2084,"activeCount":100},[],{"intervention":2086,"totalTrials":96,"cells":2087},"Morphine",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2120},{"trials":2089,"activeCount":100},[],{"trials":2091,"activeCount":100},[2092],{"nctId":2093,"briefTitle":2094,"status":149,"phases":2095,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":34,"conditions":2099,"interventions":2101},"NCT01766960","Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease",[88],"2014-03","2014-06","2012-11",[2100],"Fatty Liver",[2086],{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":100},[],{"trials":2107,"activeCount":100},[2108],{"nctId":2109,"briefTitle":2110,"status":301,"phases":2111,"primaryCompletion":2112,"completion":2112,"start":2113,"enrollment":100,"conditions":2114,"interventions":2116},"NCT06784180","Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine",[91],"2029-01","2026-02",[2115],"Opioid Use Disorder",[2086,2117,2118,2119],"Bupivacaine","Fentanyl","Hydromorphone",{"trials":2121,"activeCount":100},[],{"intervention":2123,"totalTrials":96,"cells":2124},"Estradiol Patch, 0.1 mg\u002F24 Hours Weekly Transdermal Film, Extended Release",{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2131,"PHASE4":2133,"NA":2149},{"trials":2126,"activeCount":100},[],{"trials":2128,"activeCount":100},[],{"trials":2130,"activeCount":100},[],{"trials":2132,"activeCount":100},[],{"trials":2134,"activeCount":100},[2135,2145],{"nctId":2136,"briefTitle":2137,"status":149,"phases":2138,"primaryCompletion":2139,"completion":2140,"start":1825,"enrollment":869,"conditions":2141,"interventions":2143},"NCT05388656","Estrogen Variability and Irritability During the Menopause Transition",[91],"2024-12-17","2025-01-17",[1920,2142],"Irritable Mood",[2123,2144],"Progesterone 200 mg",{"nctId":729,"briefTitle":730,"status":731,"phases":2146,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":2147,"interventions":2148},[91],[737,738],[740,120],{"trials":2150,"activeCount":100},[],{"intervention":2152,"totalTrials":96,"cells":2153},"Recombivax",{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2171,"PHASE4":2173,"NA":2187},{"trials":2155,"activeCount":100},[],{"trials":2157,"activeCount":100},[],{"trials":2159,"activeCount":100},[2160],{"nctId":2161,"briefTitle":2162,"status":149,"phases":2163,"primaryCompletion":2164,"completion":2164,"start":2165,"enrollment":2166,"conditions":2167,"interventions":2169},"NCT00107042","Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths",[89],"2008-07","2004-02",123,[2168],"Hepatitis B",[2152,2170],"Twinrix",{"trials":2172,"activeCount":100},[],{"trials":2174,"activeCount":100},[2175],{"nctId":2176,"briefTitle":2177,"status":149,"phases":2178,"primaryCompletion":2179,"completion":2179,"start":2180,"enrollment":2181,"conditions":2182,"interventions":2183},"NCT00142753","Immunologic Memory (Supp. of ATN 024)",[91],"2007-11","2005-08",95,[21],[2184,2185,2152,2186],"Engerix B","Twinrix for ATN 024","Twinrix for ATN 025",{"trials":2188,"activeCount":100},[],{"intervention":2190,"totalTrials":96,"cells":2191},"acamprosate",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2198,"PHASE4":2211,"NA":2222},{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[],{"trials":2199,"activeCount":100},[2200],{"nctId":2201,"briefTitle":2202,"status":149,"phases":2203,"completion":2204,"start":2205,"enrollment":2206,"conditions":2207,"interventions":2209},"NCT00006206","COMBINE (Acamprosate\u002FNaltrexone)",[90],"2006-05","1997-08",1375,[2208],"Alcoholism",[2210,2190],"naltrexone",{"trials":2212,"activeCount":100},[2213],{"nctId":2214,"briefTitle":2215,"status":149,"phases":2216,"primaryCompletion":2164,"completion":2164,"start":2217,"enrollment":805,"conditions":2218,"interventions":2220},"NCT00381043","Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic",[91],"2006-08",[2219],"Alcohol Dependence",[2221],"Acamprosate",{"trials":2223,"activeCount":100},[],{"intervention":1972,"totalTrials":96,"cells":2225},{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2234,"PHASE3":2236,"PHASE4":2238,"NA":2244},{"trials":2227,"activeCount":100},[],{"trials":2229,"activeCount":100},[2230],{"nctId":1938,"briefTitle":1939,"status":149,"phases":2231,"primaryCompletion":1811,"completion":289,"start":291,"enrollment":1941,"conditions":2232,"interventions":2233},[88],[1943,21],[1945,1946,1931],{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[],{"trials":2239,"activeCount":100},[2240],{"nctId":1964,"briefTitle":1965,"status":731,"phases":2241,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":165,"conditions":2242,"interventions":2243},[91],[1970,21],[1972,1946,1931],{"trials":2245,"activeCount":100},[],{"intervention":2247,"totalTrials":183,"cells":2248},"Contraceptive implant",{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2255,"PHASE4":2257,"NA":2271},{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"trials":2254,"activeCount":100},[],{"trials":2256,"activeCount":100},[],{"trials":2258,"activeCount":100},[2259],{"nctId":2260,"briefTitle":2261,"status":149,"phases":2262,"primaryCompletion":2263,"completion":2263,"start":2264,"enrollment":2265,"conditions":2266,"interventions":2270},"NCT01666912","Postpartum Etonogestrel Implant for Adolescents",[91],"2015-04","2012-08",96,[2267,2268,2269],"Adolescence","Contraception","Postpartum",[2247],{"trials":2272,"activeCount":100},[],{"intervention":2274,"totalTrials":183,"cells":2275},"Tenofovir Disoproxil Fumarate 300 MG",{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2280,"PHASE3":2282,"PHASE4":2284,"NA":2297},{"trials":2277,"activeCount":100},[],{"trials":2279,"activeCount":100},[],{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[2286],{"nctId":2287,"briefTitle":2288,"status":149,"phases":2289,"primaryCompletion":2290,"completion":2290,"start":2291,"enrollment":2292,"conditions":2293,"interventions":2295},"NCT05705427","The COMBAT HBV Feasibility Trial",[91],"2025-11-25","2023-08-17",317,[2168,2294],"Vertical Transmission of Infectious Disease",[2274,2296],"Hepatitis B monovalent vaccine",{"trials":2298,"activeCount":100},[],{"intervention":2296,"totalTrials":183,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2307,"PHASE4":2309,"NA":2315},{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[],{"trials":2306,"activeCount":100},[],{"trials":2308,"activeCount":100},[],{"trials":2310,"activeCount":100},[2311],{"nctId":2287,"briefTitle":2288,"status":149,"phases":2312,"primaryCompletion":2290,"completion":2290,"start":2291,"enrollment":2292,"conditions":2313,"interventions":2314},[91],[2168,2294],[2274,2296],{"trials":2316,"activeCount":100},[],{"intervention":2318,"totalTrials":183,"cells":2319},"Sodium ferric gluconate",{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2324,"PHASE3":2326,"PHASE4":2328,"NA":2339},{"trials":2321,"activeCount":100},[],{"trials":2323,"activeCount":100},[],{"trials":2325,"activeCount":100},[],{"trials":2327,"activeCount":100},[],{"trials":2329,"activeCount":100},[2330],{"nctId":2331,"briefTitle":2332,"status":149,"phases":2333,"primaryCompletion":2334,"completion":2334,"start":1178,"enrollment":1941,"conditions":2335,"interventions":2338},"NCT01925703","Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure",[91],"2013-12",[2336,2337],"Heart Failure","Iron Deficiency Anemia",[2318],{"trials":2340,"activeCount":100},[],{"intervention":2342,"totalTrials":183,"cells":2343},"Levonorgestrel Intrauterine System",{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2350,"PHASE4":2352,"NA":2362},{"trials":2345,"activeCount":100},[],{"trials":2347,"activeCount":100},[],{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[2354],{"nctId":2355,"briefTitle":2356,"status":149,"phases":2357,"primaryCompletion":224,"completion":224,"start":2358,"enrollment":453,"conditions":2359,"interventions":2361},"NCT02121067","LNG-IUS at 2 Weeks Postpartum",[91],"2014-09",[2268,2360],"Malposition of Intrauterine Contraceptive Device",[2342],{"trials":2363,"activeCount":100},[],{"intervention":2365,"totalTrials":183,"cells":2366},"Addition of oral Metolazone",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2375,"NA":2388},{"trials":2368,"activeCount":100},[],{"trials":2370,"activeCount":100},[],{"trials":2372,"activeCount":100},[],{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":100},[2377],{"nctId":2378,"briefTitle":2379,"status":731,"phases":2380,"primaryCompletion":2381,"completion":2382,"start":2383,"enrollment":2047,"conditions":2384,"interventions":2386},"NCT00904488","Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure",[91],"2016-05-28","2017-11-14","2008-10",[2385],"Acute Decompensated Heart Failure",[2365,2387],"Furosemide dose escalation",{"trials":2389,"activeCount":100},[],{"intervention":2387,"totalTrials":183,"cells":2391},{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2396,"PHASE3":2398,"PHASE4":2400,"NA":2406},{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":100},[],{"trials":2399,"activeCount":100},[],{"trials":2401,"activeCount":100},[2402],{"nctId":2378,"briefTitle":2379,"status":731,"phases":2403,"primaryCompletion":2381,"completion":2382,"start":2383,"enrollment":2047,"conditions":2404,"interventions":2405},[91],[2385],[2365,2387],{"trials":2407,"activeCount":100},[],{"intervention":2409,"totalTrials":183,"cells":2410},"Engerix-B 20 mcg",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2417,"PHASE4":2419,"NA":2433},{"trials":2412,"activeCount":100},[],{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":100},[],{"trials":2418,"activeCount":100},[],{"trials":2420,"activeCount":100},[2421],{"nctId":2422,"briefTitle":2423,"status":149,"phases":2424,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":2428,"conditions":2429,"interventions":2430},"NCT00106964","Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth",[91],"2008-01","2009-06","2004-01",371,[30,2168],[2409,2431,2432],"Engerix-B 40 mcg","Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg",{"trials":2434,"activeCount":100},[],{"intervention":2431,"totalTrials":183,"cells":2436},{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2441,"PHASE3":2443,"PHASE4":2445,"NA":2451},{"trials":2438,"activeCount":100},[],{"trials":2440,"activeCount":100},[],{"trials":2442,"activeCount":100},[],{"trials":2444,"activeCount":100},[],{"trials":2446,"activeCount":100},[2447],{"nctId":2422,"briefTitle":2423,"status":149,"phases":2448,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":2428,"conditions":2449,"interventions":2450},[91],[30,2168],[2409,2431,2432],{"trials":2452,"activeCount":100},[],{"intervention":2432,"totalTrials":183,"cells":2454},{"EARLY_PHASE1":2455,"PHASE1":2457,"PHASE2":2459,"PHASE3":2461,"PHASE4":2463,"NA":2469},{"trials":2456,"activeCount":100},[],{"trials":2458,"activeCount":100},[],{"trials":2460,"activeCount":100},[],{"trials":2462,"activeCount":100},[],{"trials":2464,"activeCount":100},[2465],{"nctId":2422,"briefTitle":2423,"status":149,"phases":2466,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":2428,"conditions":2467,"interventions":2468},[91],[30,2168],[2409,2431,2432],{"trials":2470,"activeCount":100},[],{"intervention":2117,"totalTrials":183,"cells":2472},{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2487},{"trials":2474,"activeCount":100},[],{"trials":2476,"activeCount":100},[],{"trials":2478,"activeCount":100},[],{"trials":2480,"activeCount":100},[],{"trials":2482,"activeCount":100},[2483],{"nctId":2109,"briefTitle":2110,"status":301,"phases":2484,"primaryCompletion":2112,"completion":2112,"start":2113,"enrollment":100,"conditions":2485,"interventions":2486},[91],[2115],[2086,2117,2118,2119],{"trials":2488,"activeCount":100},[],{"intervention":2118,"totalTrials":183,"cells":2490},{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2495,"PHASE3":2497,"PHASE4":2499,"NA":2505},{"trials":2492,"activeCount":100},[],{"trials":2494,"activeCount":100},[],{"trials":2496,"activeCount":100},[],{"trials":2498,"activeCount":100},[],{"trials":2500,"activeCount":100},[2501],{"nctId":2109,"briefTitle":2110,"status":301,"phases":2502,"primaryCompletion":2112,"completion":2112,"start":2113,"enrollment":100,"conditions":2503,"interventions":2504},[91],[2115],[2086,2117,2118,2119],{"trials":2506,"activeCount":100},[],{"intervention":2119,"totalTrials":183,"cells":2508},{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2515,"PHASE4":2517,"NA":2523},{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[2519],{"nctId":2109,"briefTitle":2110,"status":301,"phases":2520,"primaryCompletion":2112,"completion":2112,"start":2113,"enrollment":100,"conditions":2521,"interventions":2522},[91],[2115],[2086,2117,2118,2119],{"trials":2524,"activeCount":100},[],{"intervention":2144,"totalTrials":183,"cells":2526},{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2535,"NA":2541},{"trials":2528,"activeCount":100},[],{"trials":2530,"activeCount":100},[],{"trials":2532,"activeCount":100},[],{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[2537],{"nctId":2136,"briefTitle":2137,"status":149,"phases":2538,"primaryCompletion":2139,"completion":2140,"start":1825,"enrollment":869,"conditions":2539,"interventions":2540},[91],[1920,2142],[2123,2144],{"trials":2542,"activeCount":100},[],{"intervention":2544,"totalTrials":183,"cells":2545},"Maraviroc Pill",{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2552,"PHASE4":2554,"NA":2567},{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[],{"trials":2551,"activeCount":100},[],{"trials":2553,"activeCount":100},[],{"trials":2555,"activeCount":100},[2556],{"nctId":2557,"briefTitle":2558,"status":149,"phases":2559,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":762,"conditions":2563,"interventions":2564},"NCT03218592","ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence",[91],"2018-12-03","2018-12-07","2017-06-28",[1943],[2544,2565,2566],"Dolutegravir Pill","Truvada Pill",{"trials":2568,"activeCount":100},[],{"intervention":2565,"totalTrials":183,"cells":2570},{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2577,"PHASE4":2579,"NA":2585},{"trials":2572,"activeCount":100},[],{"trials":2574,"activeCount":100},[],{"trials":2576,"activeCount":100},[],{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[2581],{"nctId":2557,"briefTitle":2558,"status":149,"phases":2582,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":762,"conditions":2583,"interventions":2584},[91],[1943],[2544,2565,2566],{"trials":2586,"activeCount":100},[],{"intervention":2566,"totalTrials":183,"cells":2588},{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2595,"PHASE4":2597,"NA":2603},{"trials":2590,"activeCount":100},[],{"trials":2592,"activeCount":100},[],{"trials":2594,"activeCount":100},[],{"trials":2596,"activeCount":100},[],{"trials":2598,"activeCount":100},[2599],{"nctId":2557,"briefTitle":2558,"status":149,"phases":2600,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":762,"conditions":2601,"interventions":2602},[91],[1943],[2544,2565,2566],{"trials":2604,"activeCount":100},[],{"intervention":2606,"totalTrials":183,"cells":2607},"Vaginal Progesterone",{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2612,"PHASE3":2614,"PHASE4":2616,"NA":2628},{"trials":2609,"activeCount":100},[],{"trials":2611,"activeCount":100},[],{"trials":2613,"activeCount":100},[],{"trials":2615,"activeCount":100},[],{"trials":2617,"activeCount":100},[2618],{"nctId":2619,"briefTitle":2620,"status":149,"phases":2621,"primaryCompletion":2622,"completion":2622,"start":2623,"enrollment":2624,"conditions":2625,"interventions":2627},"NCT02970552","Feasibility of Vaginal Progesterone to Reduce HIV-Associated Preterm Birth",[91],"2018-11-13","2017-07-01",140,[2626],"PreTerm Birth",[2606],{"trials":2629,"activeCount":100},[],{"intervention":2631,"totalTrials":183,"cells":2632},"1% Buffered Lidocaine 1:100,000 Epinephrine",{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2641,"NA":2653},{"trials":2634,"activeCount":100},[],{"trials":2636,"activeCount":100},[],{"trials":2638,"activeCount":100},[],{"trials":2640,"activeCount":100},[],{"trials":2642,"activeCount":100},[2643],{"nctId":2644,"briefTitle":2645,"status":149,"phases":2646,"primaryCompletion":2647,"completion":2647,"start":2648,"enrollment":28,"conditions":2649,"interventions":2651},"NCT03562481","Clinical Trial Comparing Effectiveness of Buffered Versus Unbuffered Local Anesthetic in Children Ages 10-12 Years",[91],"2019-06-30","2018-07-24",[2650,295],"Anesthesia, Local",[2631,2652],"2% Unbuffered Lidocaine 1:100,000 Epinephrine",{"trials":2654,"activeCount":100},[],{"intervention":2652,"totalTrials":183,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2663,"PHASE4":2665,"NA":2671},{"trials":2658,"activeCount":100},[],{"trials":2660,"activeCount":100},[],{"trials":2662,"activeCount":100},[],{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":100},[2667],{"nctId":2644,"briefTitle":2645,"status":149,"phases":2668,"primaryCompletion":2647,"completion":2647,"start":2648,"enrollment":28,"conditions":2669,"interventions":2670},[91],[2650,295],[2631,2652],{"trials":2672,"activeCount":100},[],{"intervention":2184,"totalTrials":183,"cells":2674},{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2679,"PHASE3":2681,"PHASE4":2683,"NA":2689},{"trials":2676,"activeCount":100},[],{"trials":2678,"activeCount":100},[],{"trials":2680,"activeCount":100},[],{"trials":2682,"activeCount":100},[],{"trials":2684,"activeCount":100},[2685],{"nctId":2176,"briefTitle":2177,"status":149,"phases":2686,"primaryCompletion":2179,"completion":2179,"start":2180,"enrollment":2181,"conditions":2687,"interventions":2688},[91],[21],[2184,2185,2152,2186],{"trials":2690,"activeCount":100},[],{"intervention":2185,"totalTrials":183,"cells":2692},{"EARLY_PHASE1":2693,"PHASE1":2695,"PHASE2":2697,"PHASE3":2699,"PHASE4":2701,"NA":2707},{"trials":2694,"activeCount":100},[],{"trials":2696,"activeCount":100},[],{"trials":2698,"activeCount":100},[],{"trials":2700,"activeCount":100},[],{"trials":2702,"activeCount":100},[2703],{"nctId":2176,"briefTitle":2177,"status":149,"phases":2704,"primaryCompletion":2179,"completion":2179,"start":2180,"enrollment":2181,"conditions":2705,"interventions":2706},[91],[21],[2184,2185,2152,2186],{"trials":2708,"activeCount":100},[],{"intervention":2186,"totalTrials":183,"cells":2710},{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2717,"PHASE4":2719,"NA":2725},{"trials":2712,"activeCount":100},[],{"trials":2714,"activeCount":100},[],{"trials":2716,"activeCount":100},[],{"trials":2718,"activeCount":100},[],{"trials":2720,"activeCount":100},[2721],{"nctId":2176,"briefTitle":2177,"status":149,"phases":2722,"primaryCompletion":2179,"completion":2179,"start":2180,"enrollment":2181,"conditions":2723,"interventions":2724},[91],[21],[2184,2185,2152,2186],{"trials":2726,"activeCount":100},[],{"intervention":2728,"totalTrials":183,"cells":2729},"Oral Viscous Budesonide",{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2736,"PHASE4":2738,"NA":2751},{"trials":2731,"activeCount":100},[],{"trials":2733,"activeCount":100},[],{"trials":2735,"activeCount":100},[],{"trials":2737,"activeCount":100},[],{"trials":2739,"activeCount":100},[2740],{"nctId":2741,"briefTitle":2742,"status":149,"phases":2743,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":2748,"interventions":2749},"NCT02019758","Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis",[91],"2018-05","2019-04","2015-01-01",129,[339],[2728,2750],"Fluticasone MDI",{"trials":2752,"activeCount":100},[],{"intervention":2750,"totalTrials":183,"cells":2754},{"EARLY_PHASE1":2755,"PHASE1":2757,"PHASE2":2759,"PHASE3":2761,"PHASE4":2763,"NA":2769},{"trials":2756,"activeCount":100},[],{"trials":2758,"activeCount":100},[],{"trials":2760,"activeCount":100},[],{"trials":2762,"activeCount":100},[],{"trials":2764,"activeCount":100},[2765],{"nctId":2741,"briefTitle":2742,"status":149,"phases":2766,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":2767,"interventions":2768},[91],[339],[2728,2750],{"trials":2770,"activeCount":100},[],{"intervention":2772,"totalTrials":183,"cells":2773},"Continuous OC",{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2793},{"trials":2775,"activeCount":100},[],{"trials":2777,"activeCount":100},[],{"trials":2779,"activeCount":100},[],{"trials":2781,"activeCount":100},[],{"trials":2783,"activeCount":100},[2784],{"nctId":2785,"briefTitle":2786,"status":149,"phases":2787,"primaryCompletion":2788,"completion":2788,"start":2164,"enrollment":11,"conditions":2789,"interventions":2791},"NCT00927095","Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)",[91],"2014-07",[2790],"Premenstrual Dysphoric Disorder",[2772,2792],"Intermittent OC",{"trials":2794,"activeCount":100},[],{"intervention":2792,"totalTrials":183,"cells":2796},{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2803,"PHASE4":2805,"NA":2811},{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[2807],{"nctId":2785,"briefTitle":2786,"status":149,"phases":2808,"primaryCompletion":2788,"completion":2788,"start":2164,"enrollment":11,"conditions":2809,"interventions":2810},[91],[2790],[2772,2792],{"trials":2812,"activeCount":100},[],{"intervention":2814,"totalTrials":183,"cells":2815},"Molindone",{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2822,"PHASE4":2824,"NA":2837},{"trials":2817,"activeCount":100},[],{"trials":2819,"activeCount":100},[],{"trials":2821,"activeCount":100},[],{"trials":2823,"activeCount":100},[],{"trials":2825,"activeCount":100},[2826],{"nctId":2827,"briefTitle":2828,"status":149,"phases":2829,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":2833,"interventions":2834},"NCT00053703","Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)",[91],"2007-05","2002-02",116,[33],[2835,2836,2814],"Risperidone","Olanzapine",{"trials":2838,"activeCount":100},[],{"intervention":2840,"totalTrials":183,"cells":2841},"Tetracaine HCl and oxymetazoline HCl nasal spray",{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2848,"PHASE4":2850,"NA":2865},{"trials":2843,"activeCount":100},[],{"trials":2845,"activeCount":100},[],{"trials":2847,"activeCount":100},[],{"trials":2849,"activeCount":100},[],{"trials":2851,"activeCount":100},[2852],{"nctId":2853,"briefTitle":2854,"status":301,"phases":2855,"primaryCompletion":2856,"completion":2857,"start":2858,"enrollment":100,"conditions":2859,"interventions":2864},"NCT03502135","Efficacy of Tetracaine\u002FOxymetazoline Nasal Spray for Endodontic Treatment",[91],"2019-06","2019-07","2018-09",[2860,2861,2862,2863],"Endodontic Disease","Endodontic Inflammation","Local Anesthesia","Dental Anesthesia",[2840],{"trials":2866,"activeCount":100},[],{"intervention":2868,"totalTrials":183,"cells":2869},"Levonorgestrel-releasing intrauterine system",{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2874,"PHASE3":2876,"PHASE4":2878,"NA":2890},{"trials":2871,"activeCount":100},[],{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[],{"trials":2877,"activeCount":100},[],{"trials":2879,"activeCount":100},[2880],{"nctId":2881,"briefTitle":2882,"status":149,"phases":2883,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":2886,"conditions":2887,"interventions":2889},"NCT01555931","Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding",[91],"2013-06","2012-03",61,[2888],"Postpartum Contraception",[2868],{"trials":2891,"activeCount":100},[],{"intervention":2893,"totalTrials":183,"cells":2894},"Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration",{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2901,"PHASE4":2903,"NA":2912},{"trials":2896,"activeCount":100},[],{"trials":2898,"activeCount":100},[],{"trials":2900,"activeCount":100},[],{"trials":2902,"activeCount":100},[],{"trials":2904,"activeCount":100},[2905],{"nctId":2906,"briefTitle":2907,"status":149,"phases":2908,"primaryCompletion":1916,"completion":2098,"start":2426,"enrollment":869,"conditions":2909,"interventions":2911},"NCT00997932","A Pilot Study of Early Postpartum Intrauterine Contraception",[91],[2910],"Unplanned Pregnancy",[2893],{"trials":2913,"activeCount":100},[],{"intervention":2915,"totalTrials":183,"cells":2916},"Hydrocortisone",{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2921,"PHASE3":2923,"PHASE4":2925,"NA":2936},{"trials":2918,"activeCount":100},[],{"trials":2920,"activeCount":100},[],{"trials":2922,"activeCount":100},[],{"trials":2924,"activeCount":100},[],{"trials":2926,"activeCount":100},[2927],{"nctId":2928,"briefTitle":2929,"status":301,"phases":2930,"primaryCompletion":2931,"completion":2931,"start":2932,"enrollment":100,"conditions":2933,"interventions":2935},"NCT06018727","Role Of Sensitivity to neuroEndocrine Systems in Social Decisions",[91],"2025-07","2024-07",[2934],"Borderline Personality Disorder",[2915],{"trials":2937,"activeCount":100},[],{"intervention":2939,"totalTrials":183,"cells":2940},"Trospium Chloride",{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2945,"PHASE3":2947,"PHASE4":2949,"NA":2962},{"trials":2942,"activeCount":100},[],{"trials":2944,"activeCount":100},[],{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[],{"trials":2950,"activeCount":100},[2951],{"nctId":2952,"briefTitle":2953,"status":149,"phases":2954,"primaryCompletion":2955,"completion":2955,"start":2884,"enrollment":2956,"conditions":2957,"interventions":2961},"NCT01922115","The Effect of Anticholinergics on Cognitive Function in the Elderly",[91],"2015-06",59,[2958,2959,2960],"Mental Competency","Urinary Bladder, Overactive","Cognitive Function",[2939],{"trials":2963,"activeCount":100},[],{"intervention":2965,"totalTrials":183,"cells":2966},"Sertraline",{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2973,"PHASE4":2975,"NA":2985},{"trials":2968,"activeCount":100},[],{"trials":2970,"activeCount":100},[],{"trials":2972,"activeCount":100},[],{"trials":2974,"activeCount":100},[],{"trials":2976,"activeCount":100},[2977],{"nctId":2978,"briefTitle":2979,"status":149,"phases":2980,"primaryCompletion":2981,"completion":2981,"start":2982,"enrollment":1955,"conditions":2983,"interventions":2984},"NCT04094870","A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women",[91],"2020-10-30","2019-10-30",[261,1411],[2965],{"trials":2986,"activeCount":100},[],{"intervention":2988,"totalTrials":183,"cells":2989},"Tacrolimus",{"EARLY_PHASE1":2990,"PHASE1":2992,"PHASE2":2994,"PHASE3":2996,"PHASE4":2998,"NA":3011},{"trials":2991,"activeCount":100},[],{"trials":2993,"activeCount":100},[],{"trials":2995,"activeCount":100},[],{"trials":2997,"activeCount":100},[],{"trials":2999,"activeCount":100},[3000],{"nctId":3001,"briefTitle":3002,"status":149,"phases":3003,"primaryCompletion":3004,"completion":3005,"start":3006,"enrollment":3007,"conditions":3008,"interventions":3010},"NCT03020589","Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients",[91],"2021-07-31","2022-06-28","2017-02-06",97,[3009],"Renal Transplant",[2988],{"trials":3012,"activeCount":100},[],{"intervention":3014,"totalTrials":183,"cells":3015},"Birth dose hepatitis B vaccine",{"EARLY_PHASE1":3016,"PHASE1":3018,"PHASE2":3020,"PHASE3":3022,"PHASE4":3024,"NA":3035},{"trials":3017,"activeCount":100},[],{"trials":3019,"activeCount":100},[],{"trials":3021,"activeCount":100},[],{"trials":3023,"activeCount":100},[],{"trials":3025,"activeCount":100},[3026],{"nctId":3027,"briefTitle":3028,"status":149,"phases":3029,"primaryCompletion":3030,"completion":3030,"start":3031,"enrollment":3032,"conditions":3033,"interventions":3034},"NCT03897946","Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC",[91],"2021-02-05","2019-08-20",569,[2168],[3014],{"trials":3036,"activeCount":100},[],{"intervention":3038,"totalTrials":183,"cells":3039},"Methylphenidate",{"EARLY_PHASE1":3040,"PHASE1":3042,"PHASE2":3044,"PHASE3":3046,"PHASE4":3048,"NA":3059},{"trials":3041,"activeCount":100},[],{"trials":3043,"activeCount":100},[],{"trials":3045,"activeCount":100},[],{"trials":3047,"activeCount":100},[],{"trials":3049,"activeCount":100},[3050],{"nctId":3051,"briefTitle":3052,"status":149,"phases":3053,"primaryCompletion":3054,"completion":3054,"start":3055,"enrollment":1877,"conditions":3056,"interventions":3058},"NCT04349917","Large-scale Brain Organization During Cognitive Control in ADHD",[91],"2020-03-14","2016-12-16",[3057],"Attention Deficit Hyperactivity Disorder",[3038],{"trials":3060,"activeCount":100},[],{"intervention":3062,"totalTrials":183,"cells":3063},"Doxycycline",{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3084},{"trials":3065,"activeCount":100},[],{"trials":3067,"activeCount":100},[],{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[3074],{"nctId":3075,"briefTitle":3076,"status":149,"phases":3077,"primaryCompletion":2097,"completion":2097,"start":3078,"enrollment":869,"conditions":3079,"interventions":3081},"NCT01825408","Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis",[91],"2013-02",[3080],"Sinusitis",[3062,3082,3083],"Azithromycin","Augmentin",{"trials":3085,"activeCount":100},[],{"intervention":3083,"totalTrials":183,"cells":3087},{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3094,"PHASE4":3096,"NA":3102},{"trials":3089,"activeCount":100},[],{"trials":3091,"activeCount":100},[],{"trials":3093,"activeCount":100},[],{"trials":3095,"activeCount":100},[],{"trials":3097,"activeCount":100},[3098],{"nctId":3075,"briefTitle":3076,"status":149,"phases":3099,"primaryCompletion":2097,"completion":2097,"start":3078,"enrollment":869,"conditions":3100,"interventions":3101},[91],[3080],[3062,3082,3083],{"trials":3103,"activeCount":100},[],{"intervention":3105,"totalTrials":183,"cells":3106},"Acthar",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3113,"PHASE4":3115,"NA":3127},{"trials":3108,"activeCount":100},[],{"trials":3110,"activeCount":100},[],{"trials":3112,"activeCount":100},[],{"trials":3114,"activeCount":100},[],{"trials":3116,"activeCount":100},[3117],{"nctId":3118,"briefTitle":3119,"status":301,"phases":3120,"primaryCompletion":3004,"completion":3004,"start":3121,"enrollment":100,"conditions":3122,"interventions":3126},"NCT02399462","Acthar for Treatment of Post-transplant FSGS",[91],"2021-03",[3123,3124,3125],"FSGS","Renal Transplantation","Kidney Transplantation",[3105],{"trials":3128,"activeCount":100},[],{"intervention":3130,"totalTrials":183,"cells":3131},"Tenofovir Disoproxil Fumarate",{"EARLY_PHASE1":3132,"PHASE1":3134,"PHASE2":3136,"PHASE3":3138,"PHASE4":3140,"NA":3153},{"trials":3133,"activeCount":100},[],{"trials":3135,"activeCount":100},[],{"trials":3137,"activeCount":100},[],{"trials":3139,"activeCount":100},[],{"trials":3141,"activeCount":100},[3142],{"nctId":3143,"briefTitle":3144,"status":149,"phases":3145,"primaryCompletion":3146,"completion":3147,"start":3148,"enrollment":3149,"conditions":3150,"interventions":3151},"NCT03567382","Arresting Vertical Transmission of Hepatitis B Virus",[91],"2020-03-06","2020-08-15","2018-09-24",179,[2168,2294],[3130,3152],"Monovalent HBV vaccine",{"trials":3154,"activeCount":100},[],{"intervention":3152,"totalTrials":183,"cells":3156},{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3161,"PHASE3":3163,"PHASE4":3165,"NA":3171},{"trials":3158,"activeCount":100},[],{"trials":3160,"activeCount":100},[],{"trials":3162,"activeCount":100},[],{"trials":3164,"activeCount":100},[],{"trials":3166,"activeCount":100},[3167],{"nctId":3143,"briefTitle":3144,"status":149,"phases":3168,"primaryCompletion":3146,"completion":3147,"start":3148,"enrollment":3149,"conditions":3169,"interventions":3170},[91],[2168,2294],[3130,3152],{"trials":3172,"activeCount":100},[],{"intervention":3174,"totalTrials":183,"cells":3175},"Estradiol Transdermal Patch 0.1 mg\u002F24 hrs",{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3180,"PHASE3":3182,"PHASE4":3184,"NA":3196},{"trials":3177,"activeCount":100},[],{"trials":3179,"activeCount":100},[],{"trials":3181,"activeCount":100},[],{"trials":3183,"activeCount":100},[],{"trials":3185,"activeCount":100},[3186],{"nctId":3187,"briefTitle":3188,"status":149,"phases":3189,"primaryCompletion":2002,"completion":2002,"start":3190,"enrollment":1409,"conditions":3191,"interventions":3193},"NCT03720847","Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality",[91],"2016-12-31",[3192],"Suicidal Ideation",[3174,3194,3195],"Oral Micronized Progesterone","Inactive Clear Patch",{"trials":3197,"activeCount":100},[],{"intervention":3194,"totalTrials":183,"cells":3199},{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3206,"PHASE4":3208,"NA":3214},{"trials":3201,"activeCount":100},[],{"trials":3203,"activeCount":100},[],{"trials":3205,"activeCount":100},[],{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[3210],{"nctId":3187,"briefTitle":3188,"status":149,"phases":3211,"primaryCompletion":2002,"completion":2002,"start":3190,"enrollment":1409,"conditions":3212,"interventions":3213},[91],[3192],[3174,3194,3195],{"trials":3215,"activeCount":100},[],{"intervention":3195,"totalTrials":183,"cells":3217},{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3224,"PHASE4":3226,"NA":3232},{"trials":3219,"activeCount":100},[],{"trials":3221,"activeCount":100},[],{"trials":3223,"activeCount":100},[],{"trials":3225,"activeCount":100},[],{"trials":3227,"activeCount":100},[3228],{"nctId":3187,"briefTitle":3188,"status":149,"phases":3229,"primaryCompletion":2002,"completion":2002,"start":3190,"enrollment":1409,"conditions":3230,"interventions":3231},[91],[3192],[3174,3194,3195],{"trials":3233,"activeCount":100},[],{"intervention":3235,"totalTrials":183,"cells":3236},"Subgingival chlorhexidine irrigation",{"EARLY_PHASE1":3237,"PHASE1":3239,"PHASE2":3241,"PHASE3":3243,"PHASE4":3245,"NA":3258},{"trials":3238,"activeCount":100},[],{"trials":3240,"activeCount":100},[],{"trials":3242,"activeCount":100},[],{"trials":3244,"activeCount":100},[],{"trials":3246,"activeCount":100},[3247],{"nctId":3248,"briefTitle":3249,"status":149,"phases":3250,"primaryCompletion":3251,"completion":3251,"start":3252,"enrollment":3253,"conditions":3254,"interventions":3257},"NCT04954313","Baseline Oral Health Study: UnCoVer the Connections to General Health",[91],"2025-02-01","2021-09-28",786,[3255,3256],"Cardiovascular Diseases","Diabetes Type 2",[3235],{"trials":3259,"activeCount":100},[],{"intervention":3261,"totalTrials":183,"cells":3262},"Exenatide",{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3267,"PHASE3":3269,"PHASE4":3271,"NA":3283},{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[],{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":100},[],{"trials":3272,"activeCount":100},[3273],{"nctId":3274,"briefTitle":3275,"status":149,"phases":3276,"primaryCompletion":3277,"completion":3277,"start":3278,"enrollment":3279,"conditions":3280,"interventions":3282},"NCT02058940","Intravenous Exenatide in Patients With Acute Brain Injury",[91],"2017-08","2015-08",8,[3281],"Brain Injuries",[3261],{"trials":3284,"activeCount":100},[],{"intervention":3286,"totalTrials":183,"cells":3287},"Dexmedetomidine",{"EARLY_PHASE1":3288,"PHASE1":3290,"PHASE2":3292,"PHASE3":3294,"PHASE4":3296,"NA":3308},{"trials":3289,"activeCount":100},[],{"trials":3291,"activeCount":100},[],{"trials":3293,"activeCount":100},[],{"trials":3295,"activeCount":100},[],{"trials":3297,"activeCount":100},[3298],{"nctId":3299,"briefTitle":3300,"status":731,"phases":3301,"primaryCompletion":3302,"completion":3302,"start":291,"enrollment":1180,"conditions":3303,"interventions":3305},"NCT01017237","Dexmedetomidine Sedation With Third Molar Surgery",[91],"2011-12",[3304],"Anesthesia",[3286,3306,3307],"Midazolam","Ketamine",{"trials":3309,"activeCount":100},[],{"intervention":3306,"totalTrials":183,"cells":3311},{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3318,"PHASE4":3320,"NA":3326},{"trials":3313,"activeCount":100},[],{"trials":3315,"activeCount":100},[],{"trials":3317,"activeCount":100},[],{"trials":3319,"activeCount":100},[],{"trials":3321,"activeCount":100},[3322],{"nctId":3299,"briefTitle":3300,"status":731,"phases":3323,"primaryCompletion":3302,"completion":3302,"start":291,"enrollment":1180,"conditions":3324,"interventions":3325},[91],[3304],[3286,3306,3307],{"trials":3327,"activeCount":100},[],{"intervention":3307,"totalTrials":183,"cells":3329},{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3334,"PHASE3":3336,"PHASE4":3338,"NA":3344},{"trials":3331,"activeCount":100},[],{"trials":3333,"activeCount":100},[],{"trials":3335,"activeCount":100},[],{"trials":3337,"activeCount":100},[],{"trials":3339,"activeCount":100},[3340],{"nctId":3299,"briefTitle":3300,"status":731,"phases":3341,"primaryCompletion":3302,"completion":3302,"start":291,"enrollment":1180,"conditions":3342,"interventions":3343},[91],[3304],[3286,3306,3307],{"trials":3345,"activeCount":100},[],{"intervention":199,"totalTrials":183,"cells":3347},{"EARLY_PHASE1":3348,"PHASE1":3350,"PHASE2":3352,"PHASE3":3354,"PHASE4":3356,"NA":3362},{"trials":3349,"activeCount":100},[],{"trials":3351,"activeCount":100},[],{"trials":3353,"activeCount":100},[],{"trials":3355,"activeCount":100},[],{"trials":3357,"activeCount":100},[3358],{"nctId":189,"briefTitle":190,"status":149,"phases":3359,"primaryCompletion":192,"completion":192,"start":193,"enrollment":194,"conditions":3360,"interventions":3361},[91],[196,197],[199,139],{"trials":3363,"activeCount":100},[],{"intervention":2006,"totalTrials":183,"cells":3365},{"EARLY_PHASE1":3366,"PHASE1":3368,"PHASE2":3370,"PHASE3":3372,"PHASE4":3374,"NA":3380},{"trials":3367,"activeCount":100},[],{"trials":3369,"activeCount":100},[],{"trials":3371,"activeCount":100},[],{"trials":3373,"activeCount":100},[],{"trials":3375,"activeCount":100},[3376],{"nctId":1998,"briefTitle":1999,"status":301,"phases":3377,"primaryCompletion":2001,"completion":2001,"start":2002,"enrollment":100,"conditions":3378,"interventions":3379},[91],[2004],[1976,2006,2006,2007,2008,2009],{"trials":3381,"activeCount":100},[],{"intervention":2007,"totalTrials":183,"cells":3383},{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3388,"PHASE3":3390,"PHASE4":3392,"NA":3398},{"trials":3385,"activeCount":100},[],{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[],{"trials":3393,"activeCount":100},[3394],{"nctId":1998,"briefTitle":1999,"status":301,"phases":3395,"primaryCompletion":2001,"completion":2001,"start":2002,"enrollment":100,"conditions":3396,"interventions":3397},[91],[2004],[1976,2006,2006,2007,2008,2009],{"trials":3399,"activeCount":100},[],{"intervention":2008,"totalTrials":183,"cells":3401},{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3406,"PHASE3":3408,"PHASE4":3410,"NA":3416},{"trials":3403,"activeCount":100},[],{"trials":3405,"activeCount":100},[],{"trials":3407,"activeCount":100},[],{"trials":3409,"activeCount":100},[],{"trials":3411,"activeCount":100},[3412],{"nctId":1998,"briefTitle":1999,"status":301,"phases":3413,"primaryCompletion":2001,"completion":2001,"start":2002,"enrollment":100,"conditions":3414,"interventions":3415},[91],[2004],[1976,2006,2006,2007,2008,2009],{"trials":3417,"activeCount":100},[],{"intervention":2009,"totalTrials":183,"cells":3419},{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3424,"PHASE3":3426,"PHASE4":3428,"NA":3434},{"trials":3421,"activeCount":100},[],{"trials":3423,"activeCount":100},[],{"trials":3425,"activeCount":100},[],{"trials":3427,"activeCount":100},[],{"trials":3429,"activeCount":100},[3430],{"nctId":1998,"briefTitle":1999,"status":301,"phases":3431,"primaryCompletion":2001,"completion":2001,"start":2002,"enrollment":100,"conditions":3432,"interventions":3433},[91],[2004],[1976,2006,2006,2007,2008,2009],{"trials":3435,"activeCount":100},[],{"intervention":3437,"totalTrials":183,"cells":3438},"Bazedoxifene\u002FConjugated Estrogen",{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3445,"PHASE4":3447,"NA":3457},{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[],{"trials":3444,"activeCount":100},[],{"trials":3446,"activeCount":100},[],{"trials":3448,"activeCount":100},[3449],{"nctId":3450,"briefTitle":3451,"status":149,"phases":3452,"primaryCompletion":3453,"completion":3453,"start":3454,"enrollment":9,"conditions":3455,"interventions":3456},"NCT03740009","Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause\"",[91],"2021-05-17","2019-01-02",[737,27],[3437],{"trials":3458,"activeCount":100},[],{"intervention":3460,"totalTrials":183,"cells":3461},"Propanolol hydrochloride",{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3466,"PHASE3":3468,"PHASE4":3470,"NA":3483},{"trials":3463,"activeCount":100},[],{"trials":3465,"activeCount":100},[],{"trials":3467,"activeCount":100},[],{"trials":3469,"activeCount":100},[],{"trials":3471,"activeCount":100},[3472],{"nctId":3473,"briefTitle":3474,"status":149,"phases":3475,"primaryCompletion":3476,"completion":3476,"start":3477,"enrollment":3478,"conditions":3479,"interventions":3482},"NCT02972554","Does Propranolol Attenuate Inflammatory Responses to a Psychological Stressor?",[91],"2017-10-10","2016-01-26",92,[1893,2078,3480,3481],"Cortisol","Sympathetic Nervous System",[3460],{"trials":3484,"activeCount":100},[],{"intervention":3486,"totalTrials":183,"cells":3487},"Phenobarbital Sodium",{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3494,"PHASE4":3496,"NA":3521},{"trials":3489,"activeCount":100},[],{"trials":3491,"activeCount":100},[],{"trials":3493,"activeCount":100},[],{"trials":3495,"activeCount":100},[],{"trials":3497,"activeCount":100},[3498],{"nctId":3499,"briefTitle":3500,"status":731,"phases":3501,"primaryCompletion":3502,"completion":3503,"start":3504,"enrollment":1186,"conditions":3505,"interventions":3516},"NCT06081283","Antiseizure Medication in Seizure Networks at Early Acute Brain Injury",[91],"2024-12-22","2025-01-22","2023-11-20",[3506,3507,3508,3509,3510,3511,3512,3513,3514,3515],"Brain Injuries, Acute","Brain Injuries, Traumatic","Brain Ischemia","Brain Hypoxia","Hypoxia-Ischemia, Brain","Heart Arrest","Stroke","Intracranial Hemorrhages","Coma","Persistent Vegetative State",[3486,3517,3518,3519,3520],"Levetiracetam","Lacosamide Injectable Product","Valproate Sodium","Fosphenytoin",{"trials":3522,"activeCount":100},[],{"intervention":3517,"totalTrials":183,"cells":3524},{"EARLY_PHASE1":3525,"PHASE1":3527,"PHASE2":3529,"PHASE3":3531,"PHASE4":3533,"NA":3539},{"trials":3526,"activeCount":100},[],{"trials":3528,"activeCount":100},[],{"trials":3530,"activeCount":100},[],{"trials":3532,"activeCount":100},[],{"trials":3534,"activeCount":100},[3535],{"nctId":3499,"briefTitle":3500,"status":731,"phases":3536,"primaryCompletion":3502,"completion":3503,"start":3504,"enrollment":1186,"conditions":3537,"interventions":3538},[91],[3506,3507,3508,3509,3510,3511,3512,3513,3514,3515],[3486,3517,3518,3519,3520],{"trials":3540,"activeCount":100},[],{"intervention":3518,"totalTrials":183,"cells":3542},{"EARLY_PHASE1":3543,"PHASE1":3545,"PHASE2":3547,"PHASE3":3549,"PHASE4":3551,"NA":3557},{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":100},[],{"trials":3548,"activeCount":100},[],{"trials":3550,"activeCount":100},[],{"trials":3552,"activeCount":100},[3553],{"nctId":3499,"briefTitle":3500,"status":731,"phases":3554,"primaryCompletion":3502,"completion":3503,"start":3504,"enrollment":1186,"conditions":3555,"interventions":3556},[91],[3506,3507,3508,3509,3510,3511,3512,3513,3514,3515],[3486,3517,3518,3519,3520],{"trials":3558,"activeCount":100},[],{"intervention":3519,"totalTrials":183,"cells":3560},{"EARLY_PHASE1":3561,"PHASE1":3563,"PHASE2":3565,"PHASE3":3567,"PHASE4":3569,"NA":3575},{"trials":3562,"activeCount":100},[],{"trials":3564,"activeCount":100},[],{"trials":3566,"activeCount":100},[],{"trials":3568,"activeCount":100},[],{"trials":3570,"activeCount":100},[3571],{"nctId":3499,"briefTitle":3500,"status":731,"phases":3572,"primaryCompletion":3502,"completion":3503,"start":3504,"enrollment":1186,"conditions":3573,"interventions":3574},[91],[3506,3507,3508,3509,3510,3511,3512,3513,3514,3515],[3486,3517,3518,3519,3520],{"trials":3576,"activeCount":100},[],{"intervention":3520,"totalTrials":183,"cells":3578},{"EARLY_PHASE1":3579,"PHASE1":3581,"PHASE2":3583,"PHASE3":3585,"PHASE4":3587,"NA":3593},{"trials":3580,"activeCount":100},[],{"trials":3582,"activeCount":100},[],{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[],{"trials":3588,"activeCount":100},[3589],{"nctId":3499,"briefTitle":3500,"status":731,"phases":3590,"primaryCompletion":3502,"completion":3503,"start":3504,"enrollment":1186,"conditions":3591,"interventions":3592},[91],[3506,3507,3508,3509,3510,3511,3512,3513,3514,3515],[3486,3517,3518,3519,3520],{"trials":3594,"activeCount":100},[],{"intervention":1843,"totalTrials":183,"cells":3596},{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3601,"PHASE3":3603,"PHASE4":3605,"NA":3611},{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[],{"trials":3602,"activeCount":100},[],{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[3607],{"nctId":1834,"briefTitle":1835,"status":731,"phases":3608,"primaryCompletion":1837,"completion":1837,"start":1838,"enrollment":1839,"conditions":3609,"interventions":3610},[91],[33,1841,36],[1843,1779],{"trials":3612,"activeCount":100},[],{"intervention":3614,"totalTrials":183,"cells":3615},"Duloxetine",{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3620,"PHASE3":3622,"PHASE4":3624,"NA":3636},{"trials":3617,"activeCount":100},[],{"trials":3619,"activeCount":100},[],{"trials":3621,"activeCount":100},[],{"trials":3623,"activeCount":100},[],{"trials":3625,"activeCount":100},[3626],{"nctId":3627,"briefTitle":3628,"status":149,"phases":3629,"primaryCompletion":3630,"completion":3631,"start":1891,"enrollment":3632,"conditions":3633,"interventions":3635},"NCT05396014","The BEST Trial: Biomarkers for Evaluating Spine Treatments",[91],"2024-07-30","2024-10-22",1014,[3634],"Chronic Low-back Pain",[3614],{"trials":3637,"activeCount":100},[],{"intervention":3639,"totalTrials":183,"cells":3640},"Mannitol Inhalant Product",{"EARLY_PHASE1":3641,"PHASE1":3643,"PHASE2":3645,"PHASE3":3647,"PHASE4":3649,"NA":3660},{"trials":3642,"activeCount":100},[],{"trials":3644,"activeCount":100},[],{"trials":3646,"activeCount":100},[],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[3651],{"nctId":3652,"briefTitle":3653,"status":149,"phases":3654,"primaryCompletion":3655,"completion":3655,"start":3656,"enrollment":3657,"conditions":3658,"interventions":3659},"NCT05740618","Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis",[91],"2025-01-29","2023-03-28",14,[1706],[3639],{"trials":3661,"activeCount":100},[],{"intervention":3663,"totalTrials":183,"cells":3664},"efavirenz, emtricitabine, and tenofovir",{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3671,"PHASE4":3673,"NA":3682},{"trials":3666,"activeCount":100},[],{"trials":3668,"activeCount":100},[],{"trials":3670,"activeCount":100},[],{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[3675],{"nctId":3676,"briefTitle":3677,"status":149,"phases":3678,"primaryCompletion":1967,"completion":2334,"start":3679,"enrollment":3478,"conditions":3680,"interventions":3681},"NCT00924898","Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)",[91],"2005-01",[1970,21],[3663],{"trials":3683,"activeCount":100},[],{"intervention":3685,"totalTrials":183,"cells":3686},"Routine three-drug antiretroviral prophylaxis",{"EARLY_PHASE1":3687,"PHASE1":3689,"PHASE2":3691,"PHASE3":3693,"PHASE4":3695,"NA":3706},{"trials":3688,"activeCount":100},[],{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[],{"trials":3694,"activeCount":100},[],{"trials":3696,"activeCount":100},[3697],{"nctId":3698,"briefTitle":3699,"status":149,"phases":3700,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":3703,"conditions":3704,"interventions":3705},"NCT00753324","Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia",[91],"2012-01","2009-05",284,[21],[3685],{"trials":3707,"activeCount":100},[],{"intervention":3709,"totalTrials":183,"cells":3710},"Standard Care",{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3717,"PHASE4":3719,"NA":3731},{"trials":3712,"activeCount":100},[],{"trials":3714,"activeCount":100},[],{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[3721],{"nctId":3722,"briefTitle":3723,"status":149,"phases":3724,"primaryCompletion":3725,"completion":3725,"start":3726,"enrollment":735,"conditions":3727,"interventions":3729},"NCT00494494","Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery",[91],"2008-04","2007-06",[3728],"Cystoid Macular Edema",[3709,3730],"nepafenac",{"trials":3732,"activeCount":100},[],{"intervention":3730,"totalTrials":183,"cells":3734},{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3739,"PHASE3":3741,"PHASE4":3743,"NA":3749},{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[],{"trials":3742,"activeCount":100},[],{"trials":3744,"activeCount":100},[3745],{"nctId":3722,"briefTitle":3723,"status":149,"phases":3746,"primaryCompletion":3725,"completion":3725,"start":3726,"enrollment":735,"conditions":3747,"interventions":3748},[91],[3728],[3709,3730],{"trials":3750,"activeCount":100},[],{"intervention":3752,"totalTrials":183,"cells":3753},"Esomeprazole",{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3760,"PHASE4":3762,"NA":3774},{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[],{"trials":3761,"activeCount":100},[],{"trials":3763,"activeCount":100},[3764],{"nctId":3765,"briefTitle":3766,"status":149,"phases":3767,"primaryCompletion":3768,"completion":3768,"start":3769,"enrollment":869,"conditions":3770,"interventions":3773},"NCT00287339","The Utility of Nexium in Chronic Cough and Reflux Disease",[91],"2008-09","2005-09",[3771,3772],"Cough","GERD",[3752],{"trials":3775,"activeCount":100},[],{"intervention":3777,"totalTrials":1186,"cells":3778},"Oxytocin",{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3802,"PHASE3":3821,"PHASE4":3831,"NA":3833},{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[3783,3793],{"nctId":3784,"briefTitle":3785,"status":149,"phases":3786,"primaryCompletion":2358,"completion":2358,"start":3787,"enrollment":3788,"conditions":3789,"interventions":3792},"NCT01929161","Study of Wellness Behaviors as a Function of Oxytocin vs Placebo",[88],"2013-09",239,[3790,3791],"Sustained Positive Emotions","Sustained Positive Behavior Change",[3777],{"nctId":3794,"briefTitle":3795,"status":149,"phases":3796,"primaryCompletion":3797,"completion":3797,"start":2358,"enrollment":3798,"conditions":3799,"interventions":3801},"NCT01945957","Brain Imaging of Intranasal Oxytocin Treatment in Autism",[88],"2017-01",33,[3800],"Autism Spectrum Disorders",[3777],{"trials":3803,"activeCount":100},[3804,3812],{"nctId":3805,"briefTitle":3806,"status":149,"phases":3807,"primaryCompletion":193,"completion":193,"start":3808,"enrollment":526,"conditions":3809,"interventions":3811},"NCT01308749","A Study of Oxytocin in Children and Adolescents With Autistic Disorder",[89],"2011-03",[3810],"Autism",[3777],{"nctId":3813,"briefTitle":3814,"status":301,"phases":3815,"primaryCompletion":3816,"completion":3816,"start":3817,"enrollment":100,"conditions":3818,"interventions":3820},"NCT03636555","Oxytocin Treatment for Alcohol Use Disorders",[89],"2022-09","2019-10",[3819],"Alcohol Use Disorder",[3777],{"trials":3822,"activeCount":100},[3823],{"nctId":3824,"briefTitle":3825,"status":149,"phases":3826,"primaryCompletion":224,"completion":3827,"start":3828,"enrollment":247,"conditions":3829,"interventions":3830},"NCT02508103","Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study",[89,90],"2016-07","2015-07",[2790],[3777],{"trials":3832,"activeCount":100},[],{"trials":3834,"activeCount":100},[],{"intervention":2033,"totalTrials":233,"cells":3836},{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3841,"PHASE3":3856,"PHASE4":3868,"NA":3870},{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[],{"trials":3842,"activeCount":100},[3843,3847],{"nctId":2022,"briefTitle":2023,"status":149,"phases":3844,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":3845,"interventions":3846},[89],[2029],[2031,2032,2033,2034,2013,2035,2036],{"nctId":3848,"briefTitle":3849,"status":149,"phases":3850,"primaryCompletion":3851,"completion":3302,"start":3852,"enrollment":3798,"conditions":3853,"interventions":3855},"NCT00609973","Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease",[89],"2011-10","2008-05",[3854],"Crohn's Disease",[2033],{"trials":3857,"activeCount":100},[3858],{"nctId":3859,"briefTitle":3860,"status":149,"phases":3861,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":1209,"conditions":3864,"interventions":3867},"NCT02068846","BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent",[90],"2016-01","2014-04",[15,3865,3866],"Salivary Gland Disease","Benign Lymphoepithelial Lesion",[2033],{"trials":3869,"activeCount":100},[],{"trials":3871,"activeCount":100},[],{"intervention":3873,"totalTrials":233,"cells":3874},"Naltrexone",{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3879,"PHASE3":3901,"PHASE4":3907,"NA":3909},{"trials":3876,"activeCount":100},[],{"trials":3878,"activeCount":100},[],{"trials":3880,"activeCount":100},[3881,3892],{"nctId":3882,"briefTitle":3883,"status":149,"phases":3884,"primaryCompletion":3885,"completion":3885,"start":3886,"enrollment":3887,"conditions":3888,"interventions":3890},"NCT02842073","An Open Label Trial of Bupropion and Naltrexone for Binge Drinking",[89],"2017-12-13","2016-11-01",12,[3889],"Binge Drinking",[3873,3891],"Bupropion",{"nctId":3893,"briefTitle":3894,"status":149,"phases":3895,"primaryCompletion":3896,"completion":3896,"start":3897,"enrollment":1955,"conditions":3898,"interventions":3900},"NCT01296646","Sweet Preference and Alcohol Craving",[89],"2012-06","2010-01",[2219,3899],"Alcohol Abuse",[3873],{"trials":3902,"activeCount":100},[3903],{"nctId":2201,"briefTitle":2202,"status":149,"phases":3904,"completion":2204,"start":2205,"enrollment":2206,"conditions":3905,"interventions":3906},[90],[2208],[2210,2190],{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[],{"intervention":3912,"totalTrials":96,"cells":3913},"Methotrexate",{"EARLY_PHASE1":3914,"PHASE1":3916,"PHASE2":3918,"PHASE3":3929,"PHASE4":3941,"NA":3943},{"trials":3915,"activeCount":100},[],{"trials":3917,"activeCount":100},[],{"trials":3919,"activeCount":100},[3920],{"nctId":3921,"briefTitle":3922,"status":149,"phases":3923,"primaryCompletion":3924,"completion":3924,"start":3925,"enrollment":3149,"conditions":3926,"interventions":3928},"NCT01393405","Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis",[89],"2017-04","2012-02",[3927],"Ulcerative Colitis",[3912],{"trials":3930,"activeCount":100},[3931],{"nctId":3932,"briefTitle":3933,"status":149,"phases":3934,"primaryCompletion":3935,"completion":3935,"start":3936,"enrollment":3937,"conditions":3938,"interventions":3940},"NCT02772965","Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy",[90],"2022-04-07","2016-10",306,[3939],"Pediatric Crohn's Disease",[3912],{"trials":3942,"activeCount":100},[],{"trials":3944,"activeCount":100},[],{"intervention":3946,"totalTrials":96,"cells":3947},"baclofen",{"EARLY_PHASE1":3948,"PHASE1":3950,"PHASE2":3952,"PHASE3":3963,"PHASE4":3972,"NA":3974},{"trials":3949,"activeCount":100},[],{"trials":3951,"activeCount":100},[],{"trials":3953,"activeCount":100},[3954],{"nctId":3955,"briefTitle":3956,"status":149,"phases":3957,"primaryCompletion":3958,"completion":3958,"start":3959,"enrollment":317,"conditions":3960,"interventions":3961},"NCT01980706","Efficacy and Safety of High Dose Baclofen for Alcohol Dependence",[89],"2017-10-26","2013-12-12",[2208],[3962],"Baclofen",{"trials":3964,"activeCount":100},[3965],{"nctId":3966,"briefTitle":3967,"status":149,"phases":3968,"primaryCompletion":2830,"completion":3726,"start":3969,"enrollment":1955,"conditions":3970,"interventions":3971},"NCT00877734","Efficacy and Tolerability of Baclofen for Alcohol Dependence",[89,90],"2005-04",[2219],[3946],{"trials":3973,"activeCount":100},[],{"trials":3975,"activeCount":100},[],{"intervention":3977,"totalTrials":183,"cells":3978},"17P",{"EARLY_PHASE1":3979,"PHASE1":3981,"PHASE2":3983,"PHASE3":3985,"PHASE4":3998,"NA":4000},{"trials":3980,"activeCount":100},[],{"trials":3982,"activeCount":100},[],{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[3987],{"nctId":3988,"briefTitle":3989,"status":149,"phases":3990,"primaryCompletion":3991,"completion":3992,"start":3993,"enrollment":3994,"conditions":3995,"interventions":3997},"NCT03297216","Improving Pregnancy Outcomes With Progesterone",[90],"2020-06-25","2020-08-06","2018-02-07",800,[3996,1411],"Pre-term Birth",[3977],{"trials":3999,"activeCount":100},[],{"trials":4001,"activeCount":100},[],{"intervention":4003,"totalTrials":183,"cells":4004},"best medical therapy",{"EARLY_PHASE1":4005,"PHASE1":4007,"PHASE2":4009,"PHASE3":4011,"PHASE4":4023,"NA":4025},{"trials":4006,"activeCount":100},[],{"trials":4008,"activeCount":100},[],{"trials":4010,"activeCount":100},[],{"trials":4012,"activeCount":100},[4013],{"nctId":4014,"briefTitle":4015,"status":731,"phases":4016,"primaryCompletion":1802,"completion":1802,"start":4017,"enrollment":4018,"conditions":4019,"interventions":4022},"NCT00029146","Carotid Occlusion Surgery Study",[90],"2002-07",700,[3512,4020,4021],"Ischemic Attack, Transient","Cerebral Infarction",[4003],{"trials":4024,"activeCount":100},[],{"trials":4026,"activeCount":100},[],{"intervention":4028,"totalTrials":183,"cells":4029},"Transfusion",{"EARLY_PHASE1":4030,"PHASE1":4032,"PHASE2":4034,"PHASE3":4036,"PHASE4":4047,"NA":4049},{"trials":4031,"activeCount":100},[],{"trials":4033,"activeCount":100},[],{"trials":4035,"activeCount":100},[],{"trials":4037,"activeCount":100},[4038],{"nctId":4039,"briefTitle":4040,"status":149,"phases":4041,"primaryCompletion":4042,"completion":4042,"start":4043,"enrollment":28,"conditions":4044,"interventions":4046},"NCT03704922","Age of Blood in Sickle Cell Transfusion",[89,90],"2024-01-11","2017-10-04",[4045],"Sickle Cell Disease",[4028],{"trials":4048,"activeCount":100},[],{"trials":4050,"activeCount":100},[],{"intervention":4052,"totalTrials":183,"cells":4053},"Bupivacaine, Clonidine, Morphine",{"EARLY_PHASE1":4054,"PHASE1":4056,"PHASE2":4058,"PHASE3":4060,"PHASE4":4070,"NA":4072},{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[4062],{"nctId":4063,"briefTitle":4064,"status":731,"phases":4065,"completion":4066,"start":4067,"enrollment":869,"conditions":4068,"interventions":4069},"NCT00287326","Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone",[90],"2006-06","2006-01",[295],[4052],{"trials":4071,"activeCount":100},[],{"trials":4073,"activeCount":100},[],{"intervention":4075,"totalTrials":183,"cells":4076},"Tadalafil",{"EARLY_PHASE1":4077,"PHASE1":4079,"PHASE2":4081,"PHASE3":4083,"PHASE4":4093,"NA":4095},{"trials":4078,"activeCount":100},[],{"trials":4080,"activeCount":100},[],{"trials":4082,"activeCount":100},[],{"trials":4084,"activeCount":100},[4085],{"nctId":4086,"briefTitle":4087,"status":149,"phases":4088,"primaryCompletion":4089,"completion":151,"start":3808,"enrollment":3887,"conditions":4090,"interventions":4092},"NCT01324999","Tadalafil for Sarcoidosis Associated Pulmonary Hypertension",[89,90],"2013-07",[4091],"Pulmonary Hypertension",[4075],{"trials":4094,"activeCount":100},[],{"trials":4096,"activeCount":100},[],{"intervention":4098,"totalTrials":183,"cells":4099},"Fesoterodine Fumarate",{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4104,"PHASE3":4106,"PHASE4":4116,"NA":4118},{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[],{"trials":4105,"activeCount":100},[],{"trials":4107,"activeCount":100},[4108],{"nctId":4109,"briefTitle":4110,"status":149,"phases":4111,"primaryCompletion":4112,"completion":4112,"start":152,"enrollment":2886,"conditions":4113,"interventions":4115},"NCT01786967","Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)",[90],"2017-12-31",[4114],"Urge Urinary Incontinence",[4098],{"trials":4117,"activeCount":100},[],{"trials":4119,"activeCount":100},[],{"intervention":4121,"totalTrials":183,"cells":4122},"Nitrous Oxide",{"EARLY_PHASE1":4123,"PHASE1":4125,"PHASE2":4127,"PHASE3":4129,"PHASE4":4141,"NA":4143},{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"trials":4128,"activeCount":100},[],{"trials":4130,"activeCount":100},[4131],{"nctId":4132,"briefTitle":4133,"status":149,"phases":4134,"primaryCompletion":4135,"completion":4135,"start":4136,"enrollment":4137,"conditions":4138,"interventions":4140},"NCT03502915","Nitrous Oxide for External Cephalic Version",[90],"2019-02-14","2017-01-30",48,[4139],"External Cephalic Version",[4121],{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"intervention":4146,"totalTrials":183,"cells":4147},"Bromocriptine-QR",{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4154,"PHASE4":4167,"NA":4169},{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[],{"trials":4155,"activeCount":100},[4156],{"nctId":4157,"briefTitle":4158,"status":149,"phases":4159,"primaryCompletion":4160,"completion":4160,"start":4161,"enrollment":4162,"conditions":4163,"interventions":4166},"NCT05405244","Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM",[90],"2019-09-19","2017-09-19",55,[4164,4165],"Overweight and Obesity","Eating Behavior",[4146],{"trials":4168,"activeCount":100},[],{"trials":4170,"activeCount":100},[],{"intervention":4172,"totalTrials":716,"cells":4173},"Intranasal Oxytocin Spray",{"EARLY_PHASE1":4174,"PHASE1":4176,"PHASE2":4193,"PHASE3":4213,"PHASE4":4215,"NA":4217},{"trials":4175,"activeCount":100},[],{"trials":4177,"activeCount":100},[4178,4185],{"nctId":4179,"briefTitle":4180,"status":149,"phases":4181,"primaryCompletion":1859,"completion":1859,"start":4182,"enrollment":1755,"conditions":4183,"interventions":4184},"NCT01394471","Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia",[88],"2011-07",[33,1841],[4172],{"nctId":4186,"briefTitle":4187,"status":149,"phases":4188,"primaryCompletion":3808,"completion":3808,"start":303,"enrollment":3657,"conditions":4189,"interventions":4191},"NCT01212185","Oxytocin Treatment of Alcohol Withdrawal",[88],[4190],"Alcohol Withdrawal",[4192],"intranasal oxytocin spray",{"trials":4194,"activeCount":100},[4195,4205],{"nctId":4196,"briefTitle":4197,"status":149,"phases":4198,"primaryCompletion":4199,"completion":4199,"start":4200,"enrollment":3887,"conditions":4201,"interventions":4204},"NCT02548728","Oxytocin Treatment of Opioid Dependence",[88,89],"2016-12","2016-02",[4202,4203],"Opioid Dependence","Opioid Withdrawal",[4172],{"nctId":4206,"briefTitle":4207,"status":149,"phases":4208,"primaryCompletion":2334,"completion":2096,"start":4209,"enrollment":1941,"conditions":4210,"interventions":4211},"NCT02275611","Oxytocin Treatment of Alcohol Dependence",[89],"2013-01",[4190,2219],[4192,4212],"Intranasal Placebo Spray",{"trials":4214,"activeCount":100},[],{"trials":4216,"activeCount":100},[],{"trials":4218,"activeCount":100},[],{"intervention":4220,"totalTrials":716,"cells":4221},"Gamma Tocopherol",{"EARLY_PHASE1":4222,"PHASE1":4224,"PHASE2":4241,"PHASE3":4262,"PHASE4":4264,"NA":4266},{"trials":4223,"activeCount":100},[],{"trials":4225,"activeCount":100},[4226,4234],{"nctId":4227,"briefTitle":4228,"status":149,"phases":4229,"primaryCompletion":1967,"completion":2334,"start":1804,"enrollment":3279,"conditions":4230,"interventions":4233},"NCT00466596","Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements",[88],[4231,4232],"Allergic Rhinitis","Mild Asthma",[4220],{"nctId":4235,"briefTitle":4236,"status":149,"phases":4237,"primaryCompletion":291,"completion":291,"start":3852,"enrollment":1180,"conditions":4238,"interventions":4239},"NCT00631085","Effect of Gamma Tocopherol Supplementation on Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Normal Adults",[88],[24],[4240],"gamma tocopherol",{"trials":4242,"activeCount":100},[4243,4254],{"nctId":4244,"briefTitle":4245,"status":149,"phases":4246,"primaryCompletion":4247,"completion":4248,"start":4249,"enrollment":572,"conditions":4250,"interventions":4253},"NCT03444298","A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults",[89],"2023-03-02","2023-03-06","2018-06-08",[4251,4252],"Airway Inflammation","Asthma",[4220],{"nctId":4255,"briefTitle":4256,"status":149,"phases":4257,"primaryCompletion":4258,"completion":4258,"start":1838,"enrollment":1180,"conditions":4259,"interventions":4261},"NCT02911688","Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure",[89],"2019-02-13",[4260],"Allergic Asthma",[4240],{"trials":4263,"activeCount":100},[],{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[],{"intervention":4269,"totalTrials":233,"cells":4270},"Peanut OIT",{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4275,"PHASE3":4302,"PHASE4":4304,"NA":4306},{"trials":4272,"activeCount":100},[],{"trials":4274,"activeCount":100},[],{"trials":4276,"activeCount":100},[4277,4286,4293],{"nctId":4278,"briefTitle":4279,"status":149,"phases":4280,"primaryCompletion":4281,"completion":4281,"start":4282,"enrollment":165,"conditions":4283,"interventions":4285},"NCT03251508","Salvage Peanut Oral Immunotherapy Study",[88,89],"2021-11-23","2018-01-03",[4284],"Peanut Allergy",[4269],{"nctId":4287,"briefTitle":4288,"status":149,"phases":4289,"primaryCompletion":2097,"completion":2097,"start":1804,"enrollment":247,"conditions":4290,"interventions":4292},"NCT00597675","Oral Immunotherapy for Peanut Allergy (PMIT)",[89],[4291],"Food Hypersensitivity",[4269],{"nctId":4294,"briefTitle":4295,"status":149,"phases":4296,"primaryCompletion":4297,"completion":4297,"start":4298,"enrollment":572,"conditions":4299,"interventions":4301},"NCT00815035","Oral Immunotherapy (OIT) for Peanut Allergy",[89],"2016-12-12","2009-04",[4300],"Peanut Hypersensitivity",[4269],{"trials":4303,"activeCount":100},[],{"trials":4305,"activeCount":100},[],{"trials":4307,"activeCount":100},[],{"intervention":4309,"totalTrials":233,"cells":4310},"Anakinra",{"EARLY_PHASE1":4311,"PHASE1":4313,"PHASE2":4315,"PHASE3":4346,"PHASE4":4348,"NA":4350},{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":100},[],{"trials":4316,"activeCount":100},[4317,4326,4339],{"nctId":4318,"briefTitle":4319,"status":301,"phases":4320,"primaryCompletion":4321,"completion":4321,"start":4322,"enrollment":100,"conditions":4323,"interventions":4324},"NCT03513471","Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation",[88,89],"2021-12","2019-08-09",[4252],[4309,4325],"Dermatophagoides Farinae",{"nctId":4327,"briefTitle":4328,"status":301,"phases":4329,"primaryCompletion":4330,"completion":4331,"start":4332,"enrollment":100,"conditions":4333,"interventions":4335},"NCT04035109","Anakinra as a Rescue Treatment for Allergic Inflammation",[88,89],"2022-10","2023-10","2019-12-16",[4334],"Asthma, Allergic",[4309,4336,4337,4338],"Preservative-free 0.9% sodium chloride","House dust mite allergen","Cat hair allergen",{"nctId":4340,"briefTitle":4341,"status":301,"phases":4342,"primaryCompletion":4321,"completion":4321,"start":4343,"enrollment":100,"conditions":4344,"interventions":4345},"NCT03513458","Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation",[88,89],"2020-09",[4252],[4309,4325],{"trials":4347,"activeCount":100},[],{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[],{"intervention":1865,"totalTrials":96,"cells":4353},{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4368,"PHASE3":4374,"PHASE4":4376,"NA":4378},{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":100},[4358],{"nctId":4359,"briefTitle":4360,"status":731,"phases":4361,"primaryCompletion":4362,"completion":4362,"start":4363,"enrollment":96,"conditions":4364,"interventions":4366},"NCT01441206","Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants",[88],"2012-04","2011-09",[4365],"Infection",[4367],"rifampin",{"trials":4369,"activeCount":100},[4370],{"nctId":1856,"briefTitle":1857,"status":731,"phases":4371,"primaryCompletion":1859,"completion":1860,"start":1178,"enrollment":1861,"conditions":4372,"interventions":4373},[89],[1706,1863],[1865,1866,1847,1867,1868,1869],{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[],{"trials":4379,"activeCount":100},[],{"intervention":1867,"totalTrials":96,"cells":4381},{"EARLY_PHASE1":4382,"PHASE1":4384,"PHASE2":4386,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4383,"activeCount":100},[],{"trials":4385,"activeCount":100},[],{"trials":4387,"activeCount":100},[4388,4392],{"nctId":1856,"briefTitle":1857,"status":731,"phases":4389,"primaryCompletion":1859,"completion":1860,"start":1178,"enrollment":1861,"conditions":4390,"interventions":4391},[89],[1706,1863],[1865,1866,1847,1867,1868,1869],{"nctId":1871,"briefTitle":1872,"status":149,"phases":4393,"primaryCompletion":1874,"completion":1875,"start":1876,"enrollment":1877,"conditions":4394,"interventions":4395},[89],[1706],[1880,1847,1867,1881],{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[],{"trials":4401,"activeCount":100},[],{"intervention":4403,"totalTrials":96,"cells":4404},"Emtricitabine\u002Ftenofovir",{"EARLY_PHASE1":4405,"PHASE1":4407,"PHASE2":4409,"PHASE3":4428,"PHASE4":4430,"NA":4432},{"trials":4406,"activeCount":100},[],{"trials":4408,"activeCount":100},[],{"trials":4410,"activeCount":100},[4411,4419],{"nctId":4412,"briefTitle":4413,"status":149,"phases":4414,"primaryCompletion":4415,"completion":4415,"start":2098,"enrollment":4416,"conditions":4417,"interventions":4418},"NCT01772823","An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis",[89],"2015-11",200,[30],[4403],{"nctId":4420,"briefTitle":4421,"status":149,"phases":4422,"primaryCompletion":4415,"completion":4423,"start":4424,"enrollment":4425,"conditions":4426,"interventions":4427},"NCT01769456","An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)",[89],"2016-11","2013-03",78,[30],[4403],{"trials":4429,"activeCount":100},[],{"trials":4431,"activeCount":100},[],{"trials":4433,"activeCount":100},[],{"intervention":3891,"totalTrials":96,"cells":4435},{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4440,"PHASE3":4455,"PHASE4":4457,"NA":4459},{"trials":4437,"activeCount":100},[],{"trials":4439,"activeCount":100},[],{"trials":4441,"activeCount":100},[4442,4451],{"nctId":4443,"briefTitle":4444,"status":149,"phases":4445,"primaryCompletion":4446,"completion":163,"start":4447,"enrollment":4448,"conditions":4449,"interventions":4450},"NCT03169244","Buproprion for Binge Drinking",[89],"2019-08-19","2017-09-04",42,[3899],[3891],{"nctId":3882,"briefTitle":3883,"status":149,"phases":4452,"primaryCompletion":3885,"completion":3885,"start":3886,"enrollment":3887,"conditions":4453,"interventions":4454},[89],[3889],[3873,3891],{"trials":4456,"activeCount":100},[],{"trials":4458,"activeCount":100},[],{"trials":4460,"activeCount":100},[],{"intervention":4462,"totalTrials":96,"cells":4463},"Intranasal Oxytocin",{"EARLY_PHASE1":4464,"PHASE1":4466,"PHASE2":4468,"PHASE3":4485,"PHASE4":4487,"NA":4489},{"trials":4465,"activeCount":100},[],{"trials":4467,"activeCount":100},[],{"trials":4469,"activeCount":100},[4470,4480],{"nctId":4471,"briefTitle":4472,"status":149,"phases":4473,"primaryCompletion":4474,"completion":4474,"start":4475,"enrollment":4476,"conditions":4477,"interventions":4479},"NCT03593473","Inhaled Oxytocin and HPA Axis Reactivity",[89],"2023-07-25","2019-02-07",109,[263,4478,1893],"Anxiety Disorders",[4462],{"nctId":4481,"briefTitle":4207,"status":149,"phases":4482,"primaryCompletion":1838,"completion":1838,"start":3828,"enrollment":34,"conditions":4483,"interventions":4484},"NCT02251912",[89],[2219],[4462],{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[],{"trials":4490,"activeCount":100},[],{"intervention":4492,"totalTrials":96,"cells":4493},"Perflutren Lipid microsphere",{"EARLY_PHASE1":4494,"PHASE1":4496,"PHASE2":4498,"PHASE3":4520,"PHASE4":4522,"NA":4524},{"trials":4495,"activeCount":100},[],{"trials":4497,"activeCount":100},[],{"trials":4499,"activeCount":100},[4500,4510],{"nctId":4501,"briefTitle":4502,"status":149,"phases":4503,"primaryCompletion":4504,"completion":4504,"start":4505,"enrollment":526,"conditions":4506,"interventions":4509},"NCT03196076","Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension",[89],"2021-03-19","2017-08-28",[4507,4508],"Chronic Kidney Diseases","Cystic Kidney Disease",[4492],{"nctId":4511,"briefTitle":4512,"status":149,"phases":4513,"primaryCompletion":4514,"completion":4514,"start":4200,"enrollment":4515,"conditions":4516,"interventions":4518},"NCT02684435","Contrast-enhanced Ultrasound of the Kidney",[89],"2018-07-09",63,[4517,4508],"Chronic Kidney Disease",[4519],"Perflutren lipid microsphere",{"trials":4521,"activeCount":100},[],{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"intervention":308,"totalTrials":96,"cells":4527},{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4532,"PHASE3":4548,"PHASE4":4550,"NA":4552},{"trials":4529,"activeCount":100},[],{"trials":4531,"activeCount":100},[],{"trials":4533,"activeCount":100},[4534,4544],{"nctId":4535,"briefTitle":4536,"status":149,"phases":4537,"primaryCompletion":4538,"completion":4539,"start":4540,"enrollment":4416,"conditions":4541,"interventions":4543},"NCT02437383","Study of Orofacial Pain and PropRANOlol",[89],"2018-04-04","2018-04-25","2015-08-20",[4542],"Temporomandibular Disorders",[308],{"nctId":299,"briefTitle":300,"status":301,"phases":4545,"primaryCompletion":303,"completion":303,"start":304,"enrollment":100,"conditions":4546,"interventions":4547},[89],[306],[63,308,309],{"trials":4549,"activeCount":100},[],{"trials":4551,"activeCount":100},[],{"trials":4553,"activeCount":100},[],{"intervention":4555,"totalTrials":96,"cells":4556},"Semaglutide",{"EARLY_PHASE1":4557,"PHASE1":4559,"PHASE2":4561,"PHASE3":4583,"PHASE4":4585,"NA":4587},{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[4563,4574],{"nctId":4564,"briefTitle":4565,"status":149,"phases":4566,"primaryCompletion":4567,"completion":4567,"start":4568,"enrollment":194,"conditions":4569,"interventions":4572},"NCT05530577","Effects of Semaglutide on Nicotine Intake",[89],"2024-05-13","2022-10-07",[4570,4571],"Tobacco Use Disorder","Nicotine Addiction",[4555,4573],"Sham\u002Fplacebo",{"nctId":4575,"briefTitle":4576,"status":149,"phases":4577,"primaryCompletion":4578,"completion":780,"start":4579,"enrollment":4137,"conditions":4580,"interventions":4582},"NCT05520775","Semaglutide for Alcohol Use Disorder",[89],"2024-04-12","2022-09-02",[3819,4581],"Cigarette Smoking",[4555,4573],{"trials":4584,"activeCount":100},[],{"trials":4586,"activeCount":100},[],{"trials":4588,"activeCount":100},[],{"intervention":4573,"totalTrials":96,"cells":4590},{"EARLY_PHASE1":4591,"PHASE1":4593,"PHASE2":4595,"PHASE3":4605,"PHASE4":4607,"NA":4609},{"trials":4592,"activeCount":100},[],{"trials":4594,"activeCount":100},[],{"trials":4596,"activeCount":100},[4597,4601],{"nctId":4564,"briefTitle":4565,"status":149,"phases":4598,"primaryCompletion":4567,"completion":4567,"start":4568,"enrollment":194,"conditions":4599,"interventions":4600},[89],[4570,4571],[4555,4573],{"nctId":4575,"briefTitle":4576,"status":149,"phases":4602,"primaryCompletion":4578,"completion":780,"start":4579,"enrollment":4137,"conditions":4603,"interventions":4604},[89],[3819,4581],[4555,4573],{"trials":4606,"activeCount":100},[],{"trials":4608,"activeCount":100},[],{"trials":4610,"activeCount":100},[],{"intervention":4612,"totalTrials":96,"cells":4613},"Warfarin",{"EARLY_PHASE1":4614,"PHASE1":4616,"PHASE2":4629,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4615,"activeCount":100},[],{"trials":4617,"activeCount":100},[4618],{"nctId":4619,"briefTitle":4620,"status":149,"phases":4621,"primaryCompletion":3302,"completion":3302,"start":4622,"enrollment":4623,"conditions":4624,"interventions":4627},"NCT01250535","Human Cytochrome P450 4F Enzymes and Drug Interactions",[88],"2010-12",19,[4625,4626],"Healthy Volunteers","Drug Drug Interactions",[4612,4628],"Lovastatin",{"trials":4630,"activeCount":100},[4631],{"nctId":4632,"briefTitle":4633,"status":731,"phases":4634,"primaryCompletion":152,"completion":152,"start":4635,"enrollment":233,"conditions":4636,"interventions":4637},"NCT01036802","Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease",[89],"2009-12",[4091],[4612],{"trials":4639,"activeCount":100},[],{"trials":4641,"activeCount":100},[],{"trials":4643,"activeCount":100},[],{"intervention":4645,"totalTrials":96,"cells":4646},"Liquid Peanut Extract",{"EARLY_PHASE1":4647,"PHASE1":4649,"PHASE2":4651,"PHASE3":4669,"PHASE4":4671,"NA":4673},{"trials":4648,"activeCount":100},[],{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[4653,4661],{"nctId":4654,"briefTitle":4655,"status":149,"phases":4656,"primaryCompletion":4657,"completion":4657,"start":1859,"enrollment":453,"conditions":4658,"interventions":4660},"NCT02304991","FARE Peanut SLIT and Early Tolerance Induction",[89],"2020-12-31",[4300,4659,4291,4284],"Food Allergy",[4645],{"nctId":4662,"briefTitle":4663,"status":149,"phases":4664,"primaryCompletion":4665,"completion":4665,"start":290,"enrollment":19,"conditions":4666,"interventions":4667},"NCT01373242","Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance",[88,89],"2018-04-16",[4300,4291,4659,4284],[4668],"Liquid peanut extract",{"trials":4670,"activeCount":100},[],{"trials":4672,"activeCount":100},[],{"trials":4674,"activeCount":100},[],{"intervention":4676,"totalTrials":96,"cells":4677},"Vitamin D3",{"EARLY_PHASE1":4678,"PHASE1":4680,"PHASE2":4682,"PHASE3":4705,"PHASE4":4707,"NA":4709},{"trials":4679,"activeCount":100},[],{"trials":4681,"activeCount":100},[],{"trials":4683,"activeCount":100},[4684,4693],{"nctId":4685,"briefTitle":4686,"status":149,"phases":4687,"primaryCompletion":4688,"completion":4688,"start":4689,"enrollment":31,"conditions":4690,"interventions":4692},"NCT02464059","Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD",[89],"2020-04-15","2015-11-10",[4691],"Pulmonary Disease, Chronic Obstructive",[4676],{"nctId":4694,"briefTitle":4695,"status":731,"phases":4696,"primaryCompletion":4697,"completion":4697,"start":4698,"enrollment":194,"conditions":4699,"interventions":4701},"NCT03313076","Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury",[89],"2020-07-31","2018-07-19",[4700],"Chronic Pain Following Thermal Burn Injury",[4702,4676,4703,4704],"Omega-3 fatty acids","Vitamin D3 (cholecalciferol) placebo","Omega-3 fatty acid placebo",{"trials":4706,"activeCount":100},[],{"trials":4708,"activeCount":100},[],{"trials":4710,"activeCount":100},[],{"intervention":4712,"totalTrials":96,"cells":4713},"Peanut oral immunotherapy",{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4718,"PHASE3":4736,"PHASE4":4738,"NA":4740},{"trials":4715,"activeCount":100},[],{"trials":4717,"activeCount":100},[],{"trials":4719,"activeCount":100},[4720,4728],{"nctId":4721,"briefTitle":4722,"status":149,"phases":4723,"primaryCompletion":4724,"completion":4724,"start":4725,"enrollment":1877,"conditions":4726,"interventions":4727},"NCT00932828","Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study",[89],"2017-02-01","2009-06-22",[4291],[4712],{"nctId":4729,"briefTitle":4730,"status":149,"phases":4731,"primaryCompletion":3278,"completion":3278,"start":291,"enrollment":1941,"conditions":4732,"interventions":4733},"NCT00932282","Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy",[88,89],[4300],[4734,4735],"Peanut Oral Immunotherapy","Omalizumab",{"trials":4737,"activeCount":100},[],{"trials":4739,"activeCount":100},[],{"trials":4741,"activeCount":100},[],{"intervention":4325,"totalTrials":96,"cells":4743},{"EARLY_PHASE1":4744,"PHASE1":4746,"PHASE2":4748,"PHASE3":4758,"PHASE4":4760,"NA":4762},{"trials":4745,"activeCount":100},[],{"trials":4747,"activeCount":100},[],{"trials":4749,"activeCount":100},[4750,4754],{"nctId":4318,"briefTitle":4319,"status":301,"phases":4751,"primaryCompletion":4321,"completion":4321,"start":4322,"enrollment":100,"conditions":4752,"interventions":4753},[88,89],[4252],[4309,4325],{"nctId":4340,"briefTitle":4341,"status":301,"phases":4755,"primaryCompletion":4321,"completion":4321,"start":4343,"enrollment":100,"conditions":4756,"interventions":4757},[88,89],[4252],[4309,4325],{"trials":4759,"activeCount":100},[],{"trials":4761,"activeCount":100},[],{"trials":4763,"activeCount":100},[],{"intervention":4765,"totalTrials":183,"cells":4766},"Peanut flour",{"EARLY_PHASE1":4767,"PHASE1":4769,"PHASE2":4771,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4768,"activeCount":100},[],{"trials":4770,"activeCount":100},[],{"trials":4772,"activeCount":100},[4773],{"nctId":4774,"briefTitle":4775,"status":731,"phases":4776,"primaryCompletion":4415,"completion":4415,"start":4622,"enrollment":1186,"conditions":4777,"interventions":4778},"NCT01274429","Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults",[88,89],[4284],[4765],{"trials":4780,"activeCount":100},[],{"trials":4782,"activeCount":100},[],{"trials":4784,"activeCount":100},[],{"intervention":4786,"totalTrials":183,"cells":4787},"Liraglutide Pen Injector",{"EARLY_PHASE1":4788,"PHASE1":4790,"PHASE2":4792,"PHASE3":4803,"PHASE4":4805,"NA":4807},{"trials":4789,"activeCount":100},[],{"trials":4791,"activeCount":100},[],{"trials":4793,"activeCount":100},[4794],{"nctId":4795,"briefTitle":4796,"status":731,"phases":4797,"primaryCompletion":4798,"completion":4798,"start":4799,"enrollment":3279,"conditions":4800,"interventions":4802},"NCT04763564","Efficacy of Liraglutide Therapy in Patients With IPAA",[89],"2023-10-16","2022-03-22",[528,4801],"Irritable Pouch Syndrome",[4786],{"trials":4804,"activeCount":100},[],{"trials":4806,"activeCount":100},[],{"trials":4808,"activeCount":100},[],{"intervention":1866,"totalTrials":183,"cells":4810},{"EARLY_PHASE1":4811,"PHASE1":4813,"PHASE2":4815,"PHASE3":4821,"PHASE4":4823,"NA":4825},{"trials":4812,"activeCount":100},[],{"trials":4814,"activeCount":100},[],{"trials":4816,"activeCount":100},[4817],{"nctId":1856,"briefTitle":1857,"status":731,"phases":4818,"primaryCompletion":1859,"completion":1860,"start":1178,"enrollment":1861,"conditions":4819,"interventions":4820},[89],[1706,1863],[1865,1866,1847,1867,1868,1869],{"trials":4822,"activeCount":100},[],{"trials":4824,"activeCount":100},[],{"trials":4826,"activeCount":100},[],{"intervention":1868,"totalTrials":183,"cells":4828},{"EARLY_PHASE1":4829,"PHASE1":4831,"PHASE2":4833,"PHASE3":4839,"PHASE4":4841,"NA":4843},{"trials":4830,"activeCount":100},[],{"trials":4832,"activeCount":100},[],{"trials":4834,"activeCount":100},[4835],{"nctId":1856,"briefTitle":1857,"status":731,"phases":4836,"primaryCompletion":1859,"completion":1860,"start":1178,"enrollment":1861,"conditions":4837,"interventions":4838},[89],[1706,1863],[1865,1866,1847,1867,1868,1869],{"trials":4840,"activeCount":100},[],{"trials":4842,"activeCount":100},[],{"trials":4844,"activeCount":100},[],{"intervention":1869,"totalTrials":183,"cells":4846},{"EARLY_PHASE1":4847,"PHASE1":4849,"PHASE2":4851,"PHASE3":4857,"PHASE4":4859,"NA":4861},{"trials":4848,"activeCount":100},[],{"trials":4850,"activeCount":100},[],{"trials":4852,"activeCount":100},[4853],{"nctId":1856,"briefTitle":1857,"status":731,"phases":4854,"primaryCompletion":1859,"completion":1860,"start":1178,"enrollment":1861,"conditions":4855,"interventions":4856},[89],[1706,1863],[1865,1866,1847,1867,1868,1869],{"trials":4858,"activeCount":100},[],{"trials":4860,"activeCount":100},[],{"trials":4862,"activeCount":100},[],{"intervention":4864,"totalTrials":183,"cells":4865},"Budesonide Respules",{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4879,"PHASE4":4881,"NA":4883},{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[],{"trials":4871,"activeCount":100},[4872],{"nctId":4873,"briefTitle":4874,"status":301,"phases":4875,"primaryCompletion":1967,"completion":1967,"start":4424,"enrollment":100,"conditions":4876,"interventions":4878},"NCT01814618","Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery",[89],[181,3080,4877],"Paranasal Sinus Diseases",[4864],{"trials":4880,"activeCount":100},[],{"trials":4882,"activeCount":100},[],{"trials":4884,"activeCount":100},[],{"intervention":4886,"totalTrials":183,"cells":4887},"Mepolizumab 300 mg",{"EARLY_PHASE1":4888,"PHASE1":4890,"PHASE2":4892,"PHASE3":4905,"PHASE4":4907,"NA":4909},{"trials":4889,"activeCount":100},[],{"trials":4891,"activeCount":100},[],{"trials":4893,"activeCount":100},[4894],{"nctId":4895,"briefTitle":4896,"status":149,"phases":4897,"primaryCompletion":4898,"completion":4899,"start":4900,"enrollment":4901,"conditions":4902,"interventions":4903},"NCT03656380","Mepo for Eosinophilic Esophagitis (EoE) Study",[89],"2022-06-06","2022-12-09","2019-03-20",66,[340,339],[4886,4904],"Mepolizumab 100 mg",{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[],{"trials":4910,"activeCount":100},[],{"intervention":4904,"totalTrials":183,"cells":4912},{"EARLY_PHASE1":4913,"PHASE1":4915,"PHASE2":4917,"PHASE3":4923,"PHASE4":4925,"NA":4927},{"trials":4914,"activeCount":100},[],{"trials":4916,"activeCount":100},[],{"trials":4918,"activeCount":100},[4919],{"nctId":4895,"briefTitle":4896,"status":149,"phases":4920,"primaryCompletion":4898,"completion":4899,"start":4900,"enrollment":4901,"conditions":4921,"interventions":4922},[89],[340,339],[4886,4904],{"trials":4924,"activeCount":100},[],{"trials":4926,"activeCount":100},[],{"trials":4928,"activeCount":100},[],{"intervention":4930,"totalTrials":183,"cells":4931},"Tranexamic acid",{"EARLY_PHASE1":4932,"PHASE1":4934,"PHASE2":4936,"PHASE3":4949,"PHASE4":4951,"NA":4953},{"trials":4933,"activeCount":100},[],{"trials":4935,"activeCount":100},[],{"trials":4937,"activeCount":100},[4938],{"nctId":4939,"briefTitle":4940,"status":301,"phases":4941,"primaryCompletion":4942,"completion":4942,"start":4943,"enrollment":100,"conditions":4944,"interventions":4948},"NCT04863339","Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery",[89],"2022-04","2022-03",[4945,4946,4947],"Pituitary Tumor","Blood Loss","Surgery",[4930],{"trials":4950,"activeCount":100},[],{"trials":4952,"activeCount":100},[],{"trials":4954,"activeCount":100},[],{"intervention":2031,"totalTrials":183,"cells":4956},{"EARLY_PHASE1":4957,"PHASE1":4959,"PHASE2":4961,"PHASE3":4967,"PHASE4":4969,"NA":4971},{"trials":4958,"activeCount":100},[],{"trials":4960,"activeCount":100},[],{"trials":4962,"activeCount":100},[4963],{"nctId":2022,"briefTitle":2023,"status":149,"phases":4964,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":4965,"interventions":4966},[89],[2029],[2031,2032,2033,2034,2013,2035,2036],{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[],{"trials":4972,"activeCount":100},[],{"intervention":2032,"totalTrials":183,"cells":4974},{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4985,"PHASE4":4987,"NA":4989},{"trials":4976,"activeCount":100},[],{"trials":4978,"activeCount":100},[],{"trials":4980,"activeCount":100},[4981],{"nctId":2022,"briefTitle":2023,"status":149,"phases":4982,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":4983,"interventions":4984},[89],[2029],[2031,2032,2033,2034,2013,2035,2036],{"trials":4986,"activeCount":100},[],{"trials":4988,"activeCount":100},[],{"trials":4990,"activeCount":100},[],{"intervention":2034,"totalTrials":183,"cells":4992},{"EARLY_PHASE1":4993,"PHASE1":4995,"PHASE2":4997,"PHASE3":5003,"PHASE4":5005,"NA":5007},{"trials":4994,"activeCount":100},[],{"trials":4996,"activeCount":100},[],{"trials":4998,"activeCount":100},[4999],{"nctId":2022,"briefTitle":2023,"status":149,"phases":5000,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":5001,"interventions":5002},[89],[2029],[2031,2032,2033,2034,2013,2035,2036],{"trials":5004,"activeCount":100},[],{"trials":5006,"activeCount":100},[],{"trials":5008,"activeCount":100},[],{"intervention":2036,"totalTrials":183,"cells":5010},{"EARLY_PHASE1":5011,"PHASE1":5013,"PHASE2":5015,"PHASE3":5021,"PHASE4":5023,"NA":5025},{"trials":5012,"activeCount":100},[],{"trials":5014,"activeCount":100},[],{"trials":5016,"activeCount":100},[5017],{"nctId":2022,"briefTitle":2023,"status":149,"phases":5018,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":5019,"interventions":5020},[89],[2029],[2031,2032,2033,2034,2013,2035,2036],{"trials":5022,"activeCount":100},[],{"trials":5024,"activeCount":100},[],{"trials":5026,"activeCount":100},[],{"intervention":5028,"totalTrials":183,"cells":5029},"Ergocalciferol",{"EARLY_PHASE1":5030,"PHASE1":5032,"PHASE2":5034,"PHASE3":5046,"PHASE4":5048,"NA":5050},{"trials":5031,"activeCount":100},[],{"trials":5033,"activeCount":100},[],{"trials":5035,"activeCount":100},[5036],{"nctId":5037,"briefTitle":5038,"status":149,"phases":5039,"primaryCompletion":5040,"completion":5040,"start":5041,"enrollment":869,"conditions":5042,"interventions":5045},"NCT05619289","Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn",[89],"2026-01-16","2023-04-12",[5043,5044],"Burn Injury","Chronic Pain",[5028],{"trials":5047,"activeCount":100},[],{"trials":5049,"activeCount":100},[],{"trials":5051,"activeCount":100},[],{"intervention":5053,"totalTrials":183,"cells":5054},"Gamma Tocopherol 700 mg capsules,",{"EARLY_PHASE1":5055,"PHASE1":5057,"PHASE2":5059,"PHASE3":5068,"PHASE4":5070,"NA":5072},{"trials":5056,"activeCount":100},[],{"trials":5058,"activeCount":100},[],{"trials":5060,"activeCount":100},[5061],{"nctId":5062,"briefTitle":5063,"status":149,"phases":5064,"primaryCompletion":1838,"completion":3277,"start":4415,"enrollment":31,"conditions":5065,"interventions":5067},"NCT02104505","Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS",[88,89],[5066],"Mild, Allergic Asthma",[5053],{"trials":5069,"activeCount":100},[],{"trials":5071,"activeCount":100},[],{"trials":5073,"activeCount":100},[],{"intervention":5075,"totalTrials":183,"cells":5076},"Open label peanut OIT",{"EARLY_PHASE1":5077,"PHASE1":5079,"PHASE2":5081,"PHASE3":5090,"PHASE4":5092,"NA":5094},{"trials":5078,"activeCount":100},[],{"trials":5080,"activeCount":100},[],{"trials":5082,"activeCount":100},[5083],{"nctId":5084,"briefTitle":5085,"status":149,"phases":5086,"primaryCompletion":5087,"completion":5087,"start":193,"enrollment":9,"conditions":5088,"interventions":5089},"NCT01814241","Mechanisms of Desensitization During Peanut Oral Immunotherapy",[89],"2015-12",[4291],[5075],{"trials":5091,"activeCount":100},[],{"trials":5093,"activeCount":100},[],{"trials":5095,"activeCount":100},[],{"intervention":1818,"totalTrials":183,"cells":5097},{"EARLY_PHASE1":5098,"PHASE1":5100,"PHASE2":5102,"PHASE3":5108,"PHASE4":5110,"NA":5112},{"trials":5099,"activeCount":100},[],{"trials":5101,"activeCount":100},[],{"trials":5103,"activeCount":100},[5104],{"nctId":1808,"briefTitle":1809,"status":149,"phases":5105,"primaryCompletion":1811,"completion":1177,"start":1812,"enrollment":1813,"conditions":5106,"interventions":5107},[89],[1815,1816],[1779,1818],{"trials":5109,"activeCount":100},[],{"trials":5111,"activeCount":100},[],{"trials":5113,"activeCount":100},[],{"intervention":5115,"totalTrials":183,"cells":5116},"Calcium DTPA",{"EARLY_PHASE1":5117,"PHASE1":5119,"PHASE2":5121,"PHASE3":5135,"PHASE4":5137,"NA":5139},{"trials":5118,"activeCount":100},[],{"trials":5120,"activeCount":100},[],{"trials":5122,"activeCount":100},[5123],{"nctId":5124,"briefTitle":5125,"status":731,"phases":5126,"primaryCompletion":5127,"completion":5127,"start":3936,"enrollment":183,"conditions":5128,"interventions":5133},"NCT02947022","Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease",[88,89],"2017-01-31",[5129,5130,5131,5132],"Headache","Cognitive Disturbance","Skin Hyperpigmentation","Arthralgia",[5115,5134],"Zinc DTPA",{"trials":5136,"activeCount":100},[],{"trials":5138,"activeCount":100},[],{"trials":5140,"activeCount":100},[],{"intervention":5134,"totalTrials":183,"cells":5142},{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5147,"PHASE3":5153,"PHASE4":5155,"NA":5157},{"trials":5144,"activeCount":100},[],{"trials":5146,"activeCount":100},[],{"trials":5148,"activeCount":100},[5149],{"nctId":5124,"briefTitle":5125,"status":731,"phases":5150,"primaryCompletion":5127,"completion":5127,"start":3936,"enrollment":183,"conditions":5151,"interventions":5152},[88,89],[5129,5130,5131,5132],[5115,5134],{"trials":5154,"activeCount":100},[],{"trials":5156,"activeCount":100},[],{"trials":5158,"activeCount":100},[],{"intervention":5160,"totalTrials":183,"cells":5161},"Retinoic acid",{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5166,"PHASE3":5176,"PHASE4":5178,"NA":5180},{"trials":5163,"activeCount":100},[],{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[5168],{"nctId":5169,"briefTitle":5170,"status":301,"phases":5171,"primaryCompletion":2334,"completion":2334,"start":3701,"enrollment":100,"conditions":5172,"interventions":5174},"NCT01275274","Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens",[89],[5173],"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",[5160,5175],"Standard of care",{"trials":5177,"activeCount":100},[],{"trials":5179,"activeCount":100},[],{"trials":5181,"activeCount":100},[],{"intervention":5175,"totalTrials":183,"cells":5183},{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5188,"PHASE3":5194,"PHASE4":5196,"NA":5198},{"trials":5185,"activeCount":100},[],{"trials":5187,"activeCount":100},[],{"trials":5189,"activeCount":100},[5190],{"nctId":5169,"briefTitle":5170,"status":301,"phases":5191,"primaryCompletion":2334,"completion":2334,"start":3701,"enrollment":100,"conditions":5192,"interventions":5193},[89],[5173],[5160,5175],{"trials":5195,"activeCount":100},[],{"trials":5197,"activeCount":100},[],{"trials":5199,"activeCount":100},[],{"intervention":5201,"totalTrials":183,"cells":5202},"Drospirenone-Ethinyl Estradiol Oral",{"EARLY_PHASE1":5203,"PHASE1":5205,"PHASE2":5207,"PHASE3":5220,"PHASE4":5222,"NA":5224},{"trials":5204,"activeCount":100},[],{"trials":5206,"activeCount":100},[],{"trials":5208,"activeCount":100},[5209],{"nctId":5210,"briefTitle":5211,"status":731,"phases":5212,"primaryCompletion":5213,"completion":5213,"start":5214,"enrollment":3279,"conditions":5215,"interventions":5219},"NCT04278755","Binge Eating & Birth Control",[89],"2022-05-17","2020-09-24",[249,5216,5217,5218],"Binge Eating","Eating Disorders","Binge-Eating Disorder",[5201],{"trials":5221,"activeCount":100},[],{"trials":5223,"activeCount":100},[],{"trials":5225,"activeCount":100},[],{"intervention":5227,"totalTrials":183,"cells":5228},"nicotinamide",{"EARLY_PHASE1":5229,"PHASE1":5231,"PHASE2":5233,"PHASE3":5244,"PHASE4":5246,"NA":5248},{"trials":5230,"activeCount":100},[],{"trials":5232,"activeCount":100},[],{"trials":5234,"activeCount":100},[5235],{"nctId":5236,"briefTitle":5237,"status":149,"phases":5238,"primaryCompletion":5239,"completion":5239,"start":5240,"enrollment":31,"conditions":5241,"interventions":5243},"NCT03419364","Study of Nicotinamide in Early Onset Preeclampsia",[89],"2021-08-31","2017-11-01",[5242,618],"Pre-Eclampsia",[5227],{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[],{"intervention":5251,"totalTrials":183,"cells":5252},"G6PD Deficient Red Blood Cell Transfusion",{"EARLY_PHASE1":5253,"PHASE1":5255,"PHASE2":5257,"PHASE3":5270,"PHASE4":5272,"NA":5274},{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[],{"trials":5258,"activeCount":100},[5259],{"nctId":5260,"briefTitle":5261,"status":731,"phases":5262,"primaryCompletion":5263,"completion":5264,"start":5265,"enrollment":3279,"conditions":5266,"interventions":5268},"NCT04028700","The Impact of Oxidative Stress on Erythrocyte Biology",[89],"2024-07-18","2024-08-16","2022-01-02",[5267],"Sickle Cell Disease Without Crisis",[5251,5269],"Non-G6PD deficient Red Blood Cell Transfusion",{"trials":5271,"activeCount":100},[],{"trials":5273,"activeCount":100},[],{"trials":5275,"activeCount":100},[],{"intervention":5269,"totalTrials":183,"cells":5277},{"EARLY_PHASE1":5278,"PHASE1":5280,"PHASE2":5282,"PHASE3":5288,"PHASE4":5290,"NA":5292},{"trials":5279,"activeCount":100},[],{"trials":5281,"activeCount":100},[],{"trials":5283,"activeCount":100},[5284],{"nctId":5260,"briefTitle":5261,"status":731,"phases":5285,"primaryCompletion":5263,"completion":5264,"start":5265,"enrollment":3279,"conditions":5286,"interventions":5287},[89],[5267],[5251,5269],{"trials":5289,"activeCount":100},[],{"trials":5291,"activeCount":100},[],{"trials":5293,"activeCount":100},[],{"intervention":5295,"totalTrials":183,"cells":5296},"Sulforaphane",{"EARLY_PHASE1":5297,"PHASE1":5299,"PHASE2":5301,"PHASE3":5315,"PHASE4":5317,"NA":5319},{"trials":5298,"activeCount":100},[],{"trials":5300,"activeCount":100},[],{"trials":5302,"activeCount":100},[5303],{"nctId":5304,"briefTitle":5305,"status":149,"phases":5306,"primaryCompletion":5307,"completion":5307,"start":5308,"enrollment":4137,"conditions":5309,"interventions":5314},"NCT02909959","Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder",[89],"2019-05-30","2017-03-01",[5310,5311,5312,5313],"Autism Spectrum Disorder","Autistic Disorder","Neurodevelopmental Disorder","Childhood Developmental Disorders, Pervasive",[5295],{"trials":5316,"activeCount":100},[],{"trials":5318,"activeCount":100},[],{"trials":5320,"activeCount":100},[],{"intervention":1958,"totalTrials":183,"cells":5322},{"EARLY_PHASE1":5323,"PHASE1":5325,"PHASE2":5327,"PHASE3":5333,"PHASE4":5335,"NA":5337},{"trials":5324,"activeCount":100},[],{"trials":5326,"activeCount":100},[],{"trials":5328,"activeCount":100},[5329],{"nctId":1950,"briefTitle":1951,"status":149,"phases":5330,"primaryCompletion":1953,"completion":1954,"start":1179,"enrollment":1955,"conditions":5331,"interventions":5332},[89],[21],[1931,1958],{"trials":5334,"activeCount":100},[],{"trials":5336,"activeCount":100},[],{"trials":5338,"activeCount":100},[],{"intervention":5340,"totalTrials":183,"cells":5341},"Standard of care treatment",{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5357,"PHASE4":5359,"NA":5361},{"trials":5343,"activeCount":100},[],{"trials":5345,"activeCount":100},[],{"trials":5347,"activeCount":100},[5348],{"nctId":5349,"briefTitle":5350,"status":301,"phases":5351,"primaryCompletion":5352,"completion":5352,"start":5353,"enrollment":100,"conditions":5354,"interventions":5355},"NCT01275287","Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab",[89],"2012-12","2011-05",[5173],[5340,5356],"eculizumab",{"trials":5358,"activeCount":100},[],{"trials":5360,"activeCount":100},[],{"trials":5362,"activeCount":100},[],{"intervention":5356,"totalTrials":183,"cells":5364},{"EARLY_PHASE1":5365,"PHASE1":5367,"PHASE2":5369,"PHASE3":5375,"PHASE4":5377,"NA":5379},{"trials":5366,"activeCount":100},[],{"trials":5368,"activeCount":100},[],{"trials":5370,"activeCount":100},[5371],{"nctId":5349,"briefTitle":5350,"status":301,"phases":5372,"primaryCompletion":5352,"completion":5352,"start":5353,"enrollment":100,"conditions":5373,"interventions":5374},[89],[5173],[5340,5356],{"trials":5376,"activeCount":100},[],{"trials":5378,"activeCount":100},[],{"trials":5380,"activeCount":100},[],{"intervention":5382,"totalTrials":183,"cells":5383},"topical cyclosporine ophthalmic suspension 0.05%",{"EARLY_PHASE1":5384,"PHASE1":5386,"PHASE2":5388,"PHASE3":5399,"PHASE4":5401,"NA":5403},{"trials":5385,"activeCount":100},[],{"trials":5387,"activeCount":100},[],{"trials":5389,"activeCount":100},[5390],{"nctId":5391,"briefTitle":5392,"status":149,"phases":5393,"primaryCompletion":5394,"completion":5394,"start":1811,"enrollment":37,"conditions":5395,"interventions":5397},"NCT01064830","Topical Cyclosporine Suspension for the Treatment of Brittle Nails",[89],"2011-08",[5396],"Brittle Nail Syndrome",[5382,5398],"vehicle",{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[],{"trials":5404,"activeCount":100},[],{"intervention":5398,"totalTrials":183,"cells":5406},{"EARLY_PHASE1":5407,"PHASE1":5409,"PHASE2":5411,"PHASE3":5417,"PHASE4":5419,"NA":5421},{"trials":5408,"activeCount":100},[],{"trials":5410,"activeCount":100},[],{"trials":5412,"activeCount":100},[5413],{"nctId":5391,"briefTitle":5392,"status":149,"phases":5414,"primaryCompletion":5394,"completion":5394,"start":1811,"enrollment":37,"conditions":5415,"interventions":5416},[89],[5396],[5382,5398],{"trials":5418,"activeCount":100},[],{"trials":5420,"activeCount":100},[],{"trials":5422,"activeCount":100},[],{"intervention":5424,"totalTrials":183,"cells":5425},"Lucinactant first",{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5430,"PHASE3":5439,"PHASE4":5441,"NA":5443},{"trials":5427,"activeCount":100},[],{"trials":5429,"activeCount":100},[],{"trials":5431,"activeCount":100},[5432],{"nctId":5433,"briefTitle":5434,"status":149,"phases":5435,"primaryCompletion":5436,"completion":5436,"start":2383,"enrollment":572,"conditions":5437,"interventions":5438},"NCT00934362","Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease",[89],"2010-08",[1706],[5424],{"trials":5440,"activeCount":100},[],{"trials":5442,"activeCount":100},[],{"trials":5444,"activeCount":100},[],{"intervention":5446,"totalTrials":183,"cells":5447},"Combination tenofovir-emtricitabine",{"EARLY_PHASE1":5448,"PHASE1":5450,"PHASE2":5452,"PHASE3":5462,"PHASE4":5464,"NA":5466},{"trials":5449,"activeCount":100},[],{"trials":5451,"activeCount":100},[],{"trials":5453,"activeCount":100},[5454],{"nctId":5455,"briefTitle":5456,"status":149,"phases":5457,"primaryCompletion":2830,"completion":2830,"start":5458,"enrollment":5459,"conditions":5460,"interventions":5461},"NCT00204308","Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP",[89],"2005-03",400,[15,1816],[5446],{"trials":5463,"activeCount":100},[],{"trials":5465,"activeCount":100},[],{"trials":5467,"activeCount":100},[],{"intervention":297,"totalTrials":183,"cells":5469},{"EARLY_PHASE1":5470,"PHASE1":5472,"PHASE2":5474,"PHASE3":5480,"PHASE4":5482,"NA":5484},{"trials":5471,"activeCount":100},[],{"trials":5473,"activeCount":100},[],{"trials":5475,"activeCount":100},[5476],{"nctId":286,"briefTitle":287,"status":149,"phases":5477,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":5478,"interventions":5479},[89],[294,295],[63,297],{"trials":5481,"activeCount":100},[],{"trials":5483,"activeCount":100},[],{"trials":5485,"activeCount":100},[],{"intervention":5487,"totalTrials":183,"cells":5488},"Periogard",{"EARLY_PHASE1":5489,"PHASE1":5491,"PHASE2":5493,"PHASE3":5506,"PHASE4":5508,"NA":5510},{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"trials":5494,"activeCount":100},[5495],{"nctId":5496,"briefTitle":5497,"status":731,"phases":5498,"primaryCompletion":5499,"completion":5499,"start":5500,"enrollment":96,"conditions":5501,"interventions":5505},"NCT04748783","Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19",[89],"2021-04-07","2021-03-26",[5502,5503,5504],"COVID19","Coronavirus Infection","SARS CoV-2 Infection",[5487],{"trials":5507,"activeCount":100},[],{"trials":5509,"activeCount":100},[],{"trials":5511,"activeCount":100},[],{"intervention":2170,"totalTrials":183,"cells":5513},{"EARLY_PHASE1":5514,"PHASE1":5516,"PHASE2":5518,"PHASE3":5524,"PHASE4":5526,"NA":5528},{"trials":5515,"activeCount":100},[],{"trials":5517,"activeCount":100},[],{"trials":5519,"activeCount":100},[5520],{"nctId":2161,"briefTitle":2162,"status":149,"phases":5521,"primaryCompletion":2164,"completion":2164,"start":2165,"enrollment":2166,"conditions":5522,"interventions":5523},[89],[2168],[2152,2170],{"trials":5525,"activeCount":100},[],{"trials":5527,"activeCount":100},[],{"trials":5529,"activeCount":100},[],{"intervention":5531,"totalTrials":183,"cells":5532},"coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP",{"EARLY_PHASE1":5533,"PHASE1":5535,"PHASE2":5537,"PHASE3":5546,"PHASE4":5548,"NA":5550},{"trials":5534,"activeCount":100},[],{"trials":5536,"activeCount":100},[],{"trials":5538,"activeCount":100},[5539],{"nctId":5540,"briefTitle":5541,"status":149,"phases":5542,"primaryCompletion":4363,"completion":4363,"start":5543,"enrollment":1755,"conditions":5544,"interventions":5545},"NCT01033942","Pre-Exposure Prophylaxis in YMSM",[89],"2009-08",[15],[5531],{"trials":5547,"activeCount":100},[],{"trials":5549,"activeCount":100},[],{"trials":5551,"activeCount":100},[],{"intervention":265,"totalTrials":183,"cells":5553},{"EARLY_PHASE1":5554,"PHASE1":5556,"PHASE2":5558,"PHASE3":5564,"PHASE4":5566,"NA":5568},{"trials":5555,"activeCount":100},[],{"trials":5557,"activeCount":100},[],{"trials":5559,"activeCount":100},[5560],{"nctId":254,"briefTitle":255,"status":149,"phases":5561,"primaryCompletion":257,"completion":258,"start":259,"enrollment":31,"conditions":5562,"interventions":5563},[89],[261,262,263,27],[265,266,232],{"trials":5565,"activeCount":100},[],{"trials":5567,"activeCount":100},[],{"trials":5569,"activeCount":100},[],{"intervention":266,"totalTrials":183,"cells":5571},{"EARLY_PHASE1":5572,"PHASE1":5574,"PHASE2":5576,"PHASE3":5582,"PHASE4":5584,"NA":5586},{"trials":5573,"activeCount":100},[],{"trials":5575,"activeCount":100},[],{"trials":5577,"activeCount":100},[5578],{"nctId":254,"briefTitle":255,"status":149,"phases":5579,"primaryCompletion":257,"completion":258,"start":259,"enrollment":31,"conditions":5580,"interventions":5581},[89],[261,262,263,27],[265,266,232],{"trials":5583,"activeCount":100},[],{"trials":5585,"activeCount":100},[],{"trials":5587,"activeCount":100},[],{"intervention":5589,"totalTrials":183,"cells":5590},"5% topical lidocaine ointment",{"EARLY_PHASE1":5591,"PHASE1":5593,"PHASE2":5595,"PHASE3":5606,"PHASE4":5608,"NA":5610},{"trials":5592,"activeCount":100},[],{"trials":5594,"activeCount":100},[],{"trials":5596,"activeCount":100},[5597],{"nctId":5598,"briefTitle":5599,"status":731,"phases":5600,"primaryCompletion":5601,"completion":5601,"start":5602,"enrollment":3657,"conditions":5603,"interventions":5605},"NCT00450242","5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis",[89],"2009-01","2006-12",[5604],"Vulvar Vestibulitis",[5589],{"trials":5607,"activeCount":100},[],{"trials":5609,"activeCount":100},[],{"trials":5611,"activeCount":100},[],{"intervention":5613,"totalTrials":183,"cells":5614},"FTC\u002FTDF 200mg\u002F300mg",{"EARLY_PHASE1":5615,"PHASE1":5617,"PHASE2":5619,"PHASE3":5632,"PHASE4":5634,"NA":5636},{"trials":5616,"activeCount":100},[],{"trials":5618,"activeCount":100},[],{"trials":5620,"activeCount":100},[5621],{"nctId":5622,"briefTitle":5623,"status":149,"phases":5624,"primaryCompletion":5625,"completion":5625,"start":5626,"enrollment":19,"conditions":5627,"interventions":5629},"NCT06435026","Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1",[89],"2026-02-11","2024-06-18",[15,5628,1816],"Prevention",[5613,5630,5631],"FTC\u002FTDF 300mg\u002F450mg","FTC\u002FTDF 400mg\u002F600mg",{"trials":5633,"activeCount":100},[],{"trials":5635,"activeCount":100},[],{"trials":5637,"activeCount":100},[],{"intervention":5630,"totalTrials":183,"cells":5639},{"EARLY_PHASE1":5640,"PHASE1":5642,"PHASE2":5644,"PHASE3":5650,"PHASE4":5652,"NA":5654},{"trials":5641,"activeCount":100},[],{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[5646],{"nctId":5622,"briefTitle":5623,"status":149,"phases":5647,"primaryCompletion":5625,"completion":5625,"start":5626,"enrollment":19,"conditions":5648,"interventions":5649},[89],[15,5628,1816],[5613,5630,5631],{"trials":5651,"activeCount":100},[],{"trials":5653,"activeCount":100},[],{"trials":5655,"activeCount":100},[],{"intervention":5631,"totalTrials":183,"cells":5657},{"EARLY_PHASE1":5658,"PHASE1":5660,"PHASE2":5662,"PHASE3":5668,"PHASE4":5670,"NA":5672},{"trials":5659,"activeCount":100},[],{"trials":5661,"activeCount":100},[],{"trials":5663,"activeCount":100},[5664],{"nctId":5622,"briefTitle":5623,"status":149,"phases":5665,"primaryCompletion":5625,"completion":5625,"start":5626,"enrollment":19,"conditions":5666,"interventions":5667},[89],[15,5628,1816],[5613,5630,5631],{"trials":5669,"activeCount":100},[],{"trials":5671,"activeCount":100},[],{"trials":5673,"activeCount":100},[],{"intervention":5675,"totalTrials":183,"cells":5676},"1.5% w\u002Fv Hydrogen Peroxide",{"EARLY_PHASE1":5677,"PHASE1":5679,"PHASE2":5681,"PHASE3":5698,"PHASE4":5700,"NA":5702},{"trials":5678,"activeCount":100},[],{"trials":5680,"activeCount":100},[],{"trials":5682,"activeCount":100},[5683],{"nctId":5684,"briefTitle":5685,"status":731,"phases":5686,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":5690,"interventions":5693},"NCT04584684","Mouth Rinses for Inactivation of COVID-19",[89],"2021-10-21","2020-12-18",128,[5691,5503,5692],"Covid19","SARS-CoV-2 Infection",[5675,5694,5695,5696,5697],"0.12% Chlorohexidine Gluconate","27% Ethanol plus essential oils","0.5% w\u002Fv Povidone-iodide","0.075% Cetylpyridinium Chloride",{"trials":5699,"activeCount":100},[],{"trials":5701,"activeCount":100},[],{"trials":5703,"activeCount":100},[],{"intervention":5694,"totalTrials":183,"cells":5705},{"EARLY_PHASE1":5706,"PHASE1":5708,"PHASE2":5710,"PHASE3":5716,"PHASE4":5718,"NA":5720},{"trials":5707,"activeCount":100},[],{"trials":5709,"activeCount":100},[],{"trials":5711,"activeCount":100},[5712],{"nctId":5684,"briefTitle":5685,"status":731,"phases":5713,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":5714,"interventions":5715},[89],[5691,5503,5692],[5675,5694,5695,5696,5697],{"trials":5717,"activeCount":100},[],{"trials":5719,"activeCount":100},[],{"trials":5721,"activeCount":100},[],{"intervention":5695,"totalTrials":183,"cells":5723},{"EARLY_PHASE1":5724,"PHASE1":5726,"PHASE2":5728,"PHASE3":5734,"PHASE4":5736,"NA":5738},{"trials":5725,"activeCount":100},[],{"trials":5727,"activeCount":100},[],{"trials":5729,"activeCount":100},[5730],{"nctId":5684,"briefTitle":5685,"status":731,"phases":5731,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":5732,"interventions":5733},[89],[5691,5503,5692],[5675,5694,5695,5696,5697],{"trials":5735,"activeCount":100},[],{"trials":5737,"activeCount":100},[],{"trials":5739,"activeCount":100},[],{"intervention":5696,"totalTrials":183,"cells":5741},{"EARLY_PHASE1":5742,"PHASE1":5744,"PHASE2":5746,"PHASE3":5752,"PHASE4":5754,"NA":5756},{"trials":5743,"activeCount":100},[],{"trials":5745,"activeCount":100},[],{"trials":5747,"activeCount":100},[5748],{"nctId":5684,"briefTitle":5685,"status":731,"phases":5749,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":5750,"interventions":5751},[89],[5691,5503,5692],[5675,5694,5695,5696,5697],{"trials":5753,"activeCount":100},[],{"trials":5755,"activeCount":100},[],{"trials":5757,"activeCount":100},[],{"intervention":5697,"totalTrials":183,"cells":5759},{"EARLY_PHASE1":5760,"PHASE1":5762,"PHASE2":5764,"PHASE3":5770,"PHASE4":5772,"NA":5774},{"trials":5761,"activeCount":100},[],{"trials":5763,"activeCount":100},[],{"trials":5765,"activeCount":100},[5766],{"nctId":5684,"briefTitle":5685,"status":731,"phases":5767,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":5768,"interventions":5769},[89],[5691,5503,5692],[5675,5694,5695,5696,5697],{"trials":5771,"activeCount":100},[],{"trials":5773,"activeCount":100},[],{"trials":5775,"activeCount":100},[],{"intervention":5777,"totalTrials":183,"cells":5778},"Ziprasidone",{"EARLY_PHASE1":5779,"PHASE1":5781,"PHASE2":5783,"PHASE3":5793,"PHASE4":5795,"NA":5797},{"trials":5780,"activeCount":100},[],{"trials":5782,"activeCount":100},[],{"trials":5784,"activeCount":100},[5785],{"nctId":5786,"briefTitle":5787,"status":149,"phases":5788,"primaryCompletion":5789,"completion":5789,"start":5790,"enrollment":869,"conditions":5791,"interventions":5792},"NCT01006551","Ziprasidone in Early Onset Schizophrenia Spectrum Disorders",[89],"2006-02","2002-12",[33],[5777],{"trials":5794,"activeCount":100},[],{"trials":5796,"activeCount":100},[],{"trials":5798,"activeCount":100},[],{"intervention":5800,"totalTrials":183,"cells":5801},"Peanut SLIT",{"EARLY_PHASE1":5802,"PHASE1":5804,"PHASE2":5806,"PHASE3":5814,"PHASE4":5816,"NA":5818},{"trials":5803,"activeCount":100},[],{"trials":5805,"activeCount":100},[],{"trials":5807,"activeCount":100},[5808],{"nctId":5809,"briefTitle":5810,"status":149,"phases":5811,"primaryCompletion":1218,"completion":1218,"start":2425,"enrollment":176,"conditions":5812,"interventions":5813},"NCT00597727","A Study of Sublingual Immunotherapy in Peanut-allergic Children",[89],[4291],[5800],{"trials":5815,"activeCount":100},[],{"trials":5817,"activeCount":100},[],{"trials":5819,"activeCount":100},[],{"intervention":5821,"totalTrials":183,"cells":5822},"60 mg Prednisone",{"EARLY_PHASE1":5823,"PHASE1":5825,"PHASE2":5827,"PHASE3":5837,"PHASE4":5839,"NA":5841},{"trials":5824,"activeCount":100},[],{"trials":5826,"activeCount":100},[],{"trials":5828,"activeCount":100},[5829],{"nctId":5830,"briefTitle":5831,"status":149,"phases":5832,"primaryCompletion":5833,"completion":5833,"start":5834,"enrollment":3887,"conditions":5835,"interventions":5836},"NCT03861390","Woodsmoke Particulate + Prednisone",[88,89],"2023-05-12","2019-03-22",[4251],[5821],{"trials":5838,"activeCount":100},[],{"trials":5840,"activeCount":100},[],{"trials":5842,"activeCount":100},[],{"intervention":5844,"totalTrials":183,"cells":5845},"Active FMT, then open label FMT",{"EARLY_PHASE1":5846,"PHASE1":5848,"PHASE2":5850,"PHASE3":5858,"PHASE4":5860,"NA":5862},{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[],{"trials":5851,"activeCount":100},[5852],{"nctId":5853,"briefTitle":5854,"status":731,"phases":5855,"primaryCompletion":2560,"completion":2560,"start":1993,"enrollment":140,"conditions":5856,"interventions":5857},"NCT02782325","Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)",[88,89],[528],[5844],{"trials":5859,"activeCount":100},[],{"trials":5861,"activeCount":100},[],{"trials":5863,"activeCount":100},[],{"intervention":5865,"totalTrials":183,"cells":5866},"clopidogrel 75 mg",{"EARLY_PHASE1":5867,"PHASE1":5869,"PHASE2":5871,"PHASE3":5882,"PHASE4":5884,"NA":5886},{"trials":5868,"activeCount":100},[],{"trials":5870,"activeCount":100},[],{"trials":5872,"activeCount":100},[5873],{"nctId":5874,"briefTitle":5875,"status":149,"phases":5876,"primaryCompletion":1178,"completion":5353,"start":5877,"enrollment":453,"conditions":5878,"interventions":5880},"NCT01097343","Clopidogrel Pharmacogenomics Project",[89],"2010-03",[5879],"Disease Susceptibility",[5865,5881],"Clopidogrel 150 mg",{"trials":5883,"activeCount":100},[],{"trials":5885,"activeCount":100},[],{"trials":5887,"activeCount":100},[],{"intervention":5881,"totalTrials":183,"cells":5889},{"EARLY_PHASE1":5890,"PHASE1":5892,"PHASE2":5894,"PHASE3":5900,"PHASE4":5902,"NA":5904},{"trials":5891,"activeCount":100},[],{"trials":5893,"activeCount":100},[],{"trials":5895,"activeCount":100},[5896],{"nctId":5874,"briefTitle":5875,"status":149,"phases":5897,"primaryCompletion":1178,"completion":5353,"start":5877,"enrollment":453,"conditions":5898,"interventions":5899},[89],[5879],[5865,5881],{"trials":5901,"activeCount":100},[],{"trials":5903,"activeCount":100},[],{"trials":5905,"activeCount":100},[],{"intervention":5907,"totalTrials":183,"cells":5908},"Eluxadoline 100 mg",{"EARLY_PHASE1":5909,"PHASE1":5911,"PHASE2":5913,"PHASE3":5928,"PHASE4":5930,"NA":5932},{"trials":5910,"activeCount":100},[],{"trials":5912,"activeCount":100},[],{"trials":5914,"activeCount":100},[5915],{"nctId":5916,"briefTitle":5917,"status":301,"phases":5918,"primaryCompletion":5919,"completion":5920,"start":2745,"enrollment":100,"conditions":5921,"interventions":5927},"NCT03489265","Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence",[89],"2019-09","2020-03",[5922,5923,5924,5925,5926],"Fecal Incontinence","Accidental Bowel Leakage","Anal Incontinence","Diarrhea","Urge Incontinence",[5907],{"trials":5929,"activeCount":100},[],{"trials":5931,"activeCount":100},[],{"trials":5933,"activeCount":100},[],{"intervention":4702,"totalTrials":183,"cells":5935},{"EARLY_PHASE1":5936,"PHASE1":5938,"PHASE2":5940,"PHASE3":5946,"PHASE4":5948,"NA":5950},{"trials":5937,"activeCount":100},[],{"trials":5939,"activeCount":100},[],{"trials":5941,"activeCount":100},[5942],{"nctId":4694,"briefTitle":4695,"status":731,"phases":5943,"primaryCompletion":4697,"completion":4697,"start":4698,"enrollment":194,"conditions":5944,"interventions":5945},[89],[4700],[4702,4676,4703,4704],{"trials":5947,"activeCount":100},[],{"trials":5949,"activeCount":100},[],{"trials":5951,"activeCount":100},[],{"intervention":4703,"totalTrials":183,"cells":5953},{"EARLY_PHASE1":5954,"PHASE1":5956,"PHASE2":5958,"PHASE3":5964,"PHASE4":5966,"NA":5968},{"trials":5955,"activeCount":100},[],{"trials":5957,"activeCount":100},[],{"trials":5959,"activeCount":100},[5960],{"nctId":4694,"briefTitle":4695,"status":731,"phases":5961,"primaryCompletion":4697,"completion":4697,"start":4698,"enrollment":194,"conditions":5962,"interventions":5963},[89],[4700],[4702,4676,4703,4704],{"trials":5965,"activeCount":100},[],{"trials":5967,"activeCount":100},[],{"trials":5969,"activeCount":100},[],{"intervention":4704,"totalTrials":183,"cells":5971},{"EARLY_PHASE1":5972,"PHASE1":5974,"PHASE2":5976,"PHASE3":5982,"PHASE4":5984,"NA":5986},{"trials":5973,"activeCount":100},[],{"trials":5975,"activeCount":100},[],{"trials":5977,"activeCount":100},[5978],{"nctId":4694,"briefTitle":4695,"status":731,"phases":5979,"primaryCompletion":4697,"completion":4697,"start":4698,"enrollment":194,"conditions":5980,"interventions":5981},[89],[4700],[4702,4676,4703,4704],{"trials":5983,"activeCount":100},[],{"trials":5985,"activeCount":100},[],{"trials":5987,"activeCount":100},[],{"intervention":5989,"totalTrials":183,"cells":5990},"Latuda©",{"EARLY_PHASE1":5991,"PHASE1":5993,"PHASE2":5995,"PHASE3":6014,"PHASE4":6016,"NA":6018},{"trials":5992,"activeCount":100},[],{"trials":5994,"activeCount":100},[],{"trials":5996,"activeCount":100},[5997],{"nctId":5998,"briefTitle":5999,"status":149,"phases":6000,"primaryCompletion":6001,"completion":6001,"start":5352,"enrollment":1793,"conditions":6002,"interventions":6013},"NCT01731119","Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents",[89],"2014-08",[33,1841,6003,6004,5311,6005,6006,6007,6008,6009,6010,6011,6012],"Schizophreniform Disorder","Psychosis NOS","Asperger Syndrome","Child Development Disorders, Pervasive","Bipolar I Disorder","Bipolar II Disorder","Mood Disorder NOS","Severe Major Depression With Psychotic Features","Single Episode Major Depression Without Psychotic Symptoms","Severe Mood Disorder With Psychotic Features",[5989],{"trials":6015,"activeCount":100},[],{"trials":6017,"activeCount":100},[],{"trials":6019,"activeCount":100},[],{"intervention":6021,"totalTrials":183,"cells":6022},"Sildenafil",{"EARLY_PHASE1":6023,"PHASE1":6025,"PHASE2":6027,"PHASE3":6038,"PHASE4":6040,"NA":6042},{"trials":6024,"activeCount":100},[],{"trials":6026,"activeCount":100},[],{"trials":6028,"activeCount":100},[6029],{"nctId":6030,"briefTitle":6031,"status":149,"phases":6032,"primaryCompletion":6033,"completion":6033,"start":6034,"enrollment":4476,"conditions":6035,"interventions":6037},"NCT03142568","Safety of Sildenafil in Premature Infants",[89],"2025-03-01","2018-04-02",[6036],"Bronchopulmonary Dysplasia",[6021],{"trials":6039,"activeCount":100},[],{"trials":6041,"activeCount":100},[],{"trials":6043,"activeCount":100},[],{"intervention":4336,"totalTrials":183,"cells":6045},{"EARLY_PHASE1":6046,"PHASE1":6048,"PHASE2":6050,"PHASE3":6056,"PHASE4":6058,"NA":6060},{"trials":6047,"activeCount":100},[],{"trials":6049,"activeCount":100},[],{"trials":6051,"activeCount":100},[6052],{"nctId":4327,"briefTitle":4328,"status":301,"phases":6053,"primaryCompletion":4330,"completion":4331,"start":4332,"enrollment":100,"conditions":6054,"interventions":6055},[88,89],[4334],[4309,4336,4337,4338],{"trials":6057,"activeCount":100},[],{"trials":6059,"activeCount":100},[],{"trials":6061,"activeCount":100},[],{"intervention":4337,"totalTrials":183,"cells":6063},{"EARLY_PHASE1":6064,"PHASE1":6066,"PHASE2":6068,"PHASE3":6074,"PHASE4":6076,"NA":6078},{"trials":6065,"activeCount":100},[],{"trials":6067,"activeCount":100},[],{"trials":6069,"activeCount":100},[6070],{"nctId":4327,"briefTitle":4328,"status":301,"phases":6071,"primaryCompletion":4330,"completion":4331,"start":4332,"enrollment":100,"conditions":6072,"interventions":6073},[88,89],[4334],[4309,4336,4337,4338],{"trials":6075,"activeCount":100},[],{"trials":6077,"activeCount":100},[],{"trials":6079,"activeCount":100},[],{"intervention":4338,"totalTrials":183,"cells":6081},{"EARLY_PHASE1":6082,"PHASE1":6084,"PHASE2":6086,"PHASE3":6092,"PHASE4":6094,"NA":6096},{"trials":6083,"activeCount":100},[],{"trials":6085,"activeCount":100},[],{"trials":6087,"activeCount":100},[6088],{"nctId":4327,"briefTitle":4328,"status":301,"phases":6089,"primaryCompletion":4330,"completion":4331,"start":4332,"enrollment":100,"conditions":6090,"interventions":6091},[88,89],[4334],[4309,4336,4337,4338],{"trials":6093,"activeCount":100},[],{"trials":6095,"activeCount":100},[],{"trials":6097,"activeCount":100},[],{"intervention":6099,"totalTrials":183,"cells":6100},"Ulipristal Acetate",{"EARLY_PHASE1":6101,"PHASE1":6103,"PHASE2":6105,"PHASE3":6120,"PHASE4":6122,"NA":6124},{"trials":6102,"activeCount":100},[],{"trials":6104,"activeCount":100},[],{"trials":6106,"activeCount":100},[6107],{"nctId":6108,"briefTitle":6109,"status":149,"phases":6110,"primaryCompletion":6111,"completion":6112,"start":6113,"enrollment":233,"conditions":6114,"interventions":6118},"NCT05216952","Ulipristal Acetate for Use in Early Pregnancy Loss",[89],"2023-01-03","2023-04-30","2022-05-11",[6115,6116,6117],"Missed Abortion","Anembryonic Pregnancy","Non-Viable Pregnancy",[6099,6119],"Misoprostol Pill",{"trials":6121,"activeCount":100},[],{"trials":6123,"activeCount":100},[],{"trials":6125,"activeCount":100},[],{"intervention":6119,"totalTrials":183,"cells":6127},{"EARLY_PHASE1":6128,"PHASE1":6130,"PHASE2":6132,"PHASE3":6138,"PHASE4":6140,"NA":6142},{"trials":6129,"activeCount":100},[],{"trials":6131,"activeCount":100},[],{"trials":6133,"activeCount":100},[6134],{"nctId":6108,"briefTitle":6109,"status":149,"phases":6135,"primaryCompletion":6111,"completion":6112,"start":6113,"enrollment":233,"conditions":6136,"interventions":6137},[89],[6115,6116,6117],[6099,6119],{"trials":6139,"activeCount":100},[],{"trials":6141,"activeCount":100},[],{"trials":6143,"activeCount":100},[],{"intervention":6145,"totalTrials":183,"cells":6146},"Vitamin D 2",{"EARLY_PHASE1":6147,"PHASE1":6149,"PHASE2":6151,"PHASE3":6162,"PHASE4":6164,"NA":6166},{"trials":6148,"activeCount":100},[],{"trials":6150,"activeCount":100},[],{"trials":6152,"activeCount":100},[6153],{"nctId":6154,"briefTitle":6155,"status":149,"phases":6156,"primaryCompletion":316,"completion":316,"start":6157,"enrollment":1839,"conditions":6158,"interventions":6160},"NCT05458024","Vitamin D to ENhance TraUma REcovery",[89],"2023-01-24",[6159],"Musculoskeletal Pain",[6145,6161],"Vitamin D2 Placebo",{"trials":6163,"activeCount":100},[],{"trials":6165,"activeCount":100},[],{"trials":6167,"activeCount":100},[],{"intervention":6161,"totalTrials":183,"cells":6169},{"EARLY_PHASE1":6170,"PHASE1":6172,"PHASE2":6174,"PHASE3":6180,"PHASE4":6182,"NA":6184},{"trials":6171,"activeCount":100},[],{"trials":6173,"activeCount":100},[],{"trials":6175,"activeCount":100},[6176],{"nctId":6154,"briefTitle":6155,"status":149,"phases":6177,"primaryCompletion":316,"completion":316,"start":6157,"enrollment":1839,"conditions":6178,"interventions":6179},[89],[6159],[6145,6161],{"trials":6181,"activeCount":100},[],{"trials":6183,"activeCount":100},[],{"trials":6185,"activeCount":100},[],{"intervention":6187,"totalTrials":183,"cells":6188},"High-titer Convalescent COVID-19 Plasma",{"EARLY_PHASE1":6189,"PHASE1":6191,"PHASE2":6193,"PHASE3":6206,"PHASE4":6208,"NA":6210},{"trials":6190,"activeCount":100},[],{"trials":6192,"activeCount":100},[],{"trials":6194,"activeCount":100},[6195],{"nctId":6196,"briefTitle":6197,"status":149,"phases":6198,"primaryCompletion":6199,"completion":6200,"start":6201,"enrollment":207,"conditions":6202,"interventions":6204},"NCT04524507","Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients",[89],"2021-01-04","2021-06-04","2020-08-27",[6203],"COVID-19",[6187,6205],"Standard-titer Convalescent COVID-19 plasma",{"trials":6207,"activeCount":100},[],{"trials":6209,"activeCount":100},[],{"trials":6211,"activeCount":100},[],{"intervention":6205,"totalTrials":183,"cells":6213},{"EARLY_PHASE1":6214,"PHASE1":6216,"PHASE2":6218,"PHASE3":6224,"PHASE4":6226,"NA":6228},{"trials":6215,"activeCount":100},[],{"trials":6217,"activeCount":100},[],{"trials":6219,"activeCount":100},[6220],{"nctId":6196,"briefTitle":6197,"status":149,"phases":6221,"primaryCompletion":6199,"completion":6200,"start":6201,"enrollment":207,"conditions":6222,"interventions":6223},[89],[6203],[6187,6205],{"trials":6225,"activeCount":100},[],{"trials":6227,"activeCount":100},[],{"trials":6229,"activeCount":100},[],{"intervention":6231,"totalTrials":183,"cells":6232},"Furosemide Cohort 1",{"EARLY_PHASE1":6233,"PHASE1":6235,"PHASE2":6237,"PHASE3":6249,"PHASE4":6251,"NA":6253},{"trials":6234,"activeCount":100},[],{"trials":6236,"activeCount":100},[],{"trials":6238,"activeCount":100},[6239],{"nctId":6240,"briefTitle":6241,"status":149,"phases":6242,"primaryCompletion":6243,"completion":6243,"start":6244,"enrollment":735,"conditions":6245,"interventions":6246},"NCT02527798","Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)",[89],"2019-10-15","2015-11-27",[6036],[6231,6247,6248],"Furosemide Cohort 2","Furosemide Cohort 3",{"trials":6250,"activeCount":100},[],{"trials":6252,"activeCount":100},[],{"trials":6254,"activeCount":100},[],{"intervention":6247,"totalTrials":183,"cells":6256},{"EARLY_PHASE1":6257,"PHASE1":6259,"PHASE2":6261,"PHASE3":6267,"PHASE4":6269,"NA":6271},{"trials":6258,"activeCount":100},[],{"trials":6260,"activeCount":100},[],{"trials":6262,"activeCount":100},[6263],{"nctId":6240,"briefTitle":6241,"status":149,"phases":6264,"primaryCompletion":6243,"completion":6243,"start":6244,"enrollment":735,"conditions":6265,"interventions":6266},[89],[6036],[6231,6247,6248],{"trials":6268,"activeCount":100},[],{"trials":6270,"activeCount":100},[],{"trials":6272,"activeCount":100},[],{"intervention":6248,"totalTrials":183,"cells":6274},{"EARLY_PHASE1":6275,"PHASE1":6277,"PHASE2":6279,"PHASE3":6285,"PHASE4":6287,"NA":6289},{"trials":6276,"activeCount":100},[],{"trials":6278,"activeCount":100},[],{"trials":6280,"activeCount":100},[6281],{"nctId":6240,"briefTitle":6241,"status":149,"phases":6282,"primaryCompletion":6243,"completion":6243,"start":6244,"enrollment":735,"conditions":6283,"interventions":6284},[89],[6036],[6231,6247,6248],{"trials":6286,"activeCount":100},[],{"trials":6288,"activeCount":100},[],{"trials":6290,"activeCount":100},[],{"intervention":6292,"totalTrials":183,"cells":6293},"Fluoxetine",{"EARLY_PHASE1":6294,"PHASE1":6296,"PHASE2":6298,"PHASE3":6308,"PHASE4":6310,"NA":6312},{"trials":6295,"activeCount":100},[],{"trials":6297,"activeCount":100},[],{"trials":6299,"activeCount":100},[6300],{"nctId":6301,"briefTitle":6302,"status":149,"phases":6303,"primaryCompletion":6304,"completion":6304,"start":6305,"enrollment":1180,"conditions":6306,"interventions":6307},"NCT00183339","Early Intervention With Fluoxetine in Autism",[89],"2008-02","2005-07",[5311],[6292],{"trials":6309,"activeCount":100},[],{"trials":6311,"activeCount":100},[],{"trials":6313,"activeCount":100},[],{"intervention":309,"totalTrials":183,"cells":6315},{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6320,"PHASE3":6326,"PHASE4":6328,"NA":6330},{"trials":6317,"activeCount":100},[],{"trials":6319,"activeCount":100},[],{"trials":6321,"activeCount":100},[6322],{"nctId":299,"briefTitle":300,"status":301,"phases":6323,"primaryCompletion":303,"completion":303,"start":304,"enrollment":100,"conditions":6324,"interventions":6325},[89],[306],[63,308,309],{"trials":6327,"activeCount":100},[],{"trials":6329,"activeCount":100},[],{"trials":6331,"activeCount":100},[],{"intervention":4212,"totalTrials":183,"cells":6333},{"EARLY_PHASE1":6334,"PHASE1":6336,"PHASE2":6338,"PHASE3":6344,"PHASE4":6346,"NA":6348},{"trials":6335,"activeCount":100},[],{"trials":6337,"activeCount":100},[],{"trials":6339,"activeCount":100},[6340],{"nctId":4206,"briefTitle":4207,"status":149,"phases":6341,"primaryCompletion":2334,"completion":2096,"start":4209,"enrollment":1941,"conditions":6342,"interventions":6343},[89],[4190,2219],[4192,4212],{"trials":6345,"activeCount":100},[],{"trials":6347,"activeCount":100},[],{"trials":6349,"activeCount":100},[],{"intervention":6351,"totalTrials":183,"cells":6352},"Atorvastatin",{"EARLY_PHASE1":6353,"PHASE1":6355,"PHASE2":6357,"PHASE3":6367,"PHASE4":6369,"NA":6371},{"trials":6354,"activeCount":100},[],{"trials":6356,"activeCount":100},[],{"trials":6358,"activeCount":100},[6359],{"nctId":6360,"briefTitle":6361,"status":149,"phases":6362,"primaryCompletion":6363,"completion":6363,"start":3787,"enrollment":1941,"conditions":6364,"interventions":6366},"NCT01732718","Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease",[89],"2018-01-09",[4045,6365],"Sickle Cell Nephropathy",[6351],{"trials":6368,"activeCount":100},[],{"trials":6370,"activeCount":100},[],{"trials":6372,"activeCount":100},[],{"intervention":6374,"totalTrials":183,"cells":6375},"Treprostinil Inhalation Solution",{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6380,"PHASE3":6392,"PHASE4":6394,"NA":6396},{"trials":6377,"activeCount":100},[],{"trials":6379,"activeCount":100},[],{"trials":6381,"activeCount":100},[6382],{"nctId":6383,"briefTitle":6384,"status":731,"phases":6385,"primaryCompletion":6386,"completion":6387,"start":6388,"enrollment":3657,"conditions":6389,"interventions":6391},"NCT02370095","Treprostinil Sodium Inhalation for Patients At High Risk for ARDS",[89],"2017-10-11","2017-11-07","2015-02",[6390],"Respiratory Distress Syndrome, Adult",[6374],{"trials":6393,"activeCount":100},[],{"trials":6395,"activeCount":100},[],{"trials":6397,"activeCount":100},[],{"intervention":6399,"totalTrials":183,"cells":6400},"Onabotulinumtoxin A",{"EARLY_PHASE1":6401,"PHASE1":6403,"PHASE2":6405,"PHASE3":6416,"PHASE4":6418,"NA":6420},{"trials":6402,"activeCount":100},[],{"trials":6404,"activeCount":100},[],{"trials":6406,"activeCount":100},[6407],{"nctId":6408,"briefTitle":6409,"status":149,"phases":6410,"primaryCompletion":6411,"completion":6411,"start":6412,"enrollment":572,"conditions":6413,"interventions":6415},"NCT03301272","Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease",[89],"2019-08-21","2018-03-22",[6414],"Parkinson Disease",[6399],{"trials":6417,"activeCount":100},[],{"trials":6419,"activeCount":100},[],{"trials":6421,"activeCount":100},[],{"intervention":6423,"totalTrials":183,"cells":6424},"HPV vaccine for strains -6, -11, -16, and -18",{"EARLY_PHASE1":6425,"PHASE1":6427,"PHASE2":6429,"PHASE3":6438,"PHASE4":6440,"NA":6442},{"trials":6426,"activeCount":100},[],{"trials":6428,"activeCount":100},[],{"trials":6430,"activeCount":100},[6431],{"nctId":6432,"briefTitle":6433,"status":149,"phases":6434,"primaryCompletion":289,"completion":289,"start":6304,"enrollment":6435,"conditions":6436,"interventions":6437},"NCT00710593","Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women",[89],99,[30],[6423],{"trials":6439,"activeCount":100},[],{"trials":6441,"activeCount":100},[],{"trials":6443,"activeCount":100},[],{"intervention":6445,"totalTrials":183,"cells":6446},"MCT",{"EARLY_PHASE1":6447,"PHASE1":6449,"PHASE2":6451,"PHASE3":6467,"PHASE4":6469,"NA":6471},{"trials":6448,"activeCount":100},[],{"trials":6450,"activeCount":100},[],{"trials":6452,"activeCount":100},[6453],{"nctId":6454,"briefTitle":6455,"status":149,"phases":6456,"primaryCompletion":6457,"completion":6458,"start":6459,"enrollment":6460,"conditions":6461,"interventions":6462},"NCT04129931","PrecISE (Precision Interventions for Severe and\u002For Exacerbation-Prone Asthma) Network Study",[89],"2025-02-19","2025-03-19","2019-12-19",950,[4252],[6445,6463,6464,6465,6466],"Clazakizumab","Broncho-Vaxom","Imatinib Mesylate","Cavosonstat",{"trials":6468,"activeCount":100},[],{"trials":6470,"activeCount":100},[],{"trials":6472,"activeCount":100},[],{"intervention":6463,"totalTrials":183,"cells":6474},{"EARLY_PHASE1":6475,"PHASE1":6477,"PHASE2":6479,"PHASE3":6485,"PHASE4":6487,"NA":6489},{"trials":6476,"activeCount":100},[],{"trials":6478,"activeCount":100},[],{"trials":6480,"activeCount":100},[6481],{"nctId":6454,"briefTitle":6455,"status":149,"phases":6482,"primaryCompletion":6457,"completion":6458,"start":6459,"enrollment":6460,"conditions":6483,"interventions":6484},[89],[4252],[6445,6463,6464,6465,6466],{"trials":6486,"activeCount":100},[],{"trials":6488,"activeCount":100},[],{"trials":6490,"activeCount":100},[],{"intervention":6464,"totalTrials":183,"cells":6492},{"EARLY_PHASE1":6493,"PHASE1":6495,"PHASE2":6497,"PHASE3":6503,"PHASE4":6505,"NA":6507},{"trials":6494,"activeCount":100},[],{"trials":6496,"activeCount":100},[],{"trials":6498,"activeCount":100},[6499],{"nctId":6454,"briefTitle":6455,"status":149,"phases":6500,"primaryCompletion":6457,"completion":6458,"start":6459,"enrollment":6460,"conditions":6501,"interventions":6502},[89],[4252],[6445,6463,6464,6465,6466],{"trials":6504,"activeCount":100},[],{"trials":6506,"activeCount":100},[],{"trials":6508,"activeCount":100},[],{"intervention":6465,"totalTrials":183,"cells":6510},{"EARLY_PHASE1":6511,"PHASE1":6513,"PHASE2":6515,"PHASE3":6521,"PHASE4":6523,"NA":6525},{"trials":6512,"activeCount":100},[],{"trials":6514,"activeCount":100},[],{"trials":6516,"activeCount":100},[6517],{"nctId":6454,"briefTitle":6455,"status":149,"phases":6518,"primaryCompletion":6457,"completion":6458,"start":6459,"enrollment":6460,"conditions":6519,"interventions":6520},[89],[4252],[6445,6463,6464,6465,6466],{"trials":6522,"activeCount":100},[],{"trials":6524,"activeCount":100},[],{"trials":6526,"activeCount":100},[],{"intervention":6466,"totalTrials":183,"cells":6528},{"EARLY_PHASE1":6529,"PHASE1":6531,"PHASE2":6533,"PHASE3":6539,"PHASE4":6541,"NA":6543},{"trials":6530,"activeCount":100},[],{"trials":6532,"activeCount":100},[],{"trials":6534,"activeCount":100},[6535],{"nctId":6454,"briefTitle":6455,"status":149,"phases":6536,"primaryCompletion":6457,"completion":6458,"start":6459,"enrollment":6460,"conditions":6537,"interventions":6538},[89],[4252],[6445,6463,6464,6465,6466],{"trials":6540,"activeCount":100},[],{"trials":6542,"activeCount":100},[],{"trials":6544,"activeCount":100},[],{"intervention":6546,"totalTrials":183,"cells":6547},"18F-fluoroestradiol",{"EARLY_PHASE1":6548,"PHASE1":6550,"PHASE2":6552,"PHASE3":6562,"PHASE4":6564,"NA":6566},{"trials":6549,"activeCount":100},[],{"trials":6551,"activeCount":100},[],{"trials":6553,"activeCount":100},[6554],{"nctId":6555,"briefTitle":6556,"status":149,"phases":6557,"primaryCompletion":6558,"completion":6558,"start":6559,"enrollment":3279,"conditions":6560,"interventions":6561},"NCT04382911","Evaluation of Endometriosis With 18F-fluoroestradiol PET \u002F MRI",[89],"2022-07-11","2020-08-07",[1106],[6546],{"trials":6563,"activeCount":100},[],{"trials":6565,"activeCount":100},[],{"trials":6567,"activeCount":100},[],{"intervention":6569,"totalTrials":183,"cells":6570},"Walnut Protein Flour",{"EARLY_PHASE1":6571,"PHASE1":6573,"PHASE2":6575,"PHASE3":6585,"PHASE4":6587,"NA":6589},{"trials":6572,"activeCount":100},[],{"trials":6574,"activeCount":100},[],{"trials":6576,"activeCount":100},[6577],{"nctId":6578,"briefTitle":6579,"status":301,"phases":6580,"primaryCompletion":2334,"completion":2334,"start":1967,"enrollment":100,"conditions":6581,"interventions":6583},"NCT01834352","Walnut Oral Immunotherapy for Tree Nut Allergy",[88,89],[6582],"Nut Hypersensitivities",[6569,6584],"Oat flour",{"trials":6586,"activeCount":100},[],{"trials":6588,"activeCount":100},[],{"trials":6590,"activeCount":100},[],{"intervention":6584,"totalTrials":183,"cells":6592},{"EARLY_PHASE1":6593,"PHASE1":6595,"PHASE2":6597,"PHASE3":6603,"PHASE4":6605,"NA":6607},{"trials":6594,"activeCount":100},[],{"trials":6596,"activeCount":100},[],{"trials":6598,"activeCount":100},[6599],{"nctId":6578,"briefTitle":6579,"status":301,"phases":6600,"primaryCompletion":2334,"completion":2334,"start":1967,"enrollment":100,"conditions":6601,"interventions":6602},[88,89],[6582],[6569,6584],{"trials":6604,"activeCount":100},[],{"trials":6606,"activeCount":100},[],{"trials":6608,"activeCount":100},[],{"intervention":6610,"totalTrials":183,"cells":6611},"Eptifibatide",{"EARLY_PHASE1":6612,"PHASE1":6614,"PHASE2":6616,"PHASE3":6624,"PHASE4":6626,"NA":6628},{"trials":6613,"activeCount":100},[],{"trials":6615,"activeCount":100},[],{"trials":6617,"activeCount":100},[6618],{"nctId":6619,"briefTitle":6620,"status":731,"phases":6621,"primaryCompletion":2885,"completion":2885,"start":5601,"enrollment":1941,"conditions":6622,"interventions":6623},"NCT00834899","A Safety Study of Eptifibatide in Patients With Sickle Cell Disease",[88,89],[4045],[6610],{"trials":6625,"activeCount":100},[],{"trials":6627,"activeCount":100},[],{"trials":6629,"activeCount":100},[],{"intervention":6631,"totalTrials":183,"cells":6632},"Metronidazole",{"EARLY_PHASE1":6633,"PHASE1":6635,"PHASE2":6637,"PHASE3":6649,"PHASE4":6651,"NA":6653},{"trials":6634,"activeCount":100},[],{"trials":6636,"activeCount":100},[],{"trials":6638,"activeCount":100},[6639],{"nctId":6640,"briefTitle":6641,"status":731,"phases":6642,"primaryCompletion":6643,"completion":6643,"start":6644,"enrollment":1941,"conditions":6645,"interventions":6648},"NCT04186247","Personalized AZithromycin\u002FmetronidAZole Therapy in Pediatric Crohn's Disease (CD)",[89],"2023-12-31","2021-08-13",[6646,6647],"Crohn Disease","Pediatric Crohns Disease",[3082,6631],{"trials":6650,"activeCount":100},[],{"trials":6652,"activeCount":100},[],{"trials":6654,"activeCount":100},[],{"intervention":6656,"totalTrials":183,"cells":6657},"apremilast",{"EARLY_PHASE1":6658,"PHASE1":6660,"PHASE2":6662,"PHASE3":6671,"PHASE4":6673,"NA":6675},{"trials":6659,"activeCount":100},[],{"trials":6661,"activeCount":100},[],{"trials":6663,"activeCount":100},[6664],{"nctId":6665,"briefTitle":6666,"status":731,"phases":6667,"primaryCompletion":303,"completion":1916,"start":1811,"enrollment":233,"conditions":6668,"interventions":6670},"NCT01074502","Apremilast in the Treatment of Moderate to Severe Acne",[89],[6669],"Acne",[6656],{"trials":6672,"activeCount":100},[],{"trials":6674,"activeCount":100},[],{"trials":6676,"activeCount":100},[],{"intervention":6678,"totalTrials":183,"cells":6679},"Raltegravir; valproic acid",{"EARLY_PHASE1":6680,"PHASE1":6682,"PHASE2":6684,"PHASE3":6693,"PHASE4":6695,"NA":6697},{"trials":6681,"activeCount":100},[],{"trials":6683,"activeCount":100},[],{"trials":6685,"activeCount":100},[6686],{"nctId":6687,"briefTitle":6688,"status":731,"phases":6689,"primaryCompletion":3768,"completion":3768,"start":6690,"enrollment":140,"conditions":6691,"interventions":6692},"NCT00614458","MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection",[89],"2007-04",[21],[6678],{"trials":6694,"activeCount":100},[],{"trials":6696,"activeCount":100},[],{"trials":6698,"activeCount":100},[],{"intervention":6700,"totalTrials":183,"cells":6701},"Furosemide (loop diuretic)",{"EARLY_PHASE1":6702,"PHASE1":6704,"PHASE2":6706,"PHASE3":6719,"PHASE4":6721,"NA":6723},{"trials":6703,"activeCount":100},[],{"trials":6705,"activeCount":100},[],{"trials":6707,"activeCount":100},[6708],{"nctId":6709,"briefTitle":6710,"status":149,"phases":6711,"primaryCompletion":6712,"completion":6713,"start":6714,"enrollment":6715,"conditions":6716,"interventions":6718},"NCT04622709","Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis",[89],"2021-06-08","2021-06-22","2020-10-07",39,[6717],"Chronic Kidney Disease Requiring Chronic Dialysis",[6700],{"trials":6720,"activeCount":100},[],{"trials":6722,"activeCount":100},[],{"trials":6724,"activeCount":100},[],{"intervention":1880,"totalTrials":183,"cells":6726},{"EARLY_PHASE1":6727,"PHASE1":6729,"PHASE2":6731,"PHASE3":6737,"PHASE4":6739,"NA":6741},{"trials":6728,"activeCount":100},[],{"trials":6730,"activeCount":100},[],{"trials":6732,"activeCount":100},[6733],{"nctId":1871,"briefTitle":1872,"status":149,"phases":6734,"primaryCompletion":1874,"completion":1875,"start":1876,"enrollment":1877,"conditions":6735,"interventions":6736},[89],[1706],[1880,1847,1867,1881],{"trials":6738,"activeCount":100},[],{"trials":6740,"activeCount":100},[],{"trials":6742,"activeCount":100},[],{"intervention":1881,"totalTrials":183,"cells":6744},{"EARLY_PHASE1":6745,"PHASE1":6747,"PHASE2":6749,"PHASE3":6755,"PHASE4":6757,"NA":6759},{"trials":6746,"activeCount":100},[],{"trials":6748,"activeCount":100},[],{"trials":6750,"activeCount":100},[6751],{"nctId":1871,"briefTitle":1872,"status":149,"phases":6752,"primaryCompletion":1874,"completion":1875,"start":1876,"enrollment":1877,"conditions":6753,"interventions":6754},[89],[1706],[1880,1847,1867,1881],{"trials":6756,"activeCount":100},[],{"trials":6758,"activeCount":100},[],{"trials":6760,"activeCount":100},[],{"intervention":168,"totalTrials":140,"cells":6762},{"EARLY_PHASE1":6763,"PHASE1":6765,"PHASE2":6813,"PHASE3":6815,"PHASE4":6817,"NA":6819},{"trials":6764,"activeCount":100},[],{"trials":6766,"activeCount":100},[6767,6774,6783,6792,6801,6809],{"nctId":6768,"briefTitle":6769,"status":149,"phases":6770,"primaryCompletion":152,"completion":152,"start":5601,"enrollment":225,"conditions":6771,"interventions":6773},"NCT00839124","A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals",[88],[4252,6772],"Hypersensitivity",[168,168],{"nctId":6775,"briefTitle":6776,"status":731,"phases":6777,"primaryCompletion":6778,"completion":6778,"start":3852,"enrollment":716,"conditions":6779,"interventions":6782},"NCT00630461","Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma",[88],"2012-05",[6780,6781],"Mild Allergic Rhinitis","Mild Allergic Rhinitis With Mild Asthma",[168],{"nctId":6784,"briefTitle":6785,"status":149,"phases":6786,"primaryCompletion":4066,"completion":4066,"start":6787,"enrollment":2047,"conditions":6788,"interventions":6791},"NCT00839189","Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults",[88],"2002-10",[6789,6790,4252],"Rhinitis, Allergic, Perennial","Rhinitis, Allergic, Seasonal",[168],{"nctId":6793,"briefTitle":6794,"status":731,"phases":6795,"primaryCompletion":6796,"completion":6796,"start":6797,"enrollment":28,"conditions":6798,"interventions":6800},"NCT00838851","Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults",[88],"2012-07","2003-08",[6799],"Healthy Controls",[168],{"nctId":6802,"briefTitle":6803,"status":149,"phases":6804,"primaryCompletion":4089,"completion":4089,"start":6805,"enrollment":9,"conditions":6806,"interventions":6808},"NCT00654134","Inhalation of 20,000 Endotoxin Units(EU) of Clinical Center Reference Endotoxin in Healthy Volunteers",[88],"2005-10",[6807],"Healthy Adults",[168],{"nctId":160,"briefTitle":161,"status":149,"phases":6810,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":6811,"interventions":6812},[88],[24],[168,169],{"trials":6814,"activeCount":100},[],{"trials":6816,"activeCount":100},[],{"trials":6818,"activeCount":100},[],{"trials":6820,"activeCount":100},[],{"intervention":6822,"totalTrials":96,"cells":6823},"Maraviroc",{"EARLY_PHASE1":6824,"PHASE1":6826,"PHASE2":6842,"PHASE3":6844,"PHASE4":6846,"NA":6848},{"trials":6825,"activeCount":100},[],{"trials":6827,"activeCount":100},[6828,6836],{"nctId":6829,"briefTitle":6830,"status":149,"phases":6831,"primaryCompletion":3863,"completion":3863,"start":1953,"enrollment":140,"conditions":6832,"interventions":6834},"NCT02039323","A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants",[88],[6833],"Healthy Adult Females",[6835,6822],"Tenofovir",{"nctId":6837,"briefTitle":6838,"status":149,"phases":6839,"primaryCompletion":3702,"completion":5877,"start":3852,"enrollment":3657,"conditions":6840,"interventions":6841},"NCT00775294","Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue",[88],[1943],[6822],{"trials":6843,"activeCount":100},[],{"trials":6845,"activeCount":100},[],{"trials":6847,"activeCount":100},[],{"trials":6849,"activeCount":100},[],{"intervention":1212,"totalTrials":96,"cells":6851},{"EARLY_PHASE1":6852,"PHASE1":6854,"PHASE2":6869,"PHASE3":6871,"PHASE4":6873,"NA":6875},{"trials":6853,"activeCount":100},[],{"trials":6855,"activeCount":100},[6856,6860],{"nctId":1203,"briefTitle":1204,"status":149,"phases":6857,"primaryCompletion":1206,"completion":1207,"start":1208,"enrollment":1209,"conditions":6858,"interventions":6859},[88],[1199],[1185,1212],{"nctId":6861,"briefTitle":6862,"status":149,"phases":6863,"primaryCompletion":6864,"completion":6865,"start":6866,"enrollment":140,"conditions":6867,"interventions":6868},"NCT02208167","Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy",[88],"2017-01-19","2017-11-27","2015-04-07",[15],[1212],{"trials":6870,"activeCount":100},[],{"trials":6872,"activeCount":100},[],{"trials":6874,"activeCount":100},[],{"trials":6876,"activeCount":100},[],{"intervention":6878,"totalTrials":96,"cells":6879},"MVA.tHIVconsv3",{"EARLY_PHASE1":6880,"PHASE1":6882,"PHASE2":6905,"PHASE3":6907,"PHASE4":6909,"NA":6911},{"trials":6881,"activeCount":100},[],{"trials":6883,"activeCount":100},[6884,6893],{"nctId":6885,"briefTitle":6886,"status":149,"phases":6887,"primaryCompletion":6888,"completion":245,"start":6889,"enrollment":28,"conditions":6890,"interventions":6891},"NCT03844386","Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults",[88],"2021-11-11","2019-04-22",[1199],[6878,6892],"MVA.tHIVconsv4",{"nctId":6894,"briefTitle":6895,"status":149,"phases":6896,"primaryCompletion":6897,"completion":6898,"start":6899,"enrollment":1180,"conditions":6900,"interventions":6902},"NCT05604209","Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART",[88],"2024-09-12","2025-01-10","2022-10-13",[6901,1411],"HIV Vaccine",[6903,6904,6892,6878],"ChAdOx1.HIVconsv62","ChAdOx1.tHIVconsv1",{"trials":6906,"activeCount":100},[],{"trials":6908,"activeCount":100},[],{"trials":6910,"activeCount":100},[],{"trials":6912,"activeCount":100},[],{"intervention":6892,"totalTrials":96,"cells":6914},{"EARLY_PHASE1":6915,"PHASE1":6917,"PHASE2":6927,"PHASE3":6929,"PHASE4":6931,"NA":6933},{"trials":6916,"activeCount":100},[],{"trials":6918,"activeCount":100},[6919,6923],{"nctId":6885,"briefTitle":6886,"status":149,"phases":6920,"primaryCompletion":6888,"completion":245,"start":6889,"enrollment":28,"conditions":6921,"interventions":6922},[88],[1199],[6878,6892],{"nctId":6894,"briefTitle":6895,"status":149,"phases":6924,"primaryCompletion":6897,"completion":6898,"start":6899,"enrollment":1180,"conditions":6925,"interventions":6926},[88],[6901,1411],[6903,6904,6892,6878],{"trials":6928,"activeCount":100},[],{"trials":6930,"activeCount":100},[],{"trials":6932,"activeCount":100},[],{"trials":6934,"activeCount":100},[],{"intervention":6936,"totalTrials":96,"cells":6937},"Der f",{"EARLY_PHASE1":6938,"PHASE1":6948,"PHASE2":6960,"PHASE3":6962,"PHASE4":6964,"NA":6966},{"trials":6939,"activeCount":100},[6940],{"nctId":6941,"briefTitle":6942,"status":731,"phases":6943,"primaryCompletion":6944,"completion":6944,"start":6945,"enrollment":3657,"conditions":6946,"interventions":6947},"NCT03049111","Screening Inhaled Allergen Challenge for Dermatophagoides Farinae",[87],"2019-10-03","2018-01-29",[4252],[6936],{"trials":6949,"activeCount":100},[6950],{"nctId":6951,"briefTitle":6952,"status":731,"phases":6953,"primaryCompletion":4665,"completion":6954,"start":6955,"enrollment":3887,"conditions":6956,"interventions":6959},"NCT03023397","Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers.",[88],"2018-04-23","2017-03-27",[6957,6958],"Healthy Participants","Tobacco Smokers",[6936],{"trials":6961,"activeCount":100},[],{"trials":6963,"activeCount":100},[],{"trials":6965,"activeCount":100},[],{"trials":6967,"activeCount":100},[],{"intervention":6969,"totalTrials":183,"cells":6970},"Lubiprostone",{"EARLY_PHASE1":6971,"PHASE1":6973,"PHASE2":6983,"PHASE3":6985,"PHASE4":6987,"NA":6989},{"trials":6972,"activeCount":100},[],{"trials":6974,"activeCount":100},[6975],{"nctId":6976,"briefTitle":6977,"status":149,"phases":6978,"primaryCompletion":5436,"completion":5436,"start":6304,"enrollment":6979,"conditions":6980,"interventions":6982},"NCT01166789","Lubiprostone Effects on Visceral Pain Sensitivity",[88],62,[6981],"Irritable Bowel Syndrome",[6969],{"trials":6984,"activeCount":100},[],{"trials":6986,"activeCount":100},[],{"trials":6988,"activeCount":100},[],{"trials":6990,"activeCount":100},[],{"intervention":6992,"totalTrials":183,"cells":6993},"Amiloride",{"EARLY_PHASE1":6994,"PHASE1":6996,"PHASE2":7006,"PHASE3":7008,"PHASE4":7010,"NA":7012},{"trials":6995,"activeCount":100},[],{"trials":6997,"activeCount":100},[6998],{"nctId":6999,"briefTitle":7000,"status":149,"phases":7001,"primaryCompletion":4363,"completion":4363,"start":5877,"enrollment":194,"conditions":7002,"interventions":7005},"NCT01095133","Do Acid Sensing Ion Channels Contribute to Heartburn?",[88],[7003,7004],"Gastroesophageal Reflux Disease","Heartburn",[6992],{"trials":7007,"activeCount":100},[],{"trials":7009,"activeCount":100},[],{"trials":7011,"activeCount":100},[],{"trials":7013,"activeCount":100},[],{"intervention":6835,"totalTrials":183,"cells":7015},{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7024,"PHASE3":7026,"PHASE4":7028,"NA":7030},{"trials":7017,"activeCount":100},[],{"trials":7019,"activeCount":100},[7020],{"nctId":6829,"briefTitle":6830,"status":149,"phases":7021,"primaryCompletion":3863,"completion":3863,"start":1953,"enrollment":140,"conditions":7022,"interventions":7023},[88],[6833],[6835,6822],{"trials":7025,"activeCount":100},[],{"trials":7027,"activeCount":100},[],{"trials":7029,"activeCount":100},[],{"trials":7031,"activeCount":100},[],{"intervention":7033,"totalTrials":183,"cells":7034},"Triamcinolone Acetonide Extended-Release Injectable Suspension",{"EARLY_PHASE1":7035,"PHASE1":7037,"PHASE2":7049,"PHASE3":7051,"PHASE4":7053,"NA":7055},{"trials":7036,"activeCount":100},[],{"trials":7038,"activeCount":100},[7039],{"nctId":7040,"briefTitle":7041,"status":149,"phases":7042,"primaryCompletion":7043,"completion":7043,"start":7044,"enrollment":7045,"conditions":7046,"interventions":7048},"NCT04261049","Effect of Zilretta Injection",[88],"2022-01-10","2020-08-01",35,[7047],"Osteoarthritis, Knee",[7033],{"trials":7050,"activeCount":100},[],{"trials":7052,"activeCount":100},[],{"trials":7054,"activeCount":100},[],{"trials":7056,"activeCount":100},[],{"intervention":7058,"totalTrials":183,"cells":7059},"Mucinex 1200mg",{"EARLY_PHASE1":7060,"PHASE1":7062,"PHASE2":7071,"PHASE3":7073,"PHASE4":7075,"NA":7077},{"trials":7061,"activeCount":100},[],{"trials":7063,"activeCount":100},[7064],{"nctId":7065,"briefTitle":7066,"status":149,"phases":7067,"primaryCompletion":6778,"completion":6778,"start":3702,"enrollment":3887,"conditions":7068,"interventions":7070},"NCT00902707","Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung",[88],[7069],"Mucociliary Clearance",[7058],{"trials":7072,"activeCount":100},[],{"trials":7074,"activeCount":100},[],{"trials":7076,"activeCount":100},[],{"trials":7078,"activeCount":100},[],{"intervention":7080,"totalTrials":183,"cells":7081},"ceftazidime and tobramycin",{"EARLY_PHASE1":7082,"PHASE1":7084,"PHASE2":7094,"PHASE3":7096,"PHASE4":7098,"NA":7100},{"trials":7083,"activeCount":100},[],{"trials":7085,"activeCount":100},[7086],{"nctId":7087,"briefTitle":7088,"status":149,"phases":7089,"primaryCompletion":3852,"completion":3852,"start":7090,"enrollment":37,"conditions":7091,"interventions":7092},"NCT00823238","Comparison of Antibiotics for Pseudomonas in Early CF",[88],"2004-07",[1706],[7080,7093],"inhaled tobramycin",{"trials":7095,"activeCount":100},[],{"trials":7097,"activeCount":100},[],{"trials":7099,"activeCount":100},[],{"trials":7101,"activeCount":100},[],{"intervention":7093,"totalTrials":183,"cells":7103},{"EARLY_PHASE1":7104,"PHASE1":7106,"PHASE2":7112,"PHASE3":7114,"PHASE4":7116,"NA":7118},{"trials":7105,"activeCount":100},[],{"trials":7107,"activeCount":100},[7108],{"nctId":7087,"briefTitle":7088,"status":149,"phases":7109,"primaryCompletion":3852,"completion":3852,"start":7090,"enrollment":37,"conditions":7110,"interventions":7111},[88],[1706],[7080,7093],{"trials":7113,"activeCount":100},[],{"trials":7115,"activeCount":100},[],{"trials":7117,"activeCount":100},[],{"trials":7119,"activeCount":100},[],{"intervention":7121,"totalTrials":183,"cells":7122},"Interferon Alfa-2b",{"EARLY_PHASE1":7123,"PHASE1":7125,"PHASE2":7135,"PHASE3":7137,"PHASE4":7139,"NA":7141},{"trials":7124,"activeCount":100},[],{"trials":7126,"activeCount":100},[7127],{"nctId":7128,"briefTitle":7129,"status":149,"phases":7130,"primaryCompletion":2264,"completion":2264,"start":7131,"enrollment":34,"conditions":7132,"interventions":7134},"NCT01217359","Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling",[88],"2010-05",[7133],"Hepatitis C",[7121],{"trials":7136,"activeCount":100},[],{"trials":7138,"activeCount":100},[],{"trials":7140,"activeCount":100},[],{"trials":7142,"activeCount":100},[],{"intervention":1201,"totalTrials":183,"cells":7144},{"EARLY_PHASE1":7145,"PHASE1":7147,"PHASE2":7153,"PHASE3":7155,"PHASE4":7157,"NA":7159},{"trials":7146,"activeCount":100},[],{"trials":7148,"activeCount":100},[7149],{"nctId":1193,"briefTitle":1194,"status":149,"phases":7150,"primaryCompletion":1196,"completion":1196,"start":1197,"enrollment":165,"conditions":7151,"interventions":7152},[88],[1199],[1201,1185],{"trials":7154,"activeCount":100},[],{"trials":7156,"activeCount":100},[],{"trials":7158,"activeCount":100},[],{"trials":7160,"activeCount":100},[],{"intervention":7162,"totalTrials":183,"cells":7163},"curcumin",{"EARLY_PHASE1":7164,"PHASE1":7166,"PHASE2":7175,"PHASE3":7177,"PHASE4":7179,"NA":7181},{"trials":7165,"activeCount":100},[],{"trials":7167,"activeCount":100},[7168],{"nctId":7169,"briefTitle":7170,"status":149,"phases":7171,"primaryCompletion":3302,"completion":4362,"start":3808,"enrollment":3887,"conditions":7172,"interventions":7174},"NCT01330810","Curcumin Pharmacokinetics",[88],[7173],"Comparative Multidose Pharmacokinetics",[7162],{"trials":7176,"activeCount":100},[],{"trials":7178,"activeCount":100},[],{"trials":7180,"activeCount":100},[],{"trials":7182,"activeCount":100},[],{"intervention":7184,"totalTrials":183,"cells":7185},"1 dose of sildenafil",{"EARLY_PHASE1":7186,"PHASE1":7188,"PHASE2":7198,"PHASE3":7200,"PHASE4":7202,"NA":7204},{"trials":7187,"activeCount":100},[],{"trials":7189,"activeCount":100},[7190],{"nctId":7191,"briefTitle":7192,"status":149,"phases":7193,"primaryCompletion":3827,"completion":3827,"start":3078,"enrollment":7194,"conditions":7195,"interventions":7197},"NCT01670136","Pharmacokinetics of Sildenafil in Premature Infants",[88],34,[7196],"Persistent Pulmonary Hypertension of the Newborn",[7184],{"trials":7199,"activeCount":100},[],{"trials":7201,"activeCount":100},[],{"trials":7203,"activeCount":100},[],{"trials":7205,"activeCount":100},[],{"intervention":1221,"totalTrials":183,"cells":7207},{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7216,"PHASE3":7218,"PHASE4":7220,"NA":7222},{"trials":7209,"activeCount":100},[],{"trials":7211,"activeCount":100},[7212],{"nctId":1214,"briefTitle":1215,"status":731,"phases":7213,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":140,"conditions":7214,"interventions":7215},[88],[1199],[1185,1221],{"trials":7217,"activeCount":100},[],{"trials":7219,"activeCount":100},[],{"trials":7221,"activeCount":100},[],{"trials":7223,"activeCount":100},[],{"intervention":7225,"totalTrials":183,"cells":7226},"Kaletra",{"EARLY_PHASE1":7227,"PHASE1":7229,"PHASE2":7237,"PHASE3":7239,"PHASE4":7241,"NA":7243},{"trials":7228,"activeCount":100},[],{"trials":7230,"activeCount":100},[7231],{"nctId":7232,"briefTitle":7233,"status":149,"phases":7234,"primaryCompletion":5877,"completion":5877,"start":1792,"enrollment":3887,"conditions":7235,"interventions":7236},"NCT00766818","The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet",[88],[1816,15],[7225],{"trials":7238,"activeCount":100},[],{"trials":7240,"activeCount":100},[],{"trials":7242,"activeCount":100},[],{"trials":7244,"activeCount":100},[],{"intervention":7246,"totalTrials":183,"cells":7247},"Doravirine",{"EARLY_PHASE1":7248,"PHASE1":7250,"PHASE2":7262,"PHASE3":7264,"PHASE4":7266,"NA":7268},{"trials":7249,"activeCount":100},[],{"trials":7251,"activeCount":100},[7252],{"nctId":7253,"briefTitle":7254,"status":149,"phases":7255,"primaryCompletion":7256,"completion":7257,"start":7258,"enrollment":7259,"conditions":7260,"interventions":7261},"NCT04900974","Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women",[88],"2025-03-27","2025-04-08","2022-06-09",7,[21,618],[7246],{"trials":7263,"activeCount":100},[],{"trials":7265,"activeCount":100},[],{"trials":7267,"activeCount":100},[],{"trials":7269,"activeCount":100},[],{"intervention":7271,"totalTrials":183,"cells":7272},"Vitamin E supplement rich in gamma tocopherol",{"EARLY_PHASE1":7273,"PHASE1":7275,"PHASE2":7284,"PHASE3":7286,"PHASE4":7288,"NA":7290},{"trials":7274,"activeCount":100},[],{"trials":7276,"activeCount":100},[7277],{"nctId":7278,"briefTitle":7279,"status":149,"phases":7280,"primaryCompletion":3726,"completion":3726,"start":7281,"enrollment":572,"conditions":7282,"interventions":7283},"NCT00386178","Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma",[88],"2006-10",[4252],[7271],{"trials":7285,"activeCount":100},[],{"trials":7287,"activeCount":100},[],{"trials":7289,"activeCount":100},[],{"trials":7291,"activeCount":100},[],{"intervention":7293,"totalTrials":183,"cells":7294},"Thalidomide",{"EARLY_PHASE1":7295,"PHASE1":7297,"PHASE2":7305,"PHASE3":7307,"PHASE4":7309,"NA":7311},{"trials":7296,"activeCount":100},[],{"trials":7298,"activeCount":100},[7299],{"nctId":7300,"briefTitle":7301,"status":731,"phases":7302,"primaryCompletion":5543,"completion":5543,"start":7281,"enrollment":1793,"conditions":7303,"interventions":7304},"NCT01028781","Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis",[88],[1106],[7293],{"trials":7306,"activeCount":100},[],{"trials":7308,"activeCount":100},[],{"trials":7310,"activeCount":100},[],{"trials":7312,"activeCount":100},[],{"intervention":7314,"totalTrials":183,"cells":7315},"Dexlansoprazole",{"EARLY_PHASE1":7316,"PHASE1":7318,"PHASE2":7326,"PHASE3":7328,"PHASE4":7330,"NA":7332},{"trials":7317,"activeCount":100},[],{"trials":7319,"activeCount":100},[7320],{"nctId":7321,"briefTitle":7322,"status":149,"phases":7323,"primaryCompletion":4362,"completion":4362,"start":1802,"enrollment":869,"conditions":7324,"interventions":7325},"NCT01149395","Can E-cadherin Found in Tissue\u002FBlood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn",[88],[7004,7003],[7314],{"trials":7327,"activeCount":100},[],{"trials":7329,"activeCount":100},[],{"trials":7331,"activeCount":100},[],{"trials":7333,"activeCount":100},[],{"intervention":7335,"totalTrials":183,"cells":7336},"Olanzapine, Amantadine",{"EARLY_PHASE1":7337,"PHASE1":7339,"PHASE2":7351,"PHASE3":7353,"PHASE4":7355,"NA":7357},{"trials":7338,"activeCount":100},[],{"trials":7340,"activeCount":100},[7341],{"nctId":7342,"briefTitle":7343,"status":149,"phases":7344,"primaryCompletion":1179,"completion":1179,"start":7345,"enrollment":869,"conditions":7346,"interventions":7349},"NCT00287352","Study of Amantadine for Weight Stabilization During Olanzapine Treatment",[88],"2005-05",[7347,6003,33,1841,7348],"Psychotic Disorder","Mood Disorders With Psychotic Features",[7335,7350],"Olanzapine and placebo",{"trials":7352,"activeCount":100},[],{"trials":7354,"activeCount":100},[],{"trials":7356,"activeCount":100},[],{"trials":7358,"activeCount":100},[],{"intervention":7350,"totalTrials":183,"cells":7360},{"EARLY_PHASE1":7361,"PHASE1":7363,"PHASE2":7369,"PHASE3":7371,"PHASE4":7373,"NA":7375},{"trials":7362,"activeCount":100},[],{"trials":7364,"activeCount":100},[7365],{"nctId":7342,"briefTitle":7343,"status":149,"phases":7366,"primaryCompletion":1179,"completion":1179,"start":7345,"enrollment":869,"conditions":7367,"interventions":7368},[88],[7347,6003,33,1841,7348],[7335,7350],{"trials":7370,"activeCount":100},[],{"trials":7372,"activeCount":100},[],{"trials":7374,"activeCount":100},[],{"trials":7376,"activeCount":100},[],{"intervention":7378,"totalTrials":183,"cells":7379},"Platelet Rich Plasma",{"EARLY_PHASE1":7380,"PHASE1":7382,"PHASE2":7392,"PHASE3":7394,"PHASE4":7396,"NA":7398},{"trials":7381,"activeCount":100},[],{"trials":7383,"activeCount":100},[7384],{"nctId":7385,"briefTitle":7386,"status":731,"phases":7387,"primaryCompletion":1954,"completion":1954,"start":2098,"enrollment":3887,"conditions":7388,"interventions":7390},"NCT01688362","Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears",[88],[7389],"Rotator Cuff Tear",[7378,7391],"Corticosteroid",{"trials":7393,"activeCount":100},[],{"trials":7395,"activeCount":100},[],{"trials":7397,"activeCount":100},[],{"trials":7399,"activeCount":100},[],{"intervention":7391,"totalTrials":183,"cells":7401},{"EARLY_PHASE1":7402,"PHASE1":7404,"PHASE2":7410,"PHASE3":7412,"PHASE4":7414,"NA":7416},{"trials":7403,"activeCount":100},[],{"trials":7405,"activeCount":100},[7406],{"nctId":7385,"briefTitle":7386,"status":731,"phases":7407,"primaryCompletion":1954,"completion":1954,"start":2098,"enrollment":3887,"conditions":7408,"interventions":7409},[88],[7389],[7378,7391],{"trials":7411,"activeCount":100},[],{"trials":7413,"activeCount":100},[],{"trials":7415,"activeCount":100},[],{"trials":7417,"activeCount":100},[],{"intervention":7419,"totalTrials":183,"cells":7420},"Naltrexone, Baclofen, Placebo and Behavior Therapy",{"EARLY_PHASE1":7421,"PHASE1":7423,"PHASE2":7432,"PHASE3":7434,"PHASE4":7436,"NA":7438},{"trials":7422,"activeCount":100},[],{"trials":7424,"activeCount":100},[7425],{"nctId":7426,"briefTitle":7427,"status":149,"phases":7428,"primaryCompletion":3897,"completion":3897,"start":7429,"enrollment":869,"conditions":7430,"interventions":7431},"NCT00614328","Combination of Naltrexone and Baclofen for Alcohol Dependence:A Pilot Study.",[88],"2007-07",[2219],[7419],{"trials":7433,"activeCount":100},[],{"trials":7435,"activeCount":100},[],{"trials":7437,"activeCount":100},[],{"trials":7439,"activeCount":100},[],{"intervention":7441,"totalTrials":183,"cells":7442},"Citalopram",{"EARLY_PHASE1":7443,"PHASE1":7445,"PHASE2":7453,"PHASE3":7455,"PHASE4":7457,"NA":7459},{"trials":7444,"activeCount":100},[],{"trials":7446,"activeCount":100},[7447],{"nctId":7448,"briefTitle":7449,"status":149,"phases":7450,"primaryCompletion":5543,"completion":5543,"start":1792,"enrollment":3887,"conditions":7451,"interventions":7452},"NCT00609531","Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders",[88],[3800],[7441],{"trials":7454,"activeCount":100},[],{"trials":7456,"activeCount":100},[],{"trials":7458,"activeCount":100},[],{"trials":7460,"activeCount":100},[],{"intervention":4628,"totalTrials":183,"cells":7462},{"EARLY_PHASE1":7463,"PHASE1":7465,"PHASE2":7471,"PHASE3":7473,"PHASE4":7475,"NA":7477},{"trials":7464,"activeCount":100},[],{"trials":7466,"activeCount":100},[7467],{"nctId":4619,"briefTitle":4620,"status":149,"phases":7468,"primaryCompletion":3302,"completion":3302,"start":4622,"enrollment":4623,"conditions":7469,"interventions":7470},[88],[4625,4626],[4612,4628],{"trials":7472,"activeCount":100},[],{"trials":7474,"activeCount":100},[],{"trials":7476,"activeCount":100},[],{"trials":7478,"activeCount":100},[],{"intervention":7480,"totalTrials":183,"cells":7481},"20K EU CCRE",{"EARLY_PHASE1":7482,"PHASE1":7484,"PHASE2":7492,"PHASE3":7494,"PHASE4":7496,"NA":7498},{"trials":7483,"activeCount":100},[],{"trials":7485,"activeCount":100},[7486],{"nctId":7487,"briefTitle":7488,"status":149,"phases":7489,"primaryCompletion":3896,"completion":3896,"start":3702,"enrollment":3887,"conditions":7490,"interventions":7491},"NCT00924768","A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers",[88],[24,4581],[7480],{"trials":7493,"activeCount":100},[],{"trials":7495,"activeCount":100},[],{"trials":7497,"activeCount":100},[],{"trials":7499,"activeCount":100},[],{"intervention":7501,"totalTrials":183,"cells":7502},"GSK1349572",{"EARLY_PHASE1":7503,"PHASE1":7505,"PHASE2":7513,"PHASE3":7515,"PHASE4":7517,"NA":7519},{"trials":7504,"activeCount":100},[],{"trials":7506,"activeCount":100},[7507],{"nctId":7508,"briefTitle":7509,"status":149,"phases":7510,"primaryCompletion":2264,"completion":152,"start":5394,"enrollment":247,"conditions":7511,"interventions":7512},"NCT01404806","GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects",[88],[6833],[7501],{"trials":7514,"activeCount":100},[],{"trials":7516,"activeCount":100},[],{"trials":7518,"activeCount":100},[],{"trials":7520,"activeCount":100},[],{"intervention":7522,"totalTrials":183,"cells":7523},"CCRE inhalation",{"EARLY_PHASE1":7524,"PHASE1":7526,"PHASE2":7535,"PHASE3":7537,"PHASE4":7539,"NA":7541},{"trials":7525,"activeCount":100},[],{"trials":7527,"activeCount":100},[7528],{"nctId":7529,"briefTitle":7530,"status":731,"phases":7531,"primaryCompletion":4635,"completion":4635,"start":1812,"enrollment":96,"conditions":7532,"interventions":7534},"NCT00753870","Range of Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Otherwise Healthy Smokers",[88],[7533],"Healthy Smokers",[7522],{"trials":7536,"activeCount":100},[],{"trials":7538,"activeCount":100},[],{"trials":7540,"activeCount":100},[],{"trials":7542,"activeCount":100},[],{"intervention":7544,"totalTrials":183,"cells":7545},"Technetium Tc 99M Mebrofenin",{"EARLY_PHASE1":7546,"PHASE1":7548,"PHASE2":7557,"PHASE3":7559,"PHASE4":7561,"NA":7563},{"trials":7547,"activeCount":100},[],{"trials":7549,"activeCount":100},[7550],{"nctId":7551,"briefTitle":7552,"status":149,"phases":7553,"primaryCompletion":3827,"completion":3827,"start":2263,"enrollment":37,"conditions":7554,"interventions":7556},"NCT02235233","Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin",[88],[7555],"Non-alcoholic Steatohepatitis",[7544],{"trials":7558,"activeCount":100},[],{"trials":7560,"activeCount":100},[],{"trials":7562,"activeCount":100},[],{"trials":7564,"activeCount":100},[],{"intervention":7566,"totalTrials":183,"cells":7567},"Sodium Butyrate 5 mmol",{"EARLY_PHASE1":7568,"PHASE1":7570,"PHASE2":7583,"PHASE3":7585,"PHASE4":7587,"NA":7589},{"trials":7569,"activeCount":100},[],{"trials":7571,"activeCount":100},[7572],{"nctId":7573,"briefTitle":7574,"status":149,"phases":7575,"primaryCompletion":7576,"completion":7577,"start":7578,"enrollment":9,"conditions":7579,"interventions":7581},"NCT04415333","Gut Butyrate and Blood Pressure in African Americans",[88],"2021-11-01","2021-11-02","2021-07-08",[7580],"Hypertension",[7566,7582],"Sodium Butyrate 80 mmol",{"trials":7584,"activeCount":100},[],{"trials":7586,"activeCount":100},[],{"trials":7588,"activeCount":100},[],{"trials":7590,"activeCount":100},[],{"intervention":7582,"totalTrials":183,"cells":7592},{"EARLY_PHASE1":7593,"PHASE1":7595,"PHASE2":7601,"PHASE3":7603,"PHASE4":7605,"NA":7607},{"trials":7594,"activeCount":100},[],{"trials":7596,"activeCount":100},[7597],{"nctId":7573,"briefTitle":7574,"status":149,"phases":7598,"primaryCompletion":7576,"completion":7577,"start":7578,"enrollment":9,"conditions":7599,"interventions":7600},[88],[7580],[7566,7582],{"trials":7602,"activeCount":100},[],{"trials":7604,"activeCount":100},[],{"trials":7606,"activeCount":100},[],{"trials":7608,"activeCount":100},[],{"intervention":6903,"totalTrials":183,"cells":7610},{"EARLY_PHASE1":7611,"PHASE1":7613,"PHASE2":7619,"PHASE3":7621,"PHASE4":7623,"NA":7625},{"trials":7612,"activeCount":100},[],{"trials":7614,"activeCount":100},[7615],{"nctId":6894,"briefTitle":6895,"status":149,"phases":7616,"primaryCompletion":6897,"completion":6898,"start":6899,"enrollment":1180,"conditions":7617,"interventions":7618},[88],[6901,1411],[6903,6904,6892,6878],{"trials":7620,"activeCount":100},[],{"trials":7622,"activeCount":100},[],{"trials":7624,"activeCount":100},[],{"trials":7626,"activeCount":100},[],{"intervention":6904,"totalTrials":183,"cells":7628},{"EARLY_PHASE1":7629,"PHASE1":7631,"PHASE2":7637,"PHASE3":7639,"PHASE4":7641,"NA":7643},{"trials":7630,"activeCount":100},[],{"trials":7632,"activeCount":100},[7633],{"nctId":6894,"briefTitle":6895,"status":149,"phases":7634,"primaryCompletion":6897,"completion":6898,"start":6899,"enrollment":1180,"conditions":7635,"interventions":7636},[88],[6901,1411],[6903,6904,6892,6878],{"trials":7638,"activeCount":100},[],{"trials":7640,"activeCount":100},[],{"trials":7642,"activeCount":100},[],{"trials":7644,"activeCount":100},[],{"intervention":7646,"totalTrials":183,"cells":7647},"apixaban",{"EARLY_PHASE1":7648,"PHASE1":7650,"PHASE2":7662,"PHASE3":7664,"PHASE4":7666,"NA":7668},{"trials":7649,"activeCount":100},[],{"trials":7651,"activeCount":100},[7652],{"nctId":7653,"briefTitle":7654,"status":149,"phases":7655,"primaryCompletion":7656,"completion":7656,"start":7657,"enrollment":37,"conditions":7658,"interventions":7661},"NCT02599532","Pharmacokinetics of Apixaban in Nephrotic Syndrome",[88],"2019-06-28","2017-04-30",[7659,7660],"Nephrotic Syndrome","Proteinuria",[7646],{"trials":7663,"activeCount":100},[],{"trials":7665,"activeCount":100},[],{"trials":7667,"activeCount":100},[],{"trials":7669,"activeCount":100},[],{"intervention":7671,"totalTrials":183,"cells":7672},"dust mite inhalation",{"EARLY_PHASE1":7673,"PHASE1":7675,"PHASE2":7684,"PHASE3":7686,"PHASE4":7688,"NA":7690},{"trials":7674,"activeCount":100},[],{"trials":7676,"activeCount":100},[7677],{"nctId":7678,"briefTitle":7679,"status":301,"phases":7680,"primaryCompletion":3924,"completion":3924,"start":5601,"enrollment":100,"conditions":7681,"interventions":7683},"NCT00927329","Evaluation of a Nasal Allergen Challenge Procedure Using Dust Mite Extract",[88],[7682,4252,24],"Dermatophagoides Farinae Allergy",[7671],{"trials":7685,"activeCount":100},[],{"trials":7687,"activeCount":100},[],{"trials":7689,"activeCount":100},[],{"trials":7691,"activeCount":100},[],{"intervention":7693,"totalTrials":183,"cells":7694},"Nicotinamide 500 mg",{"EARLY_PHASE1":7695,"PHASE1":7697,"PHASE2":7710,"PHASE3":7712,"PHASE4":7714,"NA":7716},{"trials":7696,"activeCount":100},[],{"trials":7698,"activeCount":100},[7699],{"nctId":7700,"briefTitle":7701,"status":149,"phases":7702,"primaryCompletion":7703,"completion":7703,"start":7704,"enrollment":247,"conditions":7705,"interventions":7708},"NCT02213094","Phase I Study of Nicotinamide for Early Onset Preeclampsia",[88],"2015-12-03","2014-01-01",[7706,7707,7580],"Pregnancy Induced Hypertension","Superimposed Preeclampsia",[7693,7709],"Nicotinamide 1000 mg",{"trials":7711,"activeCount":100},[],{"trials":7713,"activeCount":100},[],{"trials":7715,"activeCount":100},[],{"trials":7717,"activeCount":100},[],{"intervention":7709,"totalTrials":183,"cells":7719},{"EARLY_PHASE1":7720,"PHASE1":7722,"PHASE2":7728,"PHASE3":7730,"PHASE4":7732,"NA":7734},{"trials":7721,"activeCount":100},[],{"trials":7723,"activeCount":100},[7724],{"nctId":7700,"briefTitle":7701,"status":149,"phases":7725,"primaryCompletion":7703,"completion":7703,"start":7704,"enrollment":247,"conditions":7726,"interventions":7727},[88],[7706,7707,7580],[7693,7709],{"trials":7729,"activeCount":100},[],{"trials":7731,"activeCount":100},[],{"trials":7733,"activeCount":100},[],{"trials":7735,"activeCount":100},[],{"intervention":7737,"totalTrials":183,"cells":7738},"Curcumin C3",{"EARLY_PHASE1":7739,"PHASE1":7741,"PHASE2":7751,"PHASE3":7753,"PHASE4":7755,"NA":7757},{"trials":7740,"activeCount":100},[],{"trials":7742,"activeCount":100},[7743],{"nctId":7744,"briefTitle":7745,"status":149,"phases":7746,"primaryCompletion":3851,"completion":4209,"start":7747,"enrollment":869,"conditions":7748,"interventions":7750},"NCT01333917","Curcumin Biomarkers",[88],"2010-11",[7749],"Colorectal Cancer",[7737],{"trials":7752,"activeCount":100},[],{"trials":7754,"activeCount":100},[],{"trials":7756,"activeCount":100},[],{"trials":7758,"activeCount":100},[],{"intervention":7760,"totalTrials":183,"cells":7761},"Ozone Exposure",{"EARLY_PHASE1":7762,"PHASE1":7764,"PHASE2":7773,"PHASE3":7775,"PHASE4":7777,"NA":7779},{"trials":7763,"activeCount":100},[],{"trials":7765,"activeCount":100},[7766],{"nctId":7767,"briefTitle":7768,"status":301,"phases":7769,"primaryCompletion":7770,"completion":7770,"start":2426,"enrollment":100,"conditions":7771,"interventions":7772},"NCT00468221","The Effect of Low Level Ozone Exposure on Healthy Volunteers",[88],"2009-11",[24],[7760],{"trials":7774,"activeCount":100},[],{"trials":7776,"activeCount":100},[],{"trials":7778,"activeCount":100},[],{"trials":7780,"activeCount":100},[],{"intervention":7782,"totalTrials":183,"cells":7783},"GS-7340",{"EARLY_PHASE1":7784,"PHASE1":7786,"PHASE2":7796,"PHASE3":7798,"PHASE4":7800,"NA":7802},{"trials":7785,"activeCount":100},[],{"trials":7787,"activeCount":100},[7788],{"nctId":7789,"briefTitle":7790,"status":149,"phases":7791,"primaryCompletion":7792,"completion":4423,"start":7793,"enrollment":194,"conditions":7794,"interventions":7795},"NCT02357602","Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women",[88],"2015-10","2015-03",[24],[7782],{"trials":7797,"activeCount":100},[],{"trials":7799,"activeCount":100},[],{"trials":7801,"activeCount":100},[],{"trials":7803,"activeCount":100},[],{"intervention":7805,"totalTrials":183,"cells":7806},"Tenofovir 300Mg Oral",{"EARLY_PHASE1":7807,"PHASE1":7809,"PHASE2":7820,"PHASE3":7822,"PHASE4":7824,"NA":7826},{"trials":7808,"activeCount":100},[],{"trials":7810,"activeCount":100},[7811],{"nctId":7812,"briefTitle":7813,"status":149,"phases":7814,"primaryCompletion":7815,"completion":7815,"start":7816,"enrollment":247,"conditions":7817,"interventions":7818},"NCT03917420","Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract",[88],"2019-09-04","2019-03-26",[1943],[7805,7819],"Emtricitabine 200 MG",{"trials":7821,"activeCount":100},[],{"trials":7823,"activeCount":100},[],{"trials":7825,"activeCount":100},[],{"trials":7827,"activeCount":100},[],{"intervention":7819,"totalTrials":183,"cells":7829},{"EARLY_PHASE1":7830,"PHASE1":7832,"PHASE2":7838,"PHASE3":7840,"PHASE4":7842,"NA":7844},{"trials":7831,"activeCount":100},[],{"trials":7833,"activeCount":100},[7834],{"nctId":7812,"briefTitle":7813,"status":149,"phases":7835,"primaryCompletion":7815,"completion":7815,"start":7816,"enrollment":247,"conditions":7836,"interventions":7837},[88],[1943],[7805,7819],{"trials":7839,"activeCount":100},[],{"trials":7841,"activeCount":100},[],{"trials":7843,"activeCount":100},[],{"trials":7845,"activeCount":100},[],{"intervention":7847,"totalTrials":183,"cells":7848},"silymarin",{"EARLY_PHASE1":7849,"PHASE1":7851,"PHASE2":7861,"PHASE3":7863,"PHASE4":7865,"NA":7867},{"trials":7850,"activeCount":100},[],{"trials":7852,"activeCount":100},[7853],{"nctId":7854,"briefTitle":7855,"status":149,"phases":7856,"primaryCompletion":193,"completion":4089,"start":7770,"enrollment":25,"conditions":7857,"interventions":7860},"NCT01018615","Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C",[88],[7858,7859],"Chronic Hepatitis C","Oxidative Stress",[7847],{"trials":7862,"activeCount":100},[],{"trials":7864,"activeCount":100},[],{"trials":7866,"activeCount":100},[],{"trials":7868,"activeCount":100},[],{"intervention":7870,"totalTrials":183,"cells":7871},"Quercetin",{"EARLY_PHASE1":7872,"PHASE1":7874,"PHASE2":7885,"PHASE3":7887,"PHASE4":7889,"NA":7891},{"trials":7873,"activeCount":100},[],{"trials":7875,"activeCount":100},[7876],{"nctId":7877,"briefTitle":7878,"status":149,"phases":7879,"primaryCompletion":7880,"completion":224,"start":6001,"enrollment":28,"conditions":7881,"interventions":7884},"NCT02226484","Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?",[88],"2016-05",[7003,3772,7882,7883],"Acid Reflux","Reflux",[7870],{"trials":7886,"activeCount":100},[],{"trials":7888,"activeCount":100},[],{"trials":7890,"activeCount":100},[],{"trials":7892,"activeCount":100},[],{"intervention":7894,"totalTrials":183,"cells":7895},"RG-HRV16",{"EARLY_PHASE1":7896,"PHASE1":7898,"PHASE2":7908,"PHASE3":7910,"PHASE4":7912,"NA":7914},{"trials":7897,"activeCount":100},[],{"trials":7899,"activeCount":100},[7900],{"nctId":7901,"briefTitle":7902,"status":301,"phases":7903,"primaryCompletion":67,"completion":570,"start":7904,"enrollment":100,"conditions":7905,"interventions":7907},"NCT03508479","Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection",[88],"2024-12",[4625,7906],"Rhinovirus",[7894],{"trials":7909,"activeCount":100},[],{"trials":7911,"activeCount":100},[],{"trials":7913,"activeCount":100},[],{"trials":7915,"activeCount":100},[],{"intervention":7917,"totalTrials":183,"cells":7918},"Felis Domesticus",{"EARLY_PHASE1":7919,"PHASE1":7921,"PHASE2":7933,"PHASE3":7935,"PHASE4":7937,"NA":7939},{"trials":7920,"activeCount":100},[],{"trials":7922,"activeCount":100},[7923],{"nctId":7924,"briefTitle":7925,"status":301,"phases":7926,"primaryCompletion":7927,"completion":7927,"start":7928,"enrollment":100,"conditions":7929,"interventions":7932},"NCT03031145","Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model",[88],"2017-12-04","2017-04-03",[7930,6957,7931],"Tobacco Smoking","E-cigarette Smokers",[7917],{"trials":7934,"activeCount":100},[],{"trials":7936,"activeCount":100},[],{"trials":7938,"activeCount":100},[],{"trials":7940,"activeCount":100},[],{"intervention":7942,"totalTrials":183,"cells":7943},"Betaine supplement",{"EARLY_PHASE1":7944,"PHASE1":7946,"PHASE2":7956,"PHASE3":7958,"PHASE4":7960,"NA":7962},{"trials":7945,"activeCount":100},[],{"trials":7947,"activeCount":100},[7948],{"nctId":7949,"briefTitle":7950,"status":149,"phases":7951,"primaryCompletion":3827,"completion":3827,"start":3863,"enrollment":140,"conditions":7952,"interventions":7955},"NCT02122211","Choline Dehydrogenase and Sperm Function: Effects of Betaine",[88],[7953,7954],"Men Carrying 2 Minor Alleles for Choline Dehydrogenase rs12676","Male Infertility",[7942],{"trials":7957,"activeCount":100},[],{"trials":7959,"activeCount":100},[],{"trials":7961,"activeCount":100},[],{"trials":7963,"activeCount":100},[],{"intervention":7965,"totalTrials":183,"cells":7966},"Enfuvirtide",{"EARLY_PHASE1":7967,"PHASE1":7969,"PHASE2":7978,"PHASE3":7980,"PHASE4":7982,"NA":7984},{"trials":7968,"activeCount":100},[],{"trials":7970,"activeCount":100},[7971],{"nctId":7972,"briefTitle":7973,"status":731,"phases":7974,"primaryCompletion":4298,"completion":304,"start":4066,"enrollment":3657,"conditions":7975,"interventions":7976},"NCT00312546","Study of Valproic Acid to Treat HIV Infected Adults",[88],[21],[7965,7977],"Valproic acid",{"trials":7979,"activeCount":100},[],{"trials":7981,"activeCount":100},[],{"trials":7983,"activeCount":100},[],{"trials":7985,"activeCount":100},[],{"intervention":7977,"totalTrials":183,"cells":7987},{"EARLY_PHASE1":7988,"PHASE1":7990,"PHASE2":7996,"PHASE3":7998,"PHASE4":8000,"NA":8002},{"trials":7989,"activeCount":100},[],{"trials":7991,"activeCount":100},[7992],{"nctId":7972,"briefTitle":7973,"status":731,"phases":7993,"primaryCompletion":4298,"completion":304,"start":4066,"enrollment":3657,"conditions":7994,"interventions":7995},[88],[21],[7965,7977],{"trials":7997,"activeCount":100},[],{"trials":7999,"activeCount":100},[],{"trials":8001,"activeCount":100},[],{"trials":8003,"activeCount":100},[],{"intervention":8005,"totalTrials":183,"cells":8006},"inhaled allergen challenge",{"EARLY_PHASE1":8007,"PHASE1":8009,"PHASE2":8019,"PHASE3":8021,"PHASE4":8023,"NA":8025},{"trials":8008,"activeCount":100},[],{"trials":8010,"activeCount":100},[8011],{"nctId":8012,"briefTitle":8013,"status":149,"phases":8014,"primaryCompletion":1179,"completion":304,"start":8015,"enrollment":1941,"conditions":8016,"interventions":8018},"NCT00448851","Study of Dust Mite Inhalation in Humans",[88],"2007-02",[4232,8017],"Allergy",[8005],{"trials":8020,"activeCount":100},[],{"trials":8022,"activeCount":100},[],{"trials":8024,"activeCount":100},[],{"trials":8026,"activeCount":100},[],{"intervention":8028,"totalTrials":183,"cells":8029},"Xenon",{"EARLY_PHASE1":8030,"PHASE1":8032,"PHASE2":8042,"PHASE3":8044,"PHASE4":8046,"NA":8048},{"trials":8031,"activeCount":100},[],{"trials":8033,"activeCount":100},[8034],{"nctId":8035,"briefTitle":8036,"status":731,"phases":8037,"primaryCompletion":8038,"completion":8038,"start":8039,"enrollment":1209,"conditions":8040,"interventions":8041},"NCT02220426","Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study",[88],"2016-07-01","2015-09-01",[18],[8028],{"trials":8043,"activeCount":100},[],{"trials":8045,"activeCount":100},[],{"trials":8047,"activeCount":100},[],{"trials":8049,"activeCount":100},[],{"intervention":8051,"totalTrials":183,"cells":8052},"sodium chloride",{"EARLY_PHASE1":8053,"PHASE1":8055,"PHASE2":8063,"PHASE3":8065,"PHASE4":8067,"NA":8069},{"trials":8054,"activeCount":100},[],{"trials":8056,"activeCount":100},[8057],{"nctId":8058,"briefTitle":8059,"status":149,"phases":8060,"primaryCompletion":7131,"completion":7131,"start":7770,"enrollment":572,"conditions":8061,"interventions":8062},"NCT01094704","Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis",[88],[1706],[8051],{"trials":8064,"activeCount":100},[],{"trials":8066,"activeCount":100},[],{"trials":8068,"activeCount":100},[],{"trials":8070,"activeCount":100},[],{"intervention":8072,"totalTrials":183,"cells":8073},"Syntocinon treatment",{"EARLY_PHASE1":8074,"PHASE1":8076,"PHASE2":8086,"PHASE3":8088,"PHASE4":8090,"NA":8092},{"trials":8075,"activeCount":100},[],{"trials":8077,"activeCount":100},[8078],{"nctId":8079,"briefTitle":8080,"status":149,"phases":8081,"primaryCompletion":8082,"completion":8082,"start":7880,"enrollment":1813,"conditions":8083,"interventions":8085},"NCT02872467","Prenatal Cocaine, Nasal Oxytocin, and Maternal Psychophysiology",[88],"2023-03",[8084,1816],"Substance Abuse Problem",[8072],{"trials":8087,"activeCount":100},[],{"trials":8089,"activeCount":100},[],{"trials":8091,"activeCount":100},[],{"trials":8093,"activeCount":100},[],{"intervention":8095,"totalTrials":183,"cells":8096},"Caffeine Citrate 5 mg\u002Fkg",{"EARLY_PHASE1":8097,"PHASE1":8099,"PHASE2":8111,"PHASE3":8113,"PHASE4":8115,"NA":8117},{"trials":8098,"activeCount":100},[],{"trials":8100,"activeCount":100},[8101],{"nctId":8102,"briefTitle":8103,"status":149,"phases":8104,"primaryCompletion":8105,"completion":8106,"start":8107,"enrollment":1209,"conditions":8108,"interventions":8109},"NCT03913221","Caffeine for Hypoxic-Ischemic Encephalopathy",[88],"2023-01-01","2024-12-31","2019-08-14",[1623],[8095,8110],"Caffeine Citrate 10 mg\u002Fkg",{"trials":8112,"activeCount":100},[],{"trials":8114,"activeCount":100},[],{"trials":8116,"activeCount":100},[],{"trials":8118,"activeCount":100},[],{"intervention":8110,"totalTrials":183,"cells":8120},{"EARLY_PHASE1":8121,"PHASE1":8123,"PHASE2":8129,"PHASE3":8131,"PHASE4":8133,"NA":8135},{"trials":8122,"activeCount":100},[],{"trials":8124,"activeCount":100},[8125],{"nctId":8102,"briefTitle":8103,"status":149,"phases":8126,"primaryCompletion":8105,"completion":8106,"start":8107,"enrollment":1209,"conditions":8127,"interventions":8128},[88],[1623],[8095,8110],{"trials":8130,"activeCount":100},[],{"trials":8132,"activeCount":100},[],{"trials":8134,"activeCount":100},[],{"trials":8136,"activeCount":100},[],{"intervention":8138,"totalTrials":183,"cells":8139},"CCRE",{"EARLY_PHASE1":8140,"PHASE1":8142,"PHASE2":8152,"PHASE3":8154,"PHASE4":8156,"NA":8158},{"trials":8141,"activeCount":100},[],{"trials":8143,"activeCount":100},[8144],{"nctId":8145,"briefTitle":8146,"status":149,"phases":8147,"primaryCompletion":8148,"completion":8148,"start":8149,"enrollment":526,"conditions":8150,"interventions":8151},"NCT02847247","Systemic Inflammatory Response to CCRE",[88],"2019-08-06","2017-12-11",[24],[8138],{"trials":8153,"activeCount":100},[],{"trials":8155,"activeCount":100},[],{"trials":8157,"activeCount":100},[],{"trials":8159,"activeCount":100},[],{"intervention":8161,"totalTrials":183,"cells":8162},"Apixaban 5 MG",{"EARLY_PHASE1":8163,"PHASE1":8165,"PHASE2":8176,"PHASE3":8178,"PHASE4":8180,"NA":8182},{"trials":8164,"activeCount":100},[],{"trials":8166,"activeCount":100},[8167],{"nctId":8168,"briefTitle":8169,"status":149,"phases":8170,"primaryCompletion":8171,"completion":8171,"start":8172,"enrollment":34,"conditions":8173,"interventions":8175},"NCT04278729","A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome",[88],"2023-09-22","2021-04-14",[7659,8174],"Membranous Nephropathy",[8161],{"trials":8177,"activeCount":100},[],{"trials":8179,"activeCount":100},[],{"trials":8181,"activeCount":100},[],{"trials":8183,"activeCount":100},[],{"intervention":8185,"totalTrials":183,"cells":8186},"Pravastatin",{"EARLY_PHASE1":8187,"PHASE1":8189,"PHASE2":8198,"PHASE3":8200,"PHASE4":8202,"NA":8204},{"trials":8188,"activeCount":100},[],{"trials":8190,"activeCount":100},[8191],{"nctId":8192,"briefTitle":8193,"status":149,"phases":8194,"primaryCompletion":3797,"completion":3797,"start":6778,"enrollment":7259,"conditions":8195,"interventions":8197},"NCT01845428","Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome",[88],[7659,8196],"Hyperlipidemia",[8185],{"trials":8199,"activeCount":100},[],{"trials":8201,"activeCount":100},[],{"trials":8203,"activeCount":100},[],{"trials":8205,"activeCount":100},[],{"intervention":8207,"totalTrials":96,"cells":8208},"PFP",{"EARLY_PHASE1":8209,"PHASE1":8229,"PHASE2":8231,"PHASE3":8233,"PHASE4":8235,"NA":8237},{"trials":8210,"activeCount":100},[8211,8221],{"nctId":8212,"briefTitle":8213,"status":149,"phases":8214,"primaryCompletion":8215,"completion":8216,"start":8217,"enrollment":2047,"conditions":8218,"interventions":8219},"NCT03482960","Comparison of 129Xe MRI With 19F MRI in CF Lung Disease",[87],"2019-04-09","2019-04-10","2018-05-29",[1706],[8220,8207],"Hyperpolarized Xenon gas",{"nctId":8222,"briefTitle":8223,"status":149,"phases":8224,"primaryCompletion":8225,"completion":8225,"start":8226,"enrollment":4448,"conditions":8227,"interventions":8228},"NCT03489590","19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis",[87],"2018-12-31","2015-07-01",[1706],[8207],{"trials":8230,"activeCount":100},[],{"trials":8232,"activeCount":100},[],{"trials":8234,"activeCount":100},[],{"trials":8236,"activeCount":100},[],{"trials":8238,"activeCount":100},[],{"intervention":8220,"totalTrials":183,"cells":8240},{"EARLY_PHASE1":8241,"PHASE1":8247,"PHASE2":8249,"PHASE3":8251,"PHASE4":8253,"NA":8255},{"trials":8242,"activeCount":100},[8243],{"nctId":8212,"briefTitle":8213,"status":149,"phases":8244,"primaryCompletion":8215,"completion":8216,"start":8217,"enrollment":2047,"conditions":8245,"interventions":8246},[87],[1706],[8220,8207],{"trials":8248,"activeCount":100},[],{"trials":8250,"activeCount":100},[],{"trials":8252,"activeCount":100},[],{"trials":8254,"activeCount":100},[],{"trials":8256,"activeCount":100},[],{"intervention":8258,"totalTrials":183,"cells":8259},"MRI with PFP",{"EARLY_PHASE1":8260,"PHASE1":8270,"PHASE2":8272,"PHASE3":8274,"PHASE4":8276,"NA":8278},{"trials":8261,"activeCount":100},[8262],{"nctId":8263,"briefTitle":8264,"status":731,"phases":8265,"primaryCompletion":8266,"completion":8266,"start":8267,"enrollment":1186,"conditions":8268,"interventions":8269},"NCT03497117","19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation",[87],"2019-09-13","2015-08-25",[1706],[8258],{"trials":8271,"activeCount":100},[],{"trials":8273,"activeCount":100},[],{"trials":8275,"activeCount":100},[],{"trials":8277,"activeCount":100},[],{"trials":8279,"activeCount":100},[],{"intervention":8281,"totalTrials":183,"cells":8282},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":8283,"PHASE1":8295,"PHASE2":8297,"PHASE3":8299,"PHASE4":8301,"NA":8303},{"trials":8284,"activeCount":100},[8285],{"nctId":8286,"briefTitle":8287,"status":301,"phases":8288,"primaryCompletion":8289,"completion":8290,"start":8291,"enrollment":100,"conditions":8292,"interventions":8294},"NCT03928808","Fecal Microbiota Transplantation (FMT) in Treatment of Severe and Enduring Anorexia Nervosa",[87],"2024-03","2024-09","2023-04-01",[8293],"Anorexia Nervosa",[8281],{"trials":8296,"activeCount":100},[],{"trials":8298,"activeCount":100},[],{"trials":8300,"activeCount":100},[],{"trials":8302,"activeCount":100},[],{"trials":8304,"activeCount":100},[],{"intervention":8306,"totalTrials":183,"cells":8307},"Gallium 68 Macro-aggregated albumin",{"EARLY_PHASE1":8308,"PHASE1":8319,"PHASE2":8321,"PHASE3":8323,"PHASE4":8325,"NA":8327},{"trials":8309,"activeCount":100},[8310],{"nctId":8311,"briefTitle":8312,"status":301,"phases":8313,"primaryCompletion":8314,"completion":8314,"start":8315,"enrollment":100,"conditions":8316,"interventions":8318},"NCT04243824","Ga-68 MAA Distribution in PAE Patients",[87],"2022-05","2021-05",[8317],"Benign Prostatic Hyperplasia",[8306],{"trials":8320,"activeCount":100},[],{"trials":8322,"activeCount":100},[],{"trials":8324,"activeCount":100},[],{"trials":8326,"activeCount":100},[],{"trials":8328,"activeCount":100},[],{"intervention":8330,"totalTrials":183,"cells":8331},"Peanut protein",{"EARLY_PHASE1":8332,"PHASE1":8343,"PHASE2":8345,"PHASE3":8347,"PHASE4":8349,"NA":8351},{"trials":8333,"activeCount":100},[8334],{"nctId":8335,"briefTitle":8336,"status":149,"phases":8337,"primaryCompletion":8338,"completion":8339,"start":8340,"enrollment":762,"conditions":8341,"interventions":8342},"NCT01891136","Oral Peanut Immunotherapy for Peanut Allergic Patients",[87],"2014-11","2014-12","2004-04",[4300],[8330],{"trials":8344,"activeCount":100},[],{"trials":8346,"activeCount":100},[],{"trials":8348,"activeCount":100},[],{"trials":8350,"activeCount":100},[],{"trials":8352,"activeCount":100},[],{"intervention":8354,"totalTrials":183,"cells":8355},"Albuterol",{"EARLY_PHASE1":8356,"PHASE1":8368,"PHASE2":8370,"PHASE3":8372,"PHASE4":8374,"NA":8376},{"trials":8357,"activeCount":100},[8358],{"nctId":8359,"briefTitle":8360,"status":149,"phases":8361,"primaryCompletion":8362,"completion":8362,"start":8363,"enrollment":8364,"conditions":8365,"interventions":8367},"NCT04901715","Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype",[87],"2024-07-22","2021-06-10",27,[8366],"Primary Ciliary Dyskinesia",[8354],{"trials":8369,"activeCount":100},[],{"trials":8371,"activeCount":100},[],{"trials":8373,"activeCount":100},[],{"trials":8375,"activeCount":100},[],{"trials":8377,"activeCount":100},[],{"intervention":8379,"totalTrials":183,"cells":8380},"Felis Catus",{"EARLY_PHASE1":8381,"PHASE1":8392,"PHASE2":8394,"PHASE3":8396,"PHASE4":8398,"NA":8400},{"trials":8382,"activeCount":100},[8383],{"nctId":8384,"briefTitle":8385,"status":731,"phases":8386,"primaryCompletion":8387,"completion":8387,"start":8388,"enrollment":183,"conditions":8389,"interventions":8391},"NCT03780387","Identification of Allergic Asthmatics Reactive to Felis Catus (Cat Hair) Allergen Inhalation",[87],"2019-11-11","2019-04-16",[8390],"Asthma Atopic",[8379],{"trials":8393,"activeCount":100},[],{"trials":8395,"activeCount":100},[],{"trials":8397,"activeCount":100},[],{"trials":8399,"activeCount":100},[],{"trials":8401,"activeCount":100},[],{"intervention":158,"totalTrials":1186,"cells":8403},{"EARLY_PHASE1":8404,"PHASE1":8406,"PHASE2":8412,"PHASE3":8414,"PHASE4":8416,"NA":8426},{"trials":8405,"activeCount":100},[],{"trials":8407,"activeCount":100},[8408],{"nctId":147,"briefTitle":148,"status":149,"phases":8409,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":8410,"interventions":8411},[88],[155,156],[158,139],{"trials":8413,"activeCount":100},[],{"trials":8415,"activeCount":100},[],{"trials":8417,"activeCount":100},[8418],{"nctId":8419,"briefTitle":8420,"status":149,"phases":8421,"primaryCompletion":8422,"completion":8422,"start":8423,"enrollment":194,"conditions":8424,"interventions":8425},"NCT03127943","Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine",[91],"2018-04-01","2017-05-01",[2650],[158],{"trials":8427,"activeCount":100},[8428,8435,8443],{"nctId":8429,"briefTitle":8430,"status":149,"phases":8431,"primaryCompletion":3277,"completion":8432,"start":1218,"enrollment":31,"conditions":8433,"interventions":8434},"NCT02708433","Clinical Outcomes of Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine",[92],"2017-09",[3304],[158],{"nctId":8436,"briefTitle":8437,"status":149,"phases":8438,"primaryCompletion":3277,"completion":8432,"start":5087,"enrollment":31,"conditions":8439,"interventions":8442},"NCT02620683","Clinical Outcomes of Buffered vs. Non-Buffered Lidocaine",[92],[8440,8441],"Blood Levels of Buffered vs Non-buffered Lidocaine","Anesthetics, Local",[158],{"nctId":8444,"briefTitle":8445,"status":149,"phases":8446,"primaryCompletion":4112,"completion":4112,"start":7880,"enrollment":194,"conditions":8447,"interventions":8448},"NCT02747186","Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine",[92],[3304],[158],{"intervention":8450,"totalTrials":716,"cells":8451},"Tolvaptan",{"EARLY_PHASE1":8452,"PHASE1":8454,"PHASE2":8464,"PHASE3":8466,"PHASE4":8468,"NA":8486},{"trials":8453,"activeCount":100},[],{"trials":8455,"activeCount":100},[8456],{"nctId":8457,"briefTitle":8458,"status":149,"phases":8459,"primaryCompletion":3701,"completion":3925,"start":8460,"enrollment":8461,"conditions":8462,"interventions":8463},"NCT01261481","Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact",[88],"2011-01",29,[24],[8450,8450],{"trials":8465,"activeCount":100},[],{"trials":8467,"activeCount":100},[],{"trials":8469,"activeCount":100},[8470,8478],{"nctId":8471,"briefTitle":8472,"status":149,"phases":8473,"primaryCompletion":1953,"completion":8339,"start":1178,"enrollment":37,"conditions":8474,"interventions":8476},"NCT01346072","Pilot Study of Using Copeptin to Predict Response to Tolvaptan",[91],[3255,8475,2336],"Heart Diseases",[8477],"tolvaptan",{"nctId":8479,"briefTitle":8480,"status":149,"phases":8481,"primaryCompletion":8482,"completion":8482,"start":3828,"enrollment":869,"conditions":8483,"interventions":8485},"NCT02476409","Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders",[91],"2021-05-13",[8484],"Congestive Heart Failure",[8477],{"trials":8487,"activeCount":100},[8488],{"nctId":8489,"briefTitle":8490,"status":731,"phases":8491,"primaryCompletion":8492,"completion":8492,"start":8338,"enrollment":183,"conditions":8493,"interventions":8496},"NCT02215148","Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients",[],"2016-08",[8494,8495],"Brain Injury","Hyponatremia",[8450],{"intervention":3082,"totalTrials":233,"cells":8498},{"EARLY_PHASE1":8499,"PHASE1":8501,"PHASE2":8503,"PHASE3":8509,"PHASE4":8511,"NA":8517},{"trials":8500,"activeCount":100},[],{"trials":8502,"activeCount":100},[],{"trials":8504,"activeCount":100},[8505],{"nctId":6640,"briefTitle":6641,"status":731,"phases":8506,"primaryCompletion":6643,"completion":6643,"start":6644,"enrollment":1941,"conditions":8507,"interventions":8508},[89],[6646,6647],[3082,6631],{"trials":8510,"activeCount":100},[],{"trials":8512,"activeCount":100},[8513],{"nctId":3075,"briefTitle":3076,"status":149,"phases":8514,"primaryCompletion":2097,"completion":2097,"start":3078,"enrollment":869,"conditions":8515,"interventions":8516},[91],[3080],[3062,3082,3083],{"trials":8518,"activeCount":100},[8519],{"nctId":8520,"briefTitle":8521,"status":149,"phases":8522,"primaryCompletion":8523,"completion":8523,"start":8524,"enrollment":4416,"conditions":8525,"interventions":8527},"NCT03862495","Genital CT Treatment to Pregnant Women to Prevent Adverse Pregnancy Outcomes: A Pilot RCT",[92],"2024-03-03","2020-05-21",[8526],"Chlamydia Trachomatis Infection",[3082],{"intervention":8529,"totalTrials":233,"cells":8530},"Aripiprazole",{"EARLY_PHASE1":8531,"PHASE1":8533,"PHASE2":8535,"PHASE3":8544,"PHASE4":8546,"NA":8554},{"trials":8532,"activeCount":100},[],{"trials":8534,"activeCount":100},[],{"trials":8536,"activeCount":100},[8537],{"nctId":8538,"briefTitle":8539,"status":149,"phases":8540,"primaryCompletion":3896,"completion":3896,"start":4067,"enrollment":1409,"conditions":8541,"interventions":8542},"NCT00619190","Study of Aripiprazole to Treat Children and Adolescents With Autism",[89],[5311,6005,5310],[8543],"aripiprazole",{"trials":8545,"activeCount":100},[],{"trials":8547,"activeCount":100},[8548],{"nctId":8549,"briefTitle":8550,"status":149,"phases":8551,"primaryCompletion":8460,"completion":8460,"start":5543,"enrollment":1941,"conditions":8552,"interventions":8553},"NCT01028820","FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders",[91],[5310],[8529],{"trials":8555,"activeCount":100},[8556],{"nctId":8557,"briefTitle":8558,"status":149,"phases":8559,"primaryCompletion":1177,"completion":1177,"start":2180,"enrollment":1409,"conditions":8560,"interventions":8562},"NCT00312598","Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine",[],[33,1841,6003,8561],"Mood Disorders",[8529],{"intervention":1946,"totalTrials":233,"cells":8564},{"EARLY_PHASE1":8565,"PHASE1":8567,"PHASE2":8573,"PHASE3":8575,"PHASE4":8577,"NA":8583},{"trials":8566,"activeCount":100},[],{"trials":8568,"activeCount":100},[8569],{"nctId":1938,"briefTitle":1939,"status":149,"phases":8570,"primaryCompletion":1811,"completion":289,"start":291,"enrollment":1941,"conditions":8571,"interventions":8572},[88],[1943,21],[1945,1946,1931],{"trials":8574,"activeCount":100},[],{"trials":8576,"activeCount":100},[],{"trials":8578,"activeCount":100},[8579],{"nctId":1964,"briefTitle":1965,"status":731,"phases":8580,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":165,"conditions":8581,"interventions":8582},[91],[1970,21],[1972,1946,1931],{"trials":8584,"activeCount":100},[8585],{"nctId":8586,"briefTitle":8587,"status":149,"phases":8588,"primaryCompletion":6001,"completion":6001,"start":7131,"enrollment":8589,"conditions":8590,"interventions":8592},"NCT01180075","Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population",[],85,[8591],"Human Immunodeficiency Virus",[8593,8594,8595,1946],"tenofovir\u002Femtricitabine\u002Fefavirenz","tenofovir\u002Femtricitabine","Atazanavir",{"intervention":8597,"totalTrials":233,"cells":8598},"Raltegravir",{"EARLY_PHASE1":8599,"PHASE1":8601,"PHASE2":8611,"PHASE3":8613,"PHASE4":8615,"NA":8617},{"trials":8600,"activeCount":100},[],{"trials":8602,"activeCount":100},[8603],{"nctId":8604,"briefTitle":8605,"status":149,"phases":8606,"primaryCompletion":8607,"completion":8607,"start":3768,"enrollment":7259,"conditions":8608,"interventions":8610},"NCT00746499","Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.",[88],"2008-11",[8609],"Pharmacokinetics",[8597],{"trials":8612,"activeCount":100},[],{"trials":8614,"activeCount":100},[],{"trials":8616,"activeCount":100},[],{"trials":8618,"activeCount":100},[8619,8627],{"nctId":8620,"briefTitle":8621,"status":149,"phases":8622,"primaryCompletion":2788,"completion":2788,"start":3851,"enrollment":8623,"conditions":8624,"interventions":8625},"NCT01450189","A Key Link for Transmission Prevention",[92],46,[15],[8597,8626],"emtricitabine\u002Ftenofovir disoproxil fumarate",{"nctId":8628,"briefTitle":8629,"status":149,"phases":8630,"primaryCompletion":7792,"completion":7792,"start":8631,"enrollment":9,"conditions":8632,"interventions":8633},"NCT02218320","Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults",[],"2014-10",[8591],[8597,8634],"Dolutegravir",{"intervention":252,"totalTrials":96,"cells":8636},{"EARLY_PHASE1":8637,"PHASE1":8639,"PHASE2":8641,"PHASE3":8647,"PHASE4":8649,"NA":8651},{"trials":8638,"activeCount":100},[],{"trials":8640,"activeCount":100},[],{"trials":8642,"activeCount":100},[8643],{"nctId":242,"briefTitle":243,"status":149,"phases":8644,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":8645,"interventions":8646},[89],[249],[251,232,252],{"trials":8648,"activeCount":100},[],{"trials":8650,"activeCount":100},[],{"trials":8652,"activeCount":100},[8653],{"nctId":757,"briefTitle":758,"status":149,"phases":8654,"primaryCompletion":760,"completion":760,"start":761,"enrollment":762,"conditions":8655,"interventions":8656},[92],[764],[252,766,120],{"intervention":8658,"totalTrials":96,"cells":8659},"Rivaroxaban",{"EARLY_PHASE1":8660,"PHASE1":8662,"PHASE2":8664,"PHASE3":8676,"PHASE4":8678,"NA":8680},{"trials":8661,"activeCount":100},[],{"trials":8663,"activeCount":100},[],{"trials":8665,"activeCount":100},[8666],{"nctId":8667,"briefTitle":8668,"status":149,"phases":8669,"primaryCompletion":8670,"completion":8670,"start":1953,"enrollment":3657,"conditions":8671,"interventions":8674},"NCT02072668","The Effect of Rivaroxaban in Sickle Cell Disease",[89],"2018-10-04",[8672,8673],"Sickle Cell Anemia","Sickle Cell-Beta0-Thalassemia",[8675],"rivaroxaban",{"trials":8677,"activeCount":100},[],{"trials":8679,"activeCount":100},[],{"trials":8681,"activeCount":100},[8682],{"nctId":8683,"briefTitle":8684,"status":149,"phases":8685,"primaryCompletion":4424,"completion":6001,"start":1791,"enrollment":2027,"conditions":8686,"interventions":8688},"NCT01743898","A Prospective Pharmacodynamic Study of Rivaroxaban",[],[8687],"Blood Clot",[8658],{"intervention":8690,"totalTrials":96,"cells":8691},"LAIV",{"EARLY_PHASE1":8692,"PHASE1":8703,"PHASE2":8705,"PHASE3":8707,"PHASE4":8709,"NA":8711},{"trials":8693,"activeCount":100},[8694],{"nctId":8695,"briefTitle":8696,"status":149,"phases":8697,"primaryCompletion":8698,"completion":8698,"start":8699,"enrollment":194,"conditions":8700,"interventions":8702},"NCT04901455","Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)",[87],"2026-02-16","2022-10-03",[8701],"COPD",[8690],{"trials":8704,"activeCount":100},[],{"trials":8706,"activeCount":100},[],{"trials":8708,"activeCount":100},[],{"trials":8710,"activeCount":100},[],{"trials":8712,"activeCount":100},[8713],{"nctId":8714,"briefTitle":8715,"status":149,"phases":8716,"primaryCompletion":224,"completion":224,"start":2097,"enrollment":6979,"conditions":8717,"interventions":8722},"NCT02019745","Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers",[],[8718,8719,8720,8721],"Influenza, Human","Smoking","Respiratory Tract Infections","Habits",[8690],{"intervention":8724,"totalTrials":96,"cells":8725},"dolutegravir",{"EARLY_PHASE1":8726,"PHASE1":8728,"PHASE2":8737,"PHASE3":8739,"PHASE4":8741,"NA":8743},{"trials":8727,"activeCount":100},[],{"trials":8729,"activeCount":100},[8730],{"nctId":8731,"briefTitle":8732,"status":149,"phases":8733,"primaryCompletion":2098,"completion":5352,"start":8734,"enrollment":3657,"conditions":8735,"interventions":8736},"NCT01459315","GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male Subjects",[88],"2011-11",[24],[8724],{"trials":8738,"activeCount":100},[],{"trials":8740,"activeCount":100},[],{"trials":8742,"activeCount":100},[],{"trials":8744,"activeCount":100},[8745],{"nctId":8628,"briefTitle":8629,"status":149,"phases":8746,"primaryCompletion":7792,"completion":7792,"start":8631,"enrollment":9,"conditions":8747,"interventions":8748},[],[8591],[8597,8634],{"intervention":2835,"totalTrials":96,"cells":8750},{"EARLY_PHASE1":8751,"PHASE1":8753,"PHASE2":8755,"PHASE3":8757,"PHASE4":8759,"NA":8765},{"trials":8752,"activeCount":100},[],{"trials":8754,"activeCount":100},[],{"trials":8756,"activeCount":100},[],{"trials":8758,"activeCount":100},[],{"trials":8760,"activeCount":100},[8761],{"nctId":2827,"briefTitle":2828,"status":149,"phases":8762,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":8763,"interventions":8764},[91],[33],[2835,2836,2814],{"trials":8766,"activeCount":100},[8767],{"nctId":8768,"briefTitle":8769,"status":149,"phases":8770,"primaryCompletion":8771,"completion":8772,"start":8773,"enrollment":7194,"conditions":8774,"interventions":8775},"NCT01234454","Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI",[92],"2005-06","2007-12","2002-01",[33],[2835,2836],{"intervention":2836,"totalTrials":96,"cells":8777},{"EARLY_PHASE1":8778,"PHASE1":8780,"PHASE2":8782,"PHASE3":8784,"PHASE4":8786,"NA":8792},{"trials":8779,"activeCount":100},[],{"trials":8781,"activeCount":100},[],{"trials":8783,"activeCount":100},[],{"trials":8785,"activeCount":100},[],{"trials":8787,"activeCount":100},[8788],{"nctId":2827,"briefTitle":2828,"status":149,"phases":8789,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":8790,"interventions":8791},[91],[33],[2835,2836,2814],{"trials":8793,"activeCount":100},[8794],{"nctId":8768,"briefTitle":8769,"status":149,"phases":8795,"primaryCompletion":8771,"completion":8772,"start":8773,"enrollment":7194,"conditions":8796,"interventions":8797},[92],[33],[2835,2836],{"intervention":8799,"totalTrials":96,"cells":8800},"Brexanolone",{"EARLY_PHASE1":8801,"PHASE1":8812,"PHASE2":8814,"PHASE3":8816,"PHASE4":8818,"NA":8820},{"trials":8802,"activeCount":100},[8803],{"nctId":8804,"briefTitle":8805,"status":149,"phases":8806,"primaryCompletion":8807,"completion":8807,"start":8808,"enrollment":247,"conditions":8809,"interventions":8811},"NCT05314153","Effects Zulresso on Postpartum Psychosis",[87],"2024-06-01","2022-02-23",[8810],"Postpartum Psychosis",[8799],{"trials":8813,"activeCount":100},[],{"trials":8815,"activeCount":100},[],{"trials":8817,"activeCount":100},[],{"trials":8819,"activeCount":100},[],{"trials":8821,"activeCount":100},[8822],{"nctId":8823,"briefTitle":8824,"status":149,"phases":8825,"primaryCompletion":8826,"completion":8826,"start":8827,"enrollment":247,"conditions":8828,"interventions":8829},"NCT05543746","Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression",[],"2023-11-15","2022-08-05",[764],[8799],{"intervention":8831,"totalTrials":96,"cells":8832},"ozone",{"EARLY_PHASE1":8833,"PHASE1":8835,"PHASE2":8847,"PHASE3":8849,"PHASE4":8851,"NA":8853},{"trials":8834,"activeCount":100},[],{"trials":8836,"activeCount":100},[8837],{"nctId":8838,"briefTitle":8839,"status":149,"phases":8840,"primaryCompletion":5688,"completion":5688,"start":8841,"enrollment":8842,"conditions":8843,"interventions":8845},"NCT03395119","Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects",[88],"2017-12-18",44,[24,8844],"Dietary Supplement",[8846],"Ozone",{"trials":8848,"activeCount":100},[],{"trials":8850,"activeCount":100},[],{"trials":8852,"activeCount":100},[],{"trials":8854,"activeCount":100},[8855],{"nctId":8856,"briefTitle":8857,"status":149,"phases":8858,"primaryCompletion":4415,"completion":4415,"start":4067,"enrollment":526,"conditions":8859,"interventions":8860},"NCT00287365","Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers",[92],[4232],[8831],{"intervention":4735,"totalTrials":96,"cells":8862},{"EARLY_PHASE1":8863,"PHASE1":8865,"PHASE2":8867,"PHASE3":8873,"PHASE4":8875,"NA":8877},{"trials":8864,"activeCount":100},[],{"trials":8866,"activeCount":100},[],{"trials":8868,"activeCount":100},[8869],{"nctId":4729,"briefTitle":4730,"status":149,"phases":8870,"primaryCompletion":3278,"completion":3278,"start":291,"enrollment":1941,"conditions":8871,"interventions":8872},[88,89],[4300],[4734,4735],{"trials":8874,"activeCount":100},[],{"trials":8876,"activeCount":100},[],{"trials":8878,"activeCount":100},[8879],{"nctId":8880,"briefTitle":8881,"status":731,"phases":8882,"primaryCompletion":7429,"completion":7429,"start":8883,"enrollment":183,"conditions":8884,"interventions":8885},"NCT00287378","Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab",[92],"2006-03",[4252,8017],[8886],"omalizumab",{"intervention":766,"totalTrials":183,"cells":8888},{"EARLY_PHASE1":8889,"PHASE1":8891,"PHASE2":8893,"PHASE3":8895,"PHASE4":8897,"NA":8899},{"trials":8890,"activeCount":100},[],{"trials":8892,"activeCount":100},[],{"trials":8894,"activeCount":100},[],{"trials":8896,"activeCount":100},[],{"trials":8898,"activeCount":100},[],{"trials":8900,"activeCount":100},[8901],{"nctId":757,"briefTitle":758,"status":149,"phases":8902,"primaryCompletion":760,"completion":760,"start":761,"enrollment":762,"conditions":8903,"interventions":8904},[92],[764],[252,766,120],{"intervention":8906,"totalTrials":183,"cells":8907},"Hypertonic Saline",{"EARLY_PHASE1":8908,"PHASE1":8910,"PHASE2":8912,"PHASE3":8914,"PHASE4":8916,"NA":8918},{"trials":8909,"activeCount":100},[],{"trials":8911,"activeCount":100},[],{"trials":8913,"activeCount":100},[],{"trials":8915,"activeCount":100},[],{"trials":8917,"activeCount":100},[],{"trials":8919,"activeCount":100},[8920],{"nctId":8921,"briefTitle":8922,"status":149,"phases":8923,"primaryCompletion":6796,"completion":6796,"start":1179,"enrollment":31,"conditions":8924,"interventions":8925},"NCT01031706","Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis",[92],[1706],[8906],{"intervention":8927,"totalTrials":183,"cells":8928},"Memantine-XR",{"EARLY_PHASE1":8929,"PHASE1":8931,"PHASE2":8933,"PHASE3":8935,"PHASE4":8937,"NA":8939},{"trials":8930,"activeCount":100},[],{"trials":8932,"activeCount":100},[],{"trials":8934,"activeCount":100},[],{"trials":8936,"activeCount":100},[],{"trials":8938,"activeCount":100},[],{"trials":8940,"activeCount":100},[8941],{"nctId":8942,"briefTitle":8943,"status":301,"phases":8944,"primaryCompletion":5087,"completion":5087,"start":3828,"enrollment":100,"conditions":8945,"interventions":8946},"NCT02353130","Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment",[],[3800],[8927],{"intervention":8948,"totalTrials":183,"cells":8949},"Hydrochlorothiazide",{"EARLY_PHASE1":8950,"PHASE1":8952,"PHASE2":8954,"PHASE3":8956,"PHASE4":8958,"NA":8960},{"trials":8951,"activeCount":100},[],{"trials":8953,"activeCount":100},[],{"trials":8955,"activeCount":100},[],{"trials":8957,"activeCount":100},[],{"trials":8959,"activeCount":100},[],{"trials":8961,"activeCount":100},[8962],{"nctId":8963,"briefTitle":8964,"status":149,"phases":8965,"primaryCompletion":2788,"completion":2788,"start":1791,"enrollment":1209,"conditions":8966,"interventions":8968},"NCT01658657","A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension",[92],[7580,8967],"Plasma Renin Activity",[8948,8969,8970,8971,8972],"Lisinopril","Amlodipine","metoprolol","lisinopril\u002Fhydrochlorothiazide",{"intervention":8969,"totalTrials":183,"cells":8974},{"EARLY_PHASE1":8975,"PHASE1":8977,"PHASE2":8979,"PHASE3":8981,"PHASE4":8983,"NA":8985},{"trials":8976,"activeCount":100},[],{"trials":8978,"activeCount":100},[],{"trials":8980,"activeCount":100},[],{"trials":8982,"activeCount":100},[],{"trials":8984,"activeCount":100},[],{"trials":8986,"activeCount":100},[8987],{"nctId":8963,"briefTitle":8964,"status":149,"phases":8988,"primaryCompletion":2788,"completion":2788,"start":1791,"enrollment":1209,"conditions":8989,"interventions":8990},[92],[7580,8967],[8948,8969,8970,8971,8972],{"intervention":8970,"totalTrials":183,"cells":8992},{"EARLY_PHASE1":8993,"PHASE1":8995,"PHASE2":8997,"PHASE3":8999,"PHASE4":9001,"NA":9003},{"trials":8994,"activeCount":100},[],{"trials":8996,"activeCount":100},[],{"trials":8998,"activeCount":100},[],{"trials":9000,"activeCount":100},[],{"trials":9002,"activeCount":100},[],{"trials":9004,"activeCount":100},[9005],{"nctId":8963,"briefTitle":8964,"status":149,"phases":9006,"primaryCompletion":2788,"completion":2788,"start":1791,"enrollment":1209,"conditions":9007,"interventions":9008},[92],[7580,8967],[8948,8969,8970,8971,8972],{"intervention":8971,"totalTrials":183,"cells":9010},{"EARLY_PHASE1":9011,"PHASE1":9013,"PHASE2":9015,"PHASE3":9017,"PHASE4":9019,"NA":9021},{"trials":9012,"activeCount":100},[],{"trials":9014,"activeCount":100},[],{"trials":9016,"activeCount":100},[],{"trials":9018,"activeCount":100},[],{"trials":9020,"activeCount":100},[],{"trials":9022,"activeCount":100},[9023],{"nctId":8963,"briefTitle":8964,"status":149,"phases":9024,"primaryCompletion":2788,"completion":2788,"start":1791,"enrollment":1209,"conditions":9025,"interventions":9026},[92],[7580,8967],[8948,8969,8970,8971,8972],{"intervention":8972,"totalTrials":183,"cells":9028},{"EARLY_PHASE1":9029,"PHASE1":9031,"PHASE2":9033,"PHASE3":9035,"PHASE4":9037,"NA":9039},{"trials":9030,"activeCount":100},[],{"trials":9032,"activeCount":100},[],{"trials":9034,"activeCount":100},[],{"trials":9036,"activeCount":100},[],{"trials":9038,"activeCount":100},[],{"trials":9040,"activeCount":100},[9041],{"nctId":8963,"briefTitle":8964,"status":149,"phases":9042,"primaryCompletion":2788,"completion":2788,"start":1791,"enrollment":1209,"conditions":9043,"interventions":9044},[92],[7580,8967],[8948,8969,8970,8971,8972],{"intervention":9046,"totalTrials":183,"cells":9047},"Adalimumab 40 MG\u002F0.8 ML Subcutaneous Solution [HUMIRA]",{"EARLY_PHASE1":9048,"PHASE1":9050,"PHASE2":9052,"PHASE3":9054,"PHASE4":9056,"NA":9058},{"trials":9049,"activeCount":100},[],{"trials":9051,"activeCount":100},[],{"trials":9053,"activeCount":100},[],{"trials":9055,"activeCount":100},[],{"trials":9057,"activeCount":100},[],{"trials":9059,"activeCount":100},[9060],{"nctId":9061,"briefTitle":9062,"status":149,"phases":9063,"primaryCompletion":7793,"completion":7793,"start":3808,"enrollment":1180,"conditions":9064,"interventions":9066},"NCT01320293","Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.",[92],[9065],"Psoriasis",[9046],{"intervention":9068,"totalTrials":183,"cells":9069},"PrEP",{"EARLY_PHASE1":9070,"PHASE1":9072,"PHASE2":9074,"PHASE3":9076,"PHASE4":9078,"NA":9080},{"trials":9071,"activeCount":100},[],{"trials":9073,"activeCount":100},[],{"trials":9075,"activeCount":100},[],{"trials":9077,"activeCount":100},[],{"trials":9079,"activeCount":100},[],{"trials":9081,"activeCount":100},[9082],{"nctId":9083,"briefTitle":9084,"status":149,"phases":9085,"primaryCompletion":9086,"completion":9086,"start":9087,"enrollment":9088,"conditions":9089,"interventions":9100},"NCT05307991","Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe",[],"2023-08-01","2022-03-09",249,[21,9090,9091,9092,9093,9094,9095,9096,9097,9098,9099,8526],"Sexually Transmitted Diseases","Blood-Borne Infections","Communicable Disease","Infections","Sexually Transmitted Diseases, Bacterial","Sexually Transmitted Diseases, Viral","RNA Virus Infections","Virus Disease","Syphilis","Neisseria Gonorrheae Infection",[9068],{"intervention":9102,"totalTrials":183,"cells":9103},"Dolutegravir 50 mg",{"EARLY_PHASE1":9104,"PHASE1":9106,"PHASE2":9108,"PHASE3":9110,"PHASE4":9112,"NA":9114},{"trials":9105,"activeCount":100},[],{"trials":9107,"activeCount":100},[],{"trials":9109,"activeCount":100},[],{"trials":9111,"activeCount":100},[],{"trials":9113,"activeCount":100},[],{"trials":9115,"activeCount":100},[9116],{"nctId":9117,"briefTitle":9118,"status":149,"phases":9119,"primaryCompletion":3146,"completion":9120,"start":9121,"enrollment":869,"conditions":9122,"interventions":9123},"NCT02384395","Safety and Efficacy of Fixed Dose Combination Dolutegravir\u002FAbacavir\u002FLamivudine FDC Initiated During Acute HIV Infection",[92],"2021-09-17","2015-09",[15,1970],[9102,9124,9125],"Lamivudine 300 mg","Abacavir 600 mg",{"intervention":9124,"totalTrials":183,"cells":9127},{"EARLY_PHASE1":9128,"PHASE1":9130,"PHASE2":9132,"PHASE3":9134,"PHASE4":9136,"NA":9138},{"trials":9129,"activeCount":100},[],{"trials":9131,"activeCount":100},[],{"trials":9133,"activeCount":100},[],{"trials":9135,"activeCount":100},[],{"trials":9137,"activeCount":100},[],{"trials":9139,"activeCount":100},[9140],{"nctId":9117,"briefTitle":9118,"status":149,"phases":9141,"primaryCompletion":3146,"completion":9120,"start":9121,"enrollment":869,"conditions":9142,"interventions":9143},[92],[15,1970],[9102,9124,9125],{"intervention":9125,"totalTrials":183,"cells":9145},{"EARLY_PHASE1":9146,"PHASE1":9148,"PHASE2":9150,"PHASE3":9152,"PHASE4":9154,"NA":9156},{"trials":9147,"activeCount":100},[],{"trials":9149,"activeCount":100},[],{"trials":9151,"activeCount":100},[],{"trials":9153,"activeCount":100},[],{"trials":9155,"activeCount":100},[],{"trials":9157,"activeCount":100},[9158],{"nctId":9117,"briefTitle":9118,"status":149,"phases":9159,"primaryCompletion":3146,"completion":9120,"start":9121,"enrollment":869,"conditions":9160,"interventions":9161},[92],[15,1970],[9102,9124,9125],{"intervention":9163,"totalTrials":183,"cells":9164},"Emtricitabine\u002Ftenofovir disoproxil",{"EARLY_PHASE1":9165,"PHASE1":9167,"PHASE2":9169,"PHASE3":9171,"PHASE4":9173,"NA":9175},{"trials":9166,"activeCount":100},[],{"trials":9168,"activeCount":100},[],{"trials":9170,"activeCount":100},[],{"trials":9172,"activeCount":100},[],{"trials":9174,"activeCount":100},[],{"trials":9176,"activeCount":100},[9177],{"nctId":9178,"briefTitle":9179,"status":149,"phases":9180,"primaryCompletion":2955,"completion":2955,"start":2884,"enrollment":9181,"conditions":9182,"interventions":9183},"NCT02411630","Factors Affecting PrEP Adherence",[],167,[30],[9163],{"intervention":8593,"totalTrials":183,"cells":9185},{"EARLY_PHASE1":9186,"PHASE1":9188,"PHASE2":9190,"PHASE3":9192,"PHASE4":9194,"NA":9196},{"trials":9187,"activeCount":100},[],{"trials":9189,"activeCount":100},[],{"trials":9191,"activeCount":100},[],{"trials":9193,"activeCount":100},[],{"trials":9195,"activeCount":100},[],{"trials":9197,"activeCount":100},[9198],{"nctId":8586,"briefTitle":8587,"status":149,"phases":9199,"primaryCompletion":6001,"completion":6001,"start":7131,"enrollment":8589,"conditions":9200,"interventions":9201},[],[8591],[8593,8594,8595,1946],{"intervention":8594,"totalTrials":183,"cells":9203},{"EARLY_PHASE1":9204,"PHASE1":9206,"PHASE2":9208,"PHASE3":9210,"PHASE4":9212,"NA":9214},{"trials":9205,"activeCount":100},[],{"trials":9207,"activeCount":100},[],{"trials":9209,"activeCount":100},[],{"trials":9211,"activeCount":100},[],{"trials":9213,"activeCount":100},[],{"trials":9215,"activeCount":100},[9216],{"nctId":8586,"briefTitle":8587,"status":149,"phases":9217,"primaryCompletion":6001,"completion":6001,"start":7131,"enrollment":8589,"conditions":9218,"interventions":9219},[],[8591],[8593,8594,8595,1946],{"intervention":8595,"totalTrials":183,"cells":9221},{"EARLY_PHASE1":9222,"PHASE1":9224,"PHASE2":9226,"PHASE3":9228,"PHASE4":9230,"NA":9232},{"trials":9223,"activeCount":100},[],{"trials":9225,"activeCount":100},[],{"trials":9227,"activeCount":100},[],{"trials":9229,"activeCount":100},[],{"trials":9231,"activeCount":100},[],{"trials":9233,"activeCount":100},[9234],{"nctId":8586,"briefTitle":8587,"status":149,"phases":9235,"primaryCompletion":6001,"completion":6001,"start":7131,"enrollment":8589,"conditions":9236,"interventions":9237},[],[8591],[8593,8594,8595,1946],{"intervention":9239,"totalTrials":183,"cells":9240},"HPV vaccine",{"EARLY_PHASE1":9241,"PHASE1":9243,"PHASE2":9245,"PHASE3":9247,"PHASE4":9249,"NA":9251},{"trials":9242,"activeCount":100},[],{"trials":9244,"activeCount":100},[],{"trials":9246,"activeCount":100},[],{"trials":9248,"activeCount":100},[],{"trials":9250,"activeCount":100},[],{"trials":9252,"activeCount":100},[9253],{"nctId":9254,"briefTitle":9255,"status":149,"phases":9256,"primaryCompletion":9257,"completion":9257,"start":3828,"enrollment":9258,"conditions":9259,"interventions":9262},"NCT01960088","Adolescent Vaccination in Pharmacies",[],"2018-04",1509,[9260,9261],"Evaluating Attitudes Toward HPV Vaccinations in Pharmacies","Evaluating the Provision of HPV Vaccines in a Pharmacy",[9239],{"intervention":9264,"totalTrials":183,"cells":9265},"FluMist",{"EARLY_PHASE1":9266,"PHASE1":9268,"PHASE2":9270,"PHASE3":9272,"PHASE4":9274,"NA":9276},{"trials":9267,"activeCount":100},[],{"trials":9269,"activeCount":100},[],{"trials":9271,"activeCount":100},[],{"trials":9273,"activeCount":100},[],{"trials":9275,"activeCount":100},[],{"trials":9277,"activeCount":100},[9278],{"nctId":9279,"briefTitle":9280,"status":149,"phases":9281,"primaryCompletion":2263,"completion":9121,"start":2358,"enrollment":9282,"conditions":9283,"interventions":9284},"NCT01938170","Home Administration of FluMist by Parents\u002FCaregivers",[92],41,[503],[9264],{"intervention":9286,"totalTrials":183,"cells":9287},"FTC\u002FTDF",{"EARLY_PHASE1":9288,"PHASE1":9290,"PHASE2":9292,"PHASE3":9294,"PHASE4":9296,"NA":9298},{"trials":9289,"activeCount":100},[],{"trials":9291,"activeCount":100},[],{"trials":9293,"activeCount":100},[],{"trials":9295,"activeCount":100},[],{"trials":9297,"activeCount":100},[],{"trials":9299,"activeCount":100},[9300],{"nctId":9301,"briefTitle":9302,"status":149,"phases":9303,"primaryCompletion":4415,"completion":4415,"start":2098,"enrollment":9304,"conditions":9305,"interventions":9306},"NCT01769469","Renal, Endocrine, and Bone Changes in Response to FTC\u002FTDF in Uninfected Young Men Who Have Sex With Men (YMSM).",[],101,[30],[9286],{"intervention":9308,"totalTrials":183,"cells":9309},"Measles vaccine",{"EARLY_PHASE1":9310,"PHASE1":9312,"PHASE2":9314,"PHASE3":9316,"PHASE4":9318,"NA":9320},{"trials":9311,"activeCount":100},[],{"trials":9313,"activeCount":100},[],{"trials":9315,"activeCount":100},[],{"trials":9317,"activeCount":100},[],{"trials":9319,"activeCount":100},[],{"trials":9321,"activeCount":100},[9322],{"nctId":9323,"briefTitle":9324,"status":149,"phases":9325,"primaryCompletion":3925,"completion":3925,"start":5353,"enrollment":9326,"conditions":9327,"interventions":9329},"NCT02058927","Immune Reconstitution to Measles Virus of HIV Infected Children in Zambia",[],203,[9328],"Measles",[9308],{"intervention":9331,"totalTrials":183,"cells":9332},"Allograft, Membrane",{"EARLY_PHASE1":9333,"PHASE1":9335,"PHASE2":9337,"PHASE3":9339,"PHASE4":9341,"NA":9343},{"trials":9334,"activeCount":100},[],{"trials":9336,"activeCount":100},[],{"trials":9338,"activeCount":100},[],{"trials":9340,"activeCount":100},[],{"trials":9342,"activeCount":100},[],{"trials":9344,"activeCount":100},[9345],{"nctId":9346,"briefTitle":9347,"status":731,"phases":9348,"primaryCompletion":9349,"completion":9349,"start":9350,"enrollment":572,"conditions":9351,"interventions":9355},"NCT02532543","Comparative Volumetric Assessment of Alveolar Ridge Preservation Utilizing Different Bone Grafting Materials",[92],"2018-02-12","2016-04",[9352,9353,9354],"Tooth Fractures","Tooth Injuries","Tooth Diseases",[9331,9356,9357,9358],"Alloplast, Membrane","Xenograft, Membrane","Membrane",{"intervention":9356,"totalTrials":183,"cells":9360},{"EARLY_PHASE1":9361,"PHASE1":9363,"PHASE2":9365,"PHASE3":9367,"PHASE4":9369,"NA":9371},{"trials":9362,"activeCount":100},[],{"trials":9364,"activeCount":100},[],{"trials":9366,"activeCount":100},[],{"trials":9368,"activeCount":100},[],{"trials":9370,"activeCount":100},[],{"trials":9372,"activeCount":100},[9373],{"nctId":9346,"briefTitle":9347,"status":731,"phases":9374,"primaryCompletion":9349,"completion":9349,"start":9350,"enrollment":572,"conditions":9375,"interventions":9376},[92],[9352,9353,9354],[9331,9356,9357,9358],{"intervention":9357,"totalTrials":183,"cells":9378},{"EARLY_PHASE1":9379,"PHASE1":9381,"PHASE2":9383,"PHASE3":9385,"PHASE4":9387,"NA":9389},{"trials":9380,"activeCount":100},[],{"trials":9382,"activeCount":100},[],{"trials":9384,"activeCount":100},[],{"trials":9386,"activeCount":100},[],{"trials":9388,"activeCount":100},[],{"trials":9390,"activeCount":100},[9391],{"nctId":9346,"briefTitle":9347,"status":731,"phases":9392,"primaryCompletion":9349,"completion":9349,"start":9350,"enrollment":572,"conditions":9393,"interventions":9394},[92],[9352,9353,9354],[9331,9356,9357,9358],{"intervention":9358,"totalTrials":183,"cells":9396},{"EARLY_PHASE1":9397,"PHASE1":9399,"PHASE2":9401,"PHASE3":9403,"PHASE4":9405,"NA":9407},{"trials":9398,"activeCount":100},[],{"trials":9400,"activeCount":100},[],{"trials":9402,"activeCount":100},[],{"trials":9404,"activeCount":100},[],{"trials":9406,"activeCount":100},[],{"trials":9408,"activeCount":100},[9409],{"nctId":9346,"briefTitle":9347,"status":731,"phases":9410,"primaryCompletion":9349,"completion":9349,"start":9350,"enrollment":572,"conditions":9411,"interventions":9412},[92],[9352,9353,9354],[9331,9356,9357,9358],{"intervention":9414,"totalTrials":183,"cells":9415},"Egg white protein",{"EARLY_PHASE1":9416,"PHASE1":9418,"PHASE2":9420,"PHASE3":9422,"PHASE4":9424,"NA":9426},{"trials":9417,"activeCount":100},[],{"trials":9419,"activeCount":100},[],{"trials":9421,"activeCount":100},[],{"trials":9423,"activeCount":100},[],{"trials":9425,"activeCount":100},[],{"trials":9427,"activeCount":100},[9428],{"nctId":9429,"briefTitle":9430,"status":149,"phases":9431,"primaryCompletion":6001,"completion":6001,"start":9432,"enrollment":1941,"conditions":9433,"interventions":9434},"NCT00597558","Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)",[92],"2003-02",[4291],[9414],{"intervention":9436,"totalTrials":183,"cells":9437},"0.125% Marcaine",{"EARLY_PHASE1":9438,"PHASE1":9440,"PHASE2":9442,"PHASE3":9444,"PHASE4":9446,"NA":9448},{"trials":9439,"activeCount":100},[],{"trials":9441,"activeCount":100},[],{"trials":9443,"activeCount":100},[],{"trials":9445,"activeCount":100},[],{"trials":9447,"activeCount":100},[],{"trials":9449,"activeCount":100},[9450],{"nctId":9451,"briefTitle":9452,"status":149,"phases":9453,"primaryCompletion":1179,"completion":1179,"start":1792,"enrollment":4448,"conditions":9454,"interventions":9456},"NCT00746863","Randomized Control Trial to Assess Postoperative Pain After Sling Placement",[92],[9455],"Stress Urinary Incontinence",[9436],{"intervention":9458,"totalTrials":183,"cells":9459},"Mycophenolic Acid",{"EARLY_PHASE1":9460,"PHASE1":9462,"PHASE2":9464,"PHASE3":9466,"PHASE4":9468,"NA":9470},{"trials":9461,"activeCount":100},[],{"trials":9463,"activeCount":100},[],{"trials":9465,"activeCount":100},[],{"trials":9467,"activeCount":100},[],{"trials":9469,"activeCount":100},[],{"trials":9471,"activeCount":100},[9472],{"nctId":9473,"briefTitle":9474,"status":149,"phases":9475,"primaryCompletion":4635,"completion":4635,"start":9476,"enrollment":1813,"conditions":9477,"interventions":9479},"NCT00619216","Myfortic Conversion Trial in OLT Recipients With GI Intolerance",[],"2008-03",[9478],"GI Disturbance",[9458],{"intervention":9481,"totalTrials":183,"cells":9482},"inhaled\u002Fswallowed budesonide",{"EARLY_PHASE1":9483,"PHASE1":9485,"PHASE2":9487,"PHASE3":9489,"PHASE4":9491,"NA":9493},{"trials":9484,"activeCount":100},[],{"trials":9486,"activeCount":100},[],{"trials":9488,"activeCount":100},[],{"trials":9490,"activeCount":100},[],{"trials":9492,"activeCount":100},[],{"trials":9494,"activeCount":100},[9495],{"nctId":9496,"briefTitle":9497,"status":149,"phases":9498,"primaryCompletion":5394,"completion":8734,"start":304,"enrollment":526,"conditions":9499,"interventions":9500},"NCT00961233","Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)",[92],[339],[9481,9501],"viscous\u002Fswallowed budesonide",{"intervention":9501,"totalTrials":183,"cells":9503},{"EARLY_PHASE1":9504,"PHASE1":9506,"PHASE2":9508,"PHASE3":9510,"PHASE4":9512,"NA":9514},{"trials":9505,"activeCount":100},[],{"trials":9507,"activeCount":100},[],{"trials":9509,"activeCount":100},[],{"trials":9511,"activeCount":100},[],{"trials":9513,"activeCount":100},[],{"trials":9515,"activeCount":100},[9516],{"nctId":9496,"briefTitle":9497,"status":149,"phases":9517,"primaryCompletion":5394,"completion":8734,"start":304,"enrollment":526,"conditions":9518,"interventions":9519},[92],[339],[9481,9501],{"intervention":9521,"totalTrials":183,"cells":9522},"Epidural steroid injection as determined by routine care provider",{"EARLY_PHASE1":9523,"PHASE1":9525,"PHASE2":9527,"PHASE3":9529,"PHASE4":9531,"NA":9533},{"trials":9524,"activeCount":100},[],{"trials":9526,"activeCount":100},[],{"trials":9528,"activeCount":100},[],{"trials":9530,"activeCount":100},[],{"trials":9532,"activeCount":100},[],{"trials":9534,"activeCount":100},[9535],{"nctId":9536,"briefTitle":9537,"status":149,"phases":9538,"primaryCompletion":2744,"completion":2744,"start":7793,"enrollment":762,"conditions":9539,"interventions":9541},"NCT02420457","Tracking Outcomes in Pain Patients Using Fitness Devices",[],[5044,9540],"Back Pain",[9521],{"intervention":9543,"totalTrials":183,"cells":9544},"Well infant, whole exome sequencing",{"EARLY_PHASE1":9545,"PHASE1":9547,"PHASE2":9549,"PHASE3":9551,"PHASE4":9553,"NA":9555},{"trials":9546,"activeCount":100},[],{"trials":9548,"activeCount":100},[],{"trials":9550,"activeCount":100},[],{"trials":9552,"activeCount":100},[],{"trials":9554,"activeCount":100},[],{"trials":9556,"activeCount":100},[9557],{"nctId":9558,"briefTitle":9559,"status":149,"phases":9560,"primaryCompletion":2647,"completion":2647,"start":224,"enrollment":9561,"conditions":9562,"interventions":9566},"NCT02826694","North Carolina Newborn Exome Sequencing for Universal Screening",[92],106,[9563,9564,9565],"Metabolism, Inborn Errors","Hearing Loss","Hereditary Disease",[9543,9567],"Diagnosed, whole exome sequencing",{"intervention":9567,"totalTrials":183,"cells":9569},{"EARLY_PHASE1":9570,"PHASE1":9572,"PHASE2":9574,"PHASE3":9576,"PHASE4":9578,"NA":9580},{"trials":9571,"activeCount":100},[],{"trials":9573,"activeCount":100},[],{"trials":9575,"activeCount":100},[],{"trials":9577,"activeCount":100},[],{"trials":9579,"activeCount":100},[],{"trials":9581,"activeCount":100},[9582],{"nctId":9558,"briefTitle":9559,"status":149,"phases":9583,"primaryCompletion":2647,"completion":2647,"start":224,"enrollment":9561,"conditions":9584,"interventions":9585},[92],[9563,9564,9565],[9543,9567],{"intervention":9587,"totalTrials":183,"cells":9588},"Acyclovir",{"EARLY_PHASE1":9589,"PHASE1":9591,"PHASE2":9593,"PHASE3":9595,"PHASE4":9597,"NA":9599},{"trials":9590,"activeCount":100},[],{"trials":9592,"activeCount":100},[],{"trials":9594,"activeCount":100},[],{"trials":9596,"activeCount":100},[],{"trials":9598,"activeCount":100},[],{"trials":9600,"activeCount":100},[9601],{"nctId":9602,"briefTitle":9603,"status":149,"phases":9604,"primaryCompletion":4635,"completion":4635,"start":5601,"enrollment":9605,"conditions":9606,"interventions":9608},"NCT02053142","Acyclovir Therapy for Genital Herpes Ulcers in HIV Negative African Women",[92],74,[9607],"Ulcers of Female Genital Organs",[9587],{"intervention":9610,"totalTrials":183,"cells":9611},"Quetiapine",{"EARLY_PHASE1":9612,"PHASE1":9614,"PHASE2":9616,"PHASE3":9618,"PHASE4":9620,"NA":9622},{"trials":9613,"activeCount":100},[],{"trials":9615,"activeCount":100},[],{"trials":9617,"activeCount":100},[],{"trials":9619,"activeCount":100},[],{"trials":9621,"activeCount":100},[],{"trials":9623,"activeCount":100},[9624],{"nctId":9625,"briefTitle":9626,"status":149,"phases":9627,"primaryCompletion":3701,"completion":6778,"start":6304,"enrollment":526,"conditions":9628,"interventions":9630},"NCT00617396","Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder",[92],[9629],"Functional Bowel Disorders",[9610],{"intervention":9632,"totalTrials":183,"cells":9633},"Galantamine",{"EARLY_PHASE1":9634,"PHASE1":9636,"PHASE2":9638,"PHASE3":9640,"PHASE4":9642,"NA":9644},{"trials":9635,"activeCount":100},[],{"trials":9637,"activeCount":100},[],{"trials":9639,"activeCount":100},[],{"trials":9641,"activeCount":100},[],{"trials":9643,"activeCount":100},[],{"trials":9645,"activeCount":100},[9646],{"nctId":9647,"briefTitle":9648,"status":149,"phases":9649,"primaryCompletion":8772,"completion":8772,"start":9650,"enrollment":3279,"conditions":9651,"interventions":9653},"NCT01129479","Galantamine Treatment for Nonfluent Aphasia in Stroke Patients",[92],"2004-10",[9652,3512],"Aphasia",[9632],{"intervention":9655,"totalTrials":183,"cells":9656},"Rebif",{"EARLY_PHASE1":9657,"PHASE1":9659,"PHASE2":9661,"PHASE3":9663,"PHASE4":9665,"NA":9667},{"trials":9658,"activeCount":100},[],{"trials":9660,"activeCount":100},[],{"trials":9662,"activeCount":100},[],{"trials":9664,"activeCount":100},[],{"trials":9666,"activeCount":100},[],{"trials":9668,"activeCount":100},[9669],{"nctId":9670,"briefTitle":9671,"status":149,"phases":9672,"primaryCompletion":9673,"completion":2383,"start":9650,"enrollment":1409,"conditions":9674,"interventions":9676},"NCT00137176","EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis",[92],"2007-10",[9675],"Multiple Sclerosis",[9655],{"intervention":8626,"totalTrials":183,"cells":9678},{"EARLY_PHASE1":9679,"PHASE1":9681,"PHASE2":9683,"PHASE3":9685,"PHASE4":9687,"NA":9689},{"trials":9680,"activeCount":100},[],{"trials":9682,"activeCount":100},[],{"trials":9684,"activeCount":100},[],{"trials":9686,"activeCount":100},[],{"trials":9688,"activeCount":100},[],{"trials":9690,"activeCount":100},[9691],{"nctId":8620,"briefTitle":8621,"status":149,"phases":9692,"primaryCompletion":2788,"completion":2788,"start":3851,"enrollment":8623,"conditions":9693,"interventions":9694},[92],[15],[8597,8626],{"intervention":9696,"totalTrials":183,"cells":9697},"Albuterol eMDPI DS",{"EARLY_PHASE1":9698,"PHASE1":9700,"PHASE2":9702,"PHASE3":9704,"PHASE4":9706,"NA":9708},{"trials":9699,"activeCount":100},[],{"trials":9701,"activeCount":100},[],{"trials":9703,"activeCount":100},[],{"trials":9705,"activeCount":100},[],{"trials":9707,"activeCount":100},[],{"trials":9709,"activeCount":100},[9710],{"nctId":9711,"briefTitle":9712,"status":149,"phases":9713,"primaryCompletion":9714,"completion":9714,"start":9715,"enrollment":19,"conditions":9716,"interventions":9717},"NCT05241288","Digihaler in Chronic Obstructive Pulmonary Disease (COPD)",[92],"2023-02-13","2022-03-01",[4691],[9696],{"intervention":9719,"totalTrials":183,"cells":9720},"intranasal spray with oxytocin",{"EARLY_PHASE1":9721,"PHASE1":9723,"PHASE2":9725,"PHASE3":9727,"PHASE4":9729,"NA":9731},{"trials":9722,"activeCount":100},[],{"trials":9724,"activeCount":100},[],{"trials":9726,"activeCount":100},[],{"trials":9728,"activeCount":100},[],{"trials":9730,"activeCount":100},[],{"trials":9732,"activeCount":100},[9733],{"nctId":9734,"briefTitle":9735,"status":149,"phases":9736,"primaryCompletion":3808,"completion":3808,"start":7770,"enrollment":1209,"conditions":9737,"interventions":9739},"NCT01028677","Oxytocin Treatment of Schizophrenia",[92],[9738,33,1841],"Paranoia",[9719],{"intervention":9741,"totalTrials":183,"cells":9742},"Early Treatment with HAART",{"EARLY_PHASE1":9743,"PHASE1":9745,"PHASE2":9747,"PHASE3":9749,"PHASE4":9751,"NA":9753},{"trials":9744,"activeCount":100},[],{"trials":9746,"activeCount":100},[],{"trials":9748,"activeCount":100},[],{"trials":9750,"activeCount":100},[],{"trials":9752,"activeCount":100},[],{"trials":9754,"activeCount":100},[9755],{"nctId":9756,"briefTitle":9757,"status":149,"phases":9758,"primaryCompletion":2884,"completion":2884,"start":8772,"enrollment":9759,"conditions":9760,"interventions":9761},"NCT00683579","Neurocognitive Assessment in Youth Initiating HAART",[],220,[21],[9741,9762],"HAART Treatment - standard care",{"intervention":9762,"totalTrials":183,"cells":9764},{"EARLY_PHASE1":9765,"PHASE1":9767,"PHASE2":9769,"PHASE3":9771,"PHASE4":9773,"NA":9775},{"trials":9766,"activeCount":100},[],{"trials":9768,"activeCount":100},[],{"trials":9770,"activeCount":100},[],{"trials":9772,"activeCount":100},[],{"trials":9774,"activeCount":100},[],{"trials":9776,"activeCount":100},[9777],{"nctId":9756,"briefTitle":9757,"status":149,"phases":9778,"primaryCompletion":2884,"completion":2884,"start":8772,"enrollment":9759,"conditions":9779,"interventions":9780},[],[21],[9741,9762],{"intervention":9782,"totalTrials":183,"cells":9783},"Laxatives or anti-diarrheals",{"EARLY_PHASE1":9784,"PHASE1":9786,"PHASE2":9788,"PHASE3":9790,"PHASE4":9792,"NA":9794},{"trials":9785,"activeCount":100},[],{"trials":9787,"activeCount":100},[],{"trials":9789,"activeCount":100},[],{"trials":9791,"activeCount":100},[],{"trials":9793,"activeCount":100},[],{"trials":9795,"activeCount":100},[9796],{"nctId":9797,"briefTitle":9798,"status":731,"phases":9799,"primaryCompletion":7793,"completion":7793,"start":4209,"enrollment":1813,"conditions":9800,"interventions":9801},"NCT01717456","Educational-Medical-Behavioral Treatment of Fecal Incontinence",[92],[5922],[9782],{"intervention":9803,"totalTrials":183,"cells":9804},"warfarin, vitamin K, midazolam",{"EARLY_PHASE1":9805,"PHASE1":9807,"PHASE2":9809,"PHASE3":9811,"PHASE4":9813,"NA":9815},{"trials":9806,"activeCount":100},[],{"trials":9808,"activeCount":100},[],{"trials":9810,"activeCount":100},[],{"trials":9812,"activeCount":100},[],{"trials":9814,"activeCount":100},[],{"trials":9816,"activeCount":100},[9817],{"nctId":9818,"briefTitle":9819,"status":149,"phases":9820,"primaryCompletion":2179,"completion":9821,"start":1792,"enrollment":4623,"conditions":9822,"interventions":9823},"NCT01034124","Mechanisms Underlying Drug-Diet Interactions",[92],"2008-06",[8609],[9803],{"intervention":9825,"totalTrials":183,"cells":9826},"Vitamin K",{"EARLY_PHASE1":9827,"PHASE1":9829,"PHASE2":9831,"PHASE3":9833,"PHASE4":9835,"NA":9837},{"trials":9828,"activeCount":100},[],{"trials":9830,"activeCount":100},[],{"trials":9832,"activeCount":100},[],{"trials":9834,"activeCount":100},[],{"trials":9836,"activeCount":100},[],{"trials":9838,"activeCount":100},[9839],{"nctId":9840,"briefTitle":9841,"status":149,"phases":9842,"primaryCompletion":2204,"completion":2204,"start":6805,"enrollment":165,"conditions":9843,"interventions":9845},"NCT00287313","Daily Vitamin K in Patients on Warfarin With Unstable INRs",[92],[9844,4612],"Anticoagulants",[9825],{"intervention":9847,"totalTrials":183,"cells":9848},"COVID-19 Vaccination",{"EARLY_PHASE1":9849,"PHASE1":9851,"PHASE2":9853,"PHASE3":9855,"PHASE4":9857,"NA":9859},{"trials":9850,"activeCount":100},[],{"trials":9852,"activeCount":100},[],{"trials":9854,"activeCount":100},[],{"trials":9856,"activeCount":100},[],{"trials":9858,"activeCount":100},[],{"trials":9860,"activeCount":100},[9861],{"nctId":9862,"briefTitle":9863,"status":149,"phases":9864,"primaryCompletion":9865,"completion":9865,"start":9866,"enrollment":1839,"conditions":9867,"interventions":9869},"NCT04944134","COVID-19 Antibody Levels After Vaccines",[],"2022-04-01","2021-06-09",[9868],"Vaccine Preventable Disease",[9847],{"intervention":9871,"totalTrials":183,"cells":9872},"Salbutamol",{"EARLY_PHASE1":9873,"PHASE1":9875,"PHASE2":9877,"PHASE3":9879,"PHASE4":9881,"NA":9883},{"trials":9874,"activeCount":100},[],{"trials":9876,"activeCount":100},[],{"trials":9878,"activeCount":100},[],{"trials":9880,"activeCount":100},[],{"trials":9882,"activeCount":100},[],{"trials":9884,"activeCount":100},[9885],{"nctId":9886,"briefTitle":9887,"status":149,"phases":9888,"primaryCompletion":9889,"completion":9889,"start":9890,"enrollment":194,"conditions":9891,"interventions":9893},"NCT03556683","Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics",[92],"2024-06-06","2018-10-01",[9892],"Moderate to Severe Asthma",[9871],{"intervention":9895,"totalTrials":183,"cells":9896},"IV tpa",{"EARLY_PHASE1":9897,"PHASE1":9899,"PHASE2":9901,"PHASE3":9903,"PHASE4":9905,"NA":9907},{"trials":9898,"activeCount":100},[],{"trials":9900,"activeCount":100},[],{"trials":9902,"activeCount":100},[],{"trials":9904,"activeCount":100},[],{"trials":9906,"activeCount":100},[],{"trials":9908,"activeCount":100},[9909],{"nctId":9910,"briefTitle":9911,"status":149,"phases":9912,"primaryCompletion":9913,"completion":9914,"start":9915,"enrollment":7259,"conditions":9916,"interventions":9918},"NCT00624000","IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion",[92],"2007-09","2008-12","2004-03",[9917],"Ischemic Stroke",[9895],{"intervention":229,"totalTrials":183,"cells":9920},{"EARLY_PHASE1":9921,"PHASE1":9923,"PHASE2":9925,"PHASE3":9927,"PHASE4":9929,"NA":9931},{"trials":9922,"activeCount":100},[],{"trials":9924,"activeCount":100},[],{"trials":9926,"activeCount":100},[],{"trials":9928,"activeCount":100},[],{"trials":9930,"activeCount":100},[],{"trials":9932,"activeCount":100},[9933],{"nctId":219,"briefTitle":220,"status":149,"phases":9934,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":9935,"interventions":9936},[92],[227],[229,230,139],{"intervention":230,"totalTrials":183,"cells":9938},{"EARLY_PHASE1":9939,"PHASE1":9941,"PHASE2":9943,"PHASE3":9945,"PHASE4":9947,"NA":9949},{"trials":9940,"activeCount":100},[],{"trials":9942,"activeCount":100},[],{"trials":9944,"activeCount":100},[],{"trials":9946,"activeCount":100},[],{"trials":9948,"activeCount":100},[],{"trials":9950,"activeCount":100},[9951],{"nctId":219,"briefTitle":220,"status":149,"phases":9952,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":9953,"interventions":9954},[92],[227],[229,230,139],{"intervention":9956,"totalTrials":183,"cells":9957},"Esketamine nasal spray",{"EARLY_PHASE1":9958,"PHASE1":9960,"PHASE2":9962,"PHASE3":9964,"PHASE4":9966,"NA":9968},{"trials":9959,"activeCount":100},[],{"trials":9961,"activeCount":100},[],{"trials":9963,"activeCount":100},[],{"trials":9965,"activeCount":100},[],{"trials":9967,"activeCount":100},[],{"trials":9969,"activeCount":100},[9970],{"nctId":9971,"briefTitle":9972,"status":149,"phases":9973,"primaryCompletion":9974,"completion":9974,"start":9975,"enrollment":3279,"conditions":9976,"interventions":9978},"NCT06012916","Brain Network Dynamics of Depression During Esketamine Treatment",[],"2024-08-30","2023-07-03",[9977],"Depressive Disorder, Major",[9956],{"intervention":9980,"totalTrials":183,"cells":9981},"Fleet Enema",{"EARLY_PHASE1":9982,"PHASE1":9984,"PHASE2":9986,"PHASE3":9988,"PHASE4":9990,"NA":9992},{"trials":9983,"activeCount":100},[],{"trials":9985,"activeCount":100},[],{"trials":9987,"activeCount":100},[],{"trials":9989,"activeCount":100},[],{"trials":9991,"activeCount":100},[],{"trials":9993,"activeCount":100},[9994],{"nctId":9995,"briefTitle":9996,"status":149,"phases":9997,"primaryCompletion":761,"completion":761,"start":4362,"enrollment":9998,"conditions":9999,"interventions":10001},"NCT01576965","Mechanical Bowel Preparation Before Laparoscopic Hysterectomy and Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial",[92],160,[10000],"Laparoscopic Hysterectomy and\u002For Laparoscopic Sacrocolpopexy",[9980],{"intervention":10003,"totalTrials":183,"cells":10004},"Crowdsourced partner services intervention",{"EARLY_PHASE1":10005,"PHASE1":10007,"PHASE2":10009,"PHASE3":10011,"PHASE4":10013,"NA":10015},{"trials":10006,"activeCount":100},[],{"trials":10008,"activeCount":100},[],{"trials":10010,"activeCount":100},[],{"trials":10012,"activeCount":100},[],{"trials":10014,"activeCount":100},[],{"trials":10016,"activeCount":100},[10017],{"nctId":10018,"briefTitle":10019,"status":149,"phases":10020,"primaryCompletion":10021,"completion":10022,"start":10023,"enrollment":10024,"conditions":10025,"interventions":10027},"NCT04971967","Enhancing Partner Services Among Men Who Have Sex With Men Living With HIV",[92],"2022-08-15","2022-09-30","2021-08-01",121,[10026],"Contact Tracing",[10003],{"intervention":10029,"totalTrials":183,"cells":10030},"Antiparasitic medication",{"EARLY_PHASE1":10031,"PHASE1":10033,"PHASE2":10035,"PHASE3":10037,"PHASE4":10039,"NA":10041},{"trials":10032,"activeCount":100},[],{"trials":10034,"activeCount":100},[],{"trials":10036,"activeCount":100},[],{"trials":10038,"activeCount":100},[],{"trials":10040,"activeCount":100},[],{"trials":10042,"activeCount":100},[10043],{"nctId":10044,"briefTitle":10045,"status":149,"phases":10046,"primaryCompletion":10047,"completion":10047,"start":10048,"enrollment":317,"conditions":10049,"interventions":10051},"NCT05323396","HIV And Parasitic Infection (HAPI) Study",[92],"2023-08-04","2022-05-02",[10050],"HIV Coinfection",[10029],{"intervention":10053,"totalTrials":183,"cells":10054},"cantharidin's vehicle",{"EARLY_PHASE1":10055,"PHASE1":10057,"PHASE2":10059,"PHASE3":10061,"PHASE4":10063,"NA":10065},{"trials":10056,"activeCount":100},[],{"trials":10058,"activeCount":100},[],{"trials":10060,"activeCount":100},[],{"trials":10062,"activeCount":100},[],{"trials":10064,"activeCount":100},[],{"trials":10066,"activeCount":100},[10067],{"nctId":10068,"briefTitle":10069,"status":149,"phases":10070,"primaryCompletion":2426,"completion":2426,"start":2425,"enrollment":8461,"conditions":10071,"interventions":10073},"NCT00667225","Efficacy of Cantharidin in Molluscum Contagiosum",[92],[10072],"Molluscum Contagiosum, Skin Disease",[10053,10074],"Cantharidin 0.7%",{"intervention":10074,"totalTrials":183,"cells":10076},{"EARLY_PHASE1":10077,"PHASE1":10079,"PHASE2":10081,"PHASE3":10083,"PHASE4":10085,"NA":10087},{"trials":10078,"activeCount":100},[],{"trials":10080,"activeCount":100},[],{"trials":10082,"activeCount":100},[],{"trials":10084,"activeCount":100},[],{"trials":10086,"activeCount":100},[],{"trials":10088,"activeCount":100},[10089],{"nctId":10068,"briefTitle":10069,"status":149,"phases":10090,"primaryCompletion":2426,"completion":2426,"start":2425,"enrollment":8461,"conditions":10091,"interventions":10092},[92],[10072],[10053,10074],{"intervention":10094,"totalTrials":183,"cells":10095},"tenofovir + emtricitabine",{"EARLY_PHASE1":10096,"PHASE1":10098,"PHASE2":10100,"PHASE3":10102,"PHASE4":10104,"NA":10106},{"trials":10097,"activeCount":100},[],{"trials":10099,"activeCount":100},[],{"trials":10101,"activeCount":100},[],{"trials":10103,"activeCount":100},[],{"trials":10105,"activeCount":100},[],{"trials":10107,"activeCount":100},[10108],{"nctId":10109,"briefTitle":10110,"status":149,"phases":10111,"primaryCompletion":3702,"completion":3702,"start":2383,"enrollment":3887,"conditions":10112,"interventions":10114},"NCT01326221","Single Dose Truvada in HIV-negative Men and Women",[],[10113],"Pharmacokinetic Study in Healthy Volunteers",[10094]]